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The aim of this thesis is to develop methodology for combining multiple 
endpoints within a single statistical analysis that compares the responses of patients 
treated with a novel treatment with those of control patients treated conventionally. 
The focus is on interval-censored bivariate survival data, and five real data sets from 
previous studies concerning multiple responses are used to illustrate the techniques 
developed.
The background to survival analysis is introduced by a general description of 
survival data, and an overview of existing methods and underlying models is 
included. A review is given of two of the most popular survival analysis methods, 
namely the logrank test and Cox’s proportional hazards model. The global score test 
methodology for combining multiple endpoints is described in detail, and application 
to real data demonstrates its benefits.
The correlation between two score statistics arising from bivariate interval- 
censored survival data is the core of this research. The global score test methodology 
is extended to the case of bivariate interval-censored survival data and a 
complementary log-log link is applied to derive the covariance and the correlation 
between the two score statistics. A number of common scenarios are considered in 
this investigation and the accuracy of the estimator is evaluated by means of extensive 
simulations.
An established method, namely the approach of Wei, Lin and Weissfeld, is 
examined and compared with the proposed method using both real and simulated 
data. It is concluded that our method is accurate, consistent and comparable to the 
competitor. This study marked the first successful development of the global score 
test methodology for bivariate survival data, employing a new approach to the
derivation of the covariance between two score statistics on the basis of an interval- 
censored model. Additionally, the relationship between the jackknife technique and 
the Wei, Lin and Weissfeld method has been clarified.
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Preface
Background
In clinical trials, the main purpose is often to compare efficacy between 
experimental and control treatments. These treatment comparisons often involve 
several responses or endpoints, and this situation complicates the analysis. For 
example, sets of responses concerned with survival times in a single clinical trial 
include: time to first cardiac event and time to death from any cause; time to loss of 
vision in the left eye and time to loss of vision in the right eye; and times from entry 
to a trial until the first, the second and the third asthma exacerbations.
One approach to simplifying the analysis would be to choose one of the 
survival times and to use that alone as a single primary endpoint. This is not always 
desirable, for example, in cases where the choice would be rather subjective or where 
the endpoints are of equal interest. A single parameter relating, to an overall 
assessment, is often required to give a solid justification of treatment advantage, and 
so separate analyses of more than one endpoint might likewise not be appropriate. 
Another alternative is to use a composite endpoint, such as the time until the first of 
the events.
The cumulative treatment advantage is usually measured by the score statistic 
for each endpoint. In survival analysis, the logrank test is one of the most popular 
methods for testing the equality of two treatment groups. It is routinely used in the 
analysis of clinical trials comparing the time-to-event distribution of a group of 
patients randomised to an experimental treatment with that of a control group. When 
prognostic factors are to be adjusted for, Cox’s proportional hazards regression, which 
is a direct generalisation of the logrank test, is commonly employed. These two 
methods are extensively referred to throughout this thesis. In the case of bivariate
v
survival data, the score statistics can be summed directly, but the variance is now 
affected by the dependence structure between two endpoints.
To estimate the correlation coefficient, an approximate formula for the 
covariance between the two score statistics is derived in various settings of bivariate 
interval-censored survival data.
Motivation
In general, global test methodology can be defined as the use of a combined 
model to estimate a composite measure of treatment effect concerning multiple 
outcomes. A global null hypothesis, that the treatment has no effect on any of a 
number of patient responses, is tested. Global test methodology has been used 
successfully in major clinical trials involving binary data when multiple outcomes are 
concerned. To my knowledge thus far, it has been accepted only in stroke studies, for 
its ability to yield a single parameter of treatment advantage, which is easily 
interpreted, as well as for its cost-saving benefit in terms of the trial size.
In particular, use of a global test as a primary analysis for multiple binary 
outcomes, accompanied by secondary tests of individual outcomes, was implemented 
in the NINDS t-PA Stroke Trial (Tilley et al., 1996). Global testing was adopted also 
for the International Citicoline Trial in acUte Stroke (ICTUS) documented by Davalos 
(2007). Moreover, Bolland et al. (2009) concluded for larger samples that global tests 
gave accurate type I error rates and satisfactory power, even after adjustment for 
prognostic factors. Therefore, the global testing approach is attractive for research 
concerning situations in which two or more time-to-event responses are observed on 
each individual.
Previous work has successfully determined the correlation between two score 
statistics arising from binary data or from ordered categorical data (Whitehead, 
Branson and Todd, 2010), but the case of survival data has proved difficult. An 
existing method for combining two or more survival analyses is the method of Wei, 
Lin and Weissfeld (1989). Unlike the logrank test, their approach does not directly 
condition on risk sets and does not reproduce the familiar form of logrank variance. 
There would appear to be scope for increasing its power by taking advantage of 
conditioning on successive risk sets.
An earlier approach using the logrank test proved difficult (Whitehead et al., 
unpublished) and therefore a new strategy is now proposed. In this new approach, the 
survival data are summarised within categories and analysed as interval-censored 
survival data. Using such a formulation, it is possible to determine the correlation, 
which serves as an accurate approximation to the correlation of the logrank statistics. 
Correlations between score statistics arising from interval-censored forms of the Cox 
model are investigated. Once an estimate for the correlation between two score test 
statistics is available, it has many applications. For example, combined null 
hypotheses, testing whether a linear combination of effects is equal to zero, and global 
null hypotheses, testing whether all effects are equal to zero, can be addressed. Joint 
confidence regions for multiple hazard ratios can be determined. Multiple testing 
procedures and sequential testing approaches can be implemented.
Aims
The aim of this thesis is to develop a methodology for combining multiple 
endpoints within a single statistical analysis focussing upon bivariate interval- 
censored survival data. A complete procedure is described by which to derive an 
estimator for the covariance of two score statistics and hence the correlation. 
Estimates of overall treatment effect, adjusting for the correlation, are also derived. 
Applications to real data and simulation studies will be performed. With the 
knowledge of such a correlation, an investigation into some of its various uses will be 
carried out. Most importantly, a detailed comparison between the present method and 
that of Wei, Lin and Weissfeld (1989) will be made.
Outline
This thesis is divided into seven chapters. The first chapter introduces survival 
data and analysis, and provides an overview of the existing methods in general. The 
fundamental concepts of the logrank test, proportional hazards, and the derivation of 
the score statistics are given. A basic study design is constructed as a main reference 
for later use. In Chapter 2, the global test methodology central to this research study is 
described for binary data, with illustration using real data from previous clinical trials. 
Simulation is performed to investigate the accuracy of the method.
Chapter 3 focuses on the methods needed for analyzing interval-censored 
survival data, describing some model applications and providing a comparison of 
methods. These methods are illustrated using a real data set and the accuracy of each 
method is evaluated in a simulation study. In Chapter 4, the core component of this 
research is covered, namely the correlation between two score statistics. Bivariate 
survival data of various types and their associated modelling are described. Global
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testing methodology is then applied to the case of main interest, bivariate interval- 
censored survival data. Using the selected model, the covariance between two 
statistics is estimated and hence an approximate formula for the correlation is made 
available. The methodology developed is illustrated using three real data sets.
Chapter 5 then investigates the accuracy of the proposed method using 
extensive simulation of six different cases, which are selected on the basis of their 
practical importance. The design of the simulation study is described at great length, 
with key points and limitations carefully annotated. Meanwhile, Chapter 6 presents 
the established method of Wei, Lin and Weissfeld from a different perspective 
compared to that in the original paper. Specifically, influence diagnostics are 
described and illustrated with clarity. To form the basis of comparison, the theories 
and computation are examined in detail. The same data sets (real and simulated) are 
analyzed using this method and compared to the results from our proposed method 
(Chapters 4 and 5). Finally, conclusions are drawn and potential areas for further 
work are put forward in Chapter 7 of this thesis.
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Chapter 1. Background of Survival Analysis
This chapter begins with an introduction to survival data, in particular, covering some 
special features of survival data such as censoring, which complicate the analysis. A 
theoretical description of the survivor function, hazard function, and their relationship 
is given in subsequent sections. In order to appreciate the distinct censoring 
mechanisms involved, illustrations and examples are presented.
Section 1.2 describes univariate survival data with a review of some well 
known statistical methods. Some issues pertaining to interval-censored survival data 
and existing methods for their analysis are introduced in the following section. Section 
1.4 describes the score statistic, Z, and Fisher’s information, V, as derived from the 
likelihood function. In Section 1.5, the proportional hazards assumption is reviewed; 
its application in the context of interval-censored survival data is illustrated in 
subsequent chapters.
The logrank test, which is one of the most widely used methods for testing the 
equality of event times of two groups, is described in Section 1.6. Finally, the basic 
principles of sample size determination in clinical trials are described in Section 1.7 
for later reference.
1.1. Introduction to Survival Data
Survival data is a common term used for describing data which measure time to a 
certain event or endpoint. Originally, the term “survival” arose because in early 
developments, the event being referred to was death. However, in medical 
applications, an event may refer to an occurrence of a disease or condition, disease 
progression, tumour recurrence, and so on. In general, an event can be defined as a
1
transition from one state to another that can be indexed in time, for example, a 
transition from a state of being healthy to a state of being infected.
Apart from clarifying the definition of event, the origin of time and its 
measurement scale also need to be specified. For example, surgery time is taken as the 
time origin to, where r = 0, if the investigator is interested in the study of survival after 
surgery. Meanwhile, in clinical trials, it is the time of randomization to treatment that 
is usually designated to. The actual study time varies due to different entry times (say 
time origin to), as illustrated in Figure 1.1 (inspired by Collett, 2003 p3).
Figure 1.1: An example of study time for five patients in a 10-year study period 
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In a study involving survival outcomes, patients are observed until they reach a 
defined endpoint (for example, death). However, patients sometimes withdraw from a 
study, or the study is concluded before all patients reach the endpoint. In Figure 1.1, 
five patients (A to E) were recruited at various times over the first 2 years of a study 
which ended 10 years after the start of the study. Patients A, C and D died during the 
study, while patient B was still alive at the end of the study. Patient E was lost to 
follow-up and last known to be alive at 7 years after the start of the study. For each 
patient, the study begins at time to which is the patient’s time origin, and the time the
patient remains in the study is termed “patient time”. This type of non-parallel data 
with regard to the time origin is quite common in survival data. Figure 1.2 illustrates 
the survival times in ascending order, of the same five patients, based on patient time 
(inspired by Collett, 2003 p4).
Figure 1.2: An example of patient time, corresponding to the study times for the five
patients in Figure 1.1.
6 9 100 1 2 3 4 5 7 8
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The transformation of data from study time to patient time is shown in Figures 
1.1 and 1.2. For example, patient C who was recruited at about 6 months from the 
beginning of the study, failed after 7 years of the study time, therefore the actual 
patient time spent in the study is 6.5 years, as illustrated in Figure 1.2 above. It is to be 
clarified that in this thesis, patient time is used unless noted otherwise. The choice of 
time unit varies depending on the type of study and context. For example, in a radical 
type of cancer, the time may be weeks or months, whereas the length of treatment for 
a cardiovascular trial may be measured in years.
As shown in Figure 1.1, for patients B and E, the survival times, also known as 
failure times or event times, are censored: patients survived to a certain time beyond 
which their status is unknown. In the analysis of survival data, the absence of an event 
time is referred to as censoring and the patient for whom no event time is available is
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referred to as censored. For a patient i, the survival time, 7J, is defined as the 
minimum time observed, either the failure time or death time, Du or the censored 
time, Ci\ this definition is often represented by F, = min(£)„ C;). The most common 
type of censoring encountered in medical studies is right-censoring, followed 
respectively by interval-censoring and left-censoring of survival data. These censoring 
mechanisms are described in Section 1.1.4.
Theoretically, survival data are probabilistic in nature; the times at which 
events occur being assumed to be realizations of some random process. By definition, 
this means that, for a given individual, the time T  to the event is a random variable 
which has a probability distribution. Therefore, survival data can be described in terms 
of a cumulative distribution function (c.d.f.), probability density function (p.d.f.), 
survivor function or hazard function. The survivor function, S(t), and the hazard 
function, h{t), are paramount in survival data; their definitions and relationships are 
described in Section 1.1.2.
A good review of the development of survival analysis throughout the 20th 
century is provided by Oakes (2001), with emphasis on work since 1980. He regards 
the two landmark papers by Kaplan & Meier (1958), who formalized the product-limit 
estimator, and that by Cox (1972), who introduced the proportional hazards model, as 
primarily responsible for the present emphasis. The concepts of the latter are 
described and applied in several sections in this thesis.
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1.1.1. Special Features of Survival Data
In general, survival data have three special features that are difficult to handle and that 
render conventional statistical methods inadequate: (i) censoring, (ii) non-normality 
and (iii) time dependence of covariates, which will now be described in turn.
Consider a study of patients with stage 3 or stage 4 prostatic cancers, 
randomized to form experimental and control treatment groups. The number of days 
between randomization until death is recorded, as well as the cause of death. A simple 
logistic regression can be used to analyze the current status of the patients: whether 
they are dead or alive after some specified follow-up time, say five years. However, 
this method ignores vital information on the timing of death if it occurs. Due to the 
nature of survival studies which typically involve a long period of study time, it is 
common to encounter censored observations. Discarding censored data may be a 
tempting option for simplicity, but it may only work if the proportion censored is 
small. Censored observations contain information about survival and thus should be 
accounted for in analysis. For example, in a cancer study, an observation censored at 
15 years indicates better survival compared to that censored at 1 year.
In a survival study, a few individuals may experience the event much sooner or 
later than the majority of individuals under study, hence giving the survival 
distribution a skewed appearance and methods based on the normal distribution being 
unsuitable for use. Commonly used distributions are often either symmetric or right 
skewed, but survival distributions in many cases involve left skewed distribution of 
positive variables (Hougaard, 1999).
The most common goal of a clinical study is to determine a treatment effect. 
Additionally, when a study aims to estimate causal or predictive model parameters, in 
which the risk of an event depends on covariates, the analysis becomes more
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interesting. While some covariates such as race and gender remain constant 
throughout the study period, some covariates may change with time, for example 
marital status and employment. The latter are called time-dependent covariates.
All methods of survival analysis should allow for censoring and non­
normality. They may also need to accommodate time-dependent covariates. 
Information in the censored and uncensored observations should be combined to 
devise a procedure that can provide consistent estimates of the parameters of interest. 
This is often accomplished by the methods of maximum likelihood or partial 
likelihood, which can also be adjusted to incorporate the time-dependent covariates. 
Such methods are briefly described in Sections 1.4 and 1.5.
1.1.2. Survivor Function and Hazard Function
An analysis of survival data requires special techniques because the data are almost 
always incomplete. There exist many models for survival data, and each model is 
distinguished by its choice of the probability distribution for T, the non-negative 
random time variable, /(/)• The distribution of survival times can be summarized by a 
survivor function S(t), which is the probability that the event occurs after time t: S(t) = 
P(T > t), 0 < t < oo. Assuming T is a continuous variable, its cumulative distribution 
function (c.d.f) gives the probability that the variable T  will be less than or equal to 
any value of t: F(t) = P(T<t). The survivor function can thus be expressed in terms of 
c.d.f. of T\ S(t) = 1 -  F(t). The slope or derivative of the c.d.f. gives the p.d.f, which 
can be written as f(t) = dF(t)/dt = ~dS(t)/dt. Therefore, the c.d.f. and the survivor 
function respectively can be re-written as
F(t) = P(T ^ t )  = j'of(u)du,
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and
S(0 = 1 -  P(T < t) = 1 -  t f (u)du.
The hazard function h(t) is defined as
*->0 gt = lim
P( t<T<t  + St) 
P(T > t)St
= lim
F(t + St ) -F( t )  
S(t)St
( 1 . 1 )
where St is the time interval within which the subject fails, conditional on having
dsurvived up to time t. Therefore, h(t )~ f ( t ) /  S(t) and h(t) =  log S(t) . This
dt
implies that f ( t )  = h( t )exm-j  h(u)du\ which is the product of the hazard function and
exponential of the minus accumulated hazards until time t, also known as the 
cumulative hazard. Therefore, the survivor function can be expressed as
The cumulative hazard function is also conventionally denoted by H(t)\ thus S(t) = 
exp(~H(t)). The survivor function has the following properties; (i) the probability of 
survival at time zero is 1: S(0) = 1, (ii) the probability of infinite survival is zero, (^oo) 
= 0, and (iii) survivor function is non-increasing.
In survival analysis, discrete random variables often arise due to the rounding 
off of measurements, for example, time measured to the nearest week or month. 
Another situation arises where failure times are grouped into intervals in studies where 
patients are not monitored continuously, but rather are followed-up only at pre-defined 
time points. In this thesis, grouping of failure times into specified intervals is used.
(1.2)
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Consider T  as a discrete random variable with a probability function fitj) = P(T 
= tj)\ J = h  2, ..., n, where tj < t2 <...<tn. The survivor function is given by the 
summation of this probability function: S(t) = 1 -  Y  . /(* .). The hazard at time tj is
j  J
defined as the conditional probability that the event occurs at tj given that the event 
has not occurred before tf. hj = P(T = t j \ T  >tj) = f ( t j )  / S(tj). The survivor function
7 -1
and the hazard function, are given by S(t) = n  (1 - h j )  and f ( t j )  = hj n a - ^ )
j - . f z t j  Jk=l
respectively.
The probability density function, f(t), the survivor function, S(t), and the 
hazard function, h(t), are regarded as equivalent ways of describing the probability 
distribution of the survival time, T\ if any one of them is known, the other two can be 
recovered. The fundamental equations in this section are very useful in various 
representations of models in survival analysis.
1.1.3. Some Parametric Hazard Functions
The hazard function, h{t), as expressed in Section 1.1.2, is an unobserved function, yet 
it controls both the occurrence and the timing of the event. This hazard function or 
rate can only be estimated from the data, and it is often helpful to envisage hazard as a 
characteristic of an individual, not of a sample or population. It represents the 
instantaneous or immediate risk of the event (or death) at time t for an individual who 
has survived until time t. It is a fundamental dependent variable in survival analysis. It 
must be non negative, h(t) > 0, and its integral over [0, oo) must be infinite, but it is not 
otherwise constrained; the hazard function may be increasing or decreasing, non­
monotonic, or discontinuous.
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The simplest hazard function is that with a constant rate over time: h(t) = X or 
equivalently, log h{t) = //, where X = e ,^ for all t > 0. The corresponding survivor 
function is S(t) = e h and the density,/(r) = Xe'Xt is indeed the well known exponential 
distribution with parameter X. This relationship illustrates the importance of the 
exponential distribution in survival analysis. However, in reality the hazard is not 
always constant and therefore the assumption of an exponential distribution has its 
limitations. Increasing hazard rates often arise when there is disease progression of a 
patient or natural ageing. Although less common, decreasing hazard rates are 
sometimes observed, for example in patients experiencing organ transplant whereby 
the hazard rates are high before and just after surgery (due to infections or other 
surgical complications), but gradually decrease as the patients recover.
An alternative model which accommodates increasing, and decreasing hazard 
rates is the Weibull distribution. The hazard function is then given by h(t) = o l f '1, and 
an exponential distribution is indeed a special case of Weibull distributions when the 
shape parameter a = 1. The Weibull model is widely applicable in industrial 
applications, most importantly in engineering reliability analysis.
The hazard function has many alternative names in other fields. For example, 
it is also known as the conditional failure rate in reliability analysis, the force of 
mortality in demography, the intensity function in stochastic processes, the age- 
specific failure rate in epidemiology, and the inverse of the Mill’s ratio in economics 
(Klein and Moeschberger, 1997). In this thesis, the term hazard function is used.
Many survival studies involve comparison between the hazard functions of 
two or more groups; hence a model for the relationship between them is needed. Some 
common relationships are namely proportional, non-proportional and accelerated 
failure time (AFT). Central to this research is the proportional hazards model (Cox,
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1972), which will be briefly introduced in Section 1.5 and further described in Section
3.1.1. Other regression models such as proportional odds, additive hazards, and AFT 
are described in survival texts such as Sun (2006).
1.1.4. Censoring Mechanisms
Censoring occurs for many different reasons and may take different forms, as 
described in Section 1.1. Observations may be censored, and thus survival data are 
typically described by parameters which include a censoring indicator S  with a zero
value when censored, otherwise unity or vice versa: 8  e{0,l} Figure 1.3 shows types
of censoring often encountered include left-censored, right-censored and interval- 
censored.
Figure 1.3: Four common types of censoring in survival data 
(X indicates an occurrence o f event).
(a) Uncensored (b) Right Censored
X X
Tt =D, 00 0 R 00
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Figure 1.3 (a) shows the uncensored or complete survival data. This scenario 
occurs when the exact event time of patient i is known, 7} = Dt, which is the actual 
survival time of the patient. However, as shown in Figure 1.3 (b), when the study 
ended before an event occurred, the actual event time is unknown, but it is known that 
the patient was still alive at that time: the survival time is given by the censoring time, 
R. The fact that the actual event has not occurred and may occur only to the right of 
the observed time, gives rise to the name right censored data. The third scenario 
involving left censoring is shown in Figure 1.3 (c). Left censored data arise when it is 
known that the event occurred prior to a certain time, L  (to the left), but the exact time 
is unknown. For example in a study of tumour recurrence, the examination is at three 
months after surgery where the exact event date is unknown, but is certainly earlier 
than the detection time.
Figure 1.3 (d) portrays interval censoring which occurs when the event of 
interest is known to have occurred within a defined interval (L, R). Interval censoring 
often arises in studies of non-fatal endpoints requiring regular follow-ups or 
inspections. Consider the case of tumour recurrence where no recurrence had been 
observed at a three months examination, but one was detected at a six months check­
up. It is known that the event time is greater than three months and less than or equal 
to six months: 3 < T < 6 . Another common scenario of interval-censored data is 
present when continuous survival times are grouped into defined intervals prior to 
analysis. From Figure 1.3, left and right censoring are indeed special cases of interval 
censoring. The left, right and interval censoring can be represented by (0, L], (R, oo] 
and (L, /?] respectively, where (0, L] indicates that 0 < T < L .
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A critical assumption made in survival analysis is that failure times are 
independent of censoring times, which means that the hazard rates for the patients 
who are still at risk and those who have been censored are the same. A common 
model, specifically that known as random censoring, asserts that each subject satisfies 
this assumption. A specific condition requires that censoring be non-informative (Cox, 
1984). This means that an individual who is censored at time t should be 
representative of all those subjects who, having the same values of explanatory 
variables, survive up to that time. For example, if a patient was lost to follow-up 
because of migration, this may be non-informative censoring. However, if a patient 
was indeed lost to follow-up because of his deteriorating condition; the censoring 
becomes informative with respect to the patient’s survival. Such informative 
censoring can lead to severe biases in survival analysis, and it is often difficult to 
determine the magnitude or direction of those biases. In situations where informative 
censoring is suspected, such as those involving long trial periods, sensitivity analysis 
is often conducted to assess the degree of bias (Allison, 2001).
To appreciate the importance of the censoring mechanisms, consider the 
following scenario. Suppose a trial shows similar results for two treatments, A and B 
in the treatment of basal cell carcinoma, with a primary endpoint of 5-year disease- 
free survival. By the end of five years, about 30 percent of both treatment groups had 
withdrawn. For treatment A, withdrawal is mainly due to treatment failure or side 
effects. Meanwhile, patients on treatment B withdraw because they are completely 
cured and prefer not to be followed-up further. In a standard analysis, disease-free 
survival rates would be overestimated for treatment A and underestimated for 
treatment B because they would both be based on the patients who remained in the 
study. A way to minimize the consequences of this problem is to perform a sensitivity
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analysis of the main conclusions due to various assumptions when data on censored 
patients are scarce.
When survival curves are derived for endpoints other than death, the latter may 
be considered as a censoring event. For instance, if the endpoint is progression of 
breast cancer, then we may treat death due to heart disease as a censored event since 
there is no established relationship between these two diseases. However, in the case 
of lung cancer and smoking, treating death from heart disease as censoring might bias 
the result since smoking increases the risk of both cancer morbidity and 
cardiovascular mortality (Dupont, 2009). Whatever the type may be, censoring 
complicates the likelihood function, and hence the estimation of parameters of interest 
in survival analysis. Further reading on censoring is available from survival texts such 
as Anderson & Keiding (2006).
1.2. Univariate Survival Data
Univariate survival data occur when observations concern the time to a single event, 
for example, time to death, and individuals are assumed to be independent. As 
mentioned in Section 1.1.2, analysis of survival data requires methods that are able to 
accommodate both skewed and censored observations. Suppose there are two distinct 
groups of individuals in a study. A natural method to explore univariate survival data 
is to compute survival curves, S(t), for each group and compare the proportions 
surviving over time. The non-parametric method of Kaplan Meier (Kaplan and Meier, 
1958) allows a visual comparison of the survival experiences of the two groups, and it 
is often supplemented by a test statistic summarizing the overall survival comparison.
The logrank test is a popular method for comparing the survival of groups,
which takes the whole follow-up period into account. It has an advantage that it does
not require any knowledge about the shape of the survival curves and is a powerful
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significance test if the assumption of proportional hazards is true. The proportional 
hazards assumption asserts that the ratio of hazard functions is the same at all time 
points. This means that for any t > 0, the relationship between the hazard functions of
patients on treatment E  and C is given by hE{t) = y/hc(t), where y/ is a constant known
as the hazard ratio.
For continuous predictor variables, a univariate Cox’s proportional hazards 
regression (Cox, 1972), which is a semi-parametric model is often the popular choice. 
The proportional hazards assumption and the logrank test are described in Sections 1.5 
and 1.6 respectively, while Cox’s proportional hazards regression model is described 
in Section 3.1.1.
1.3. Interval-censored Survival Data
Interval-censored survival data commonly occur in medical or health studies that 
entail periodic follow-up examinations. Another situation giving rise to interval- 
censored data occurs when continuous survival times for all subjects are grouped into 
specific intervals for analysis purposes, as described in Chapter 3. In practice, survival 
data are often observed to the nearest time unit: day, month or year, and hence the 
analyses are generally based on interval-censored data. Consequently, it is natural to 
consider the underlying survival variables as discrete in developing methods for their 
analysis.
As described in Section 1.1.4, the interval-censoring mechanism involves two 
related variables L  and R which define the interval. From this juncture onwards, the 
notation Te{L,R] indicates that L < T < R ..  This is consistent with the definition of 
interval-censored observations viewed as a union of several non-overlapping windows 
or intervals (Turnbull, 1976). In this thesis, an assumption of independent interval-
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censoring is made. This simply means that the censoring mechanism is independent of 
the survival times. Mathematically, this condition can be represented as 
P(L <T < R \ L = l,R = r) = P(l <T <r), such that the joint distribution of L and R is free 
of the parameters concerning the survival function of T. This is also known as non- 
informative interval censoring.
Suppose that patients, whose tumours have been removed, are randomized to 
experimental and control treatments. To compare the treatment effect, the patients are 
assessed at regular intervals to detect whether a tumour recurrence has occurred. In 
reality, it is not uncommon for patients to visit either earlier or later than at the 
scheduled date. Instead of being given for fixed intervals, the data now refer to 
occurrences at times varying from those scheduled for screenings, so varying also the 
interval between screenings. A simple way to analyse such data is by ignoring the 
interval censoring. However, this may not be appropriate if the time interval between 
screenings is short relative to the average time to recurrence, due to the interval- 
detected recurrences being fewer.
Another issue is often that such interval-detected recurrences contain 
information about patients’ conditions: those experiencing symptoms visit earlier, 
while those feeling better visit later or miss altogether. Such a situation renders the 
standard survival analysis inappropriate since the length of intervals may vary widely 
between individuals and the assumption of independent censoring is thereby violated.
Unlike right-censored survival data analysis, which has been highly developed, 
its interval-censored counterpart has gained attention only quite recently. Comprising 
left and right-censoring, the analysis of interval-censored data generally cannot be 
achieved with the methods established for right-censored data. Earlier methods for 
grouped survival data have been established by Kalbfleisch & Prentice (1973) and
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Prentice & Gloeckler (1978). Meanwhile, Finkelstein (1986) proposed a method for 
fitting the proportional hazards model to interval-censored data. The use of a 
complementary log-log transformation in the analysis of interval-censored survival 
data has been described by Whitehead (1989). Further, Whitehead (1997) adapted the 
log-rank test for comparing two treatment groups for use in the analysis of interval- 
censored survival data. A survival text by Sun (2006) provides a comprehensive 
coverage of the topic of interval-censored survival data.
The properties of the many proposed methods, however, remain unknown and 
there is no approach as simple as the partial likelihood method for right-censored data 
(Anderson & Keiding, 2006). In our research, a methodology is developed and 
validated to improve the analysis of interval-censored survival data.
1.4. Score Statistic and Fisher’s Information
In an investigation of a treatment effect 0, an important sample statistic is the 
cumulative measure of the advantage of the experimental treatment, often denoted by 
Z. Its companion, denoted by V, indicates the amount of information about 0 contained 
in Z. Statistically termed as the efficient score statistic, and Fisher’s information, Z 
and V, respectively, they can be calculated at any stage of a clinical trial. As shown in 
this sub-section, both statistics can be derived from an appropriate likelihood function. 
It is to be noted that the term “treatment advantage” is used to denote a positive 
treatment effect when the parameterization is arranged so that 0  > 0 implies that the 
patients receiving the experimental treatment do better than those on the control.
Suppose we have a data set x = xu i = 1, n and a single unknown parameter 
0, for example a treatment effect. The likelihood of observing 0, given x, is the 
probability of observing x, given 0: L{0\ x) = P(0; x). The log likelihood, £(0;x) is
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defined as log {L(Q\ x)}. The first derivative of the log likelihood evaluated at 6  = 0 
gives the efficient score statistic, Z  = £ '(0), and its minus second derivative yields 
Fisher’s information, V = -£"(0). By Taylor’s expansion, for small 6 , 
£{0)« £(Q) + 0 £'(O)+V2&2£"(Q) which is approximately equal to C + 6 Z -  Vi^V, 
where C is a constant.
According to Scharfstein, Tsiatis and Robins (1997), for large sample sizes, Z 
is normally distributed with mean 0V  and variance V. This assumption that Z ~ N(9V, 
V) forms the basis for many statistical methods such as Pearson’s chi-squared test, the 
logrank test and the Wilcoxon test; as it leads to asymptotically efficient methods. Z 
and V are also known as the logrank statistics since they are used to construct the 
logrank test, as will be shown in Section 1.5.
By definition, the maximum likelihood estimate (MLE) 9 of 6  satisfies
£\0) = 0. Since the log likelihood can be approximated, £{&) ~ C + 0Z-V292V , its first
derivative £ \ 6 ) «  Z  — 6 V , and thus gives the MLE 0  « Z  / V  . In large samples, the 
MLE is unbiased and linear in Z: it is therefore efficient. This formulation is central to 
this research, thus its recall shall be anticipated throughout this thesis. The derivation 
of Z and V  for binary and survival data based upon the likelihood function is covered 
in Sections 1.4.1 and 1.4.2 respectively.
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1.4.1. Z and V for Binary Data
Consider a study to assess the effectiveness of a new treatment comprising n subjects, 
randomized to experimental or control treatment. For example, subjects are followed- 
up for a year after surgery and their binary status (either alive or dead) is recorded. At 
the end of the study, a total of /  subjects died (failed) while s subjects are still alive 
(succeeded). Subscripts E and C are used to indicate experimental and control 
treatment respectively; this convention remains throughout this thesis, unless noted 
otherwise. Table 1.1 summarizes the binary outcomes of this hypothetical study.
Table 1.1: A 2 x 2 contingency table of binary response data (failure, success) in a 
two-group clinical trial comparing experimental and control.
Response Experimental Control Total
Failure f  E f  c /
Success s  E s c
Total n E n c n
Suppose the probabilities of failure on E  and C are denoted by pe and pc 
respectively, and the likelihood can be derived by conditioning on the right hand 
margin of Table 1.1. The likelihood is thus the probability of observing the outcomes, 
as in Table 1.1, given the condition that the total number of failures F  observed is /, 
and given pe and pc■ Simply, the conditional likelihood is given by, L(pE, pc) = 
P(observed tablel F  = f). Based on conditional probability, L(pE, pc) = ^(observed 
table)/£P(table with F =f). This can be written as
J(n n y _ P(FE= f E’Fc =f c)  f E+ f c = f >  
l \PE'P c' P(F = f )
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Suppose j  is an index denoting the various possible values that the random variable / e 
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Further, a measure of treatment effect is defined as minus the log-odds ratio given by
0  = —log P e ( I - P c ) ]
Pc Q - P e )) (1.4)
such that E  is better than C if 6  > 0. The likelihood in equation (1.3) can now be 
expressed in terms of the log-odds ratio,
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Under the null hypothesis of zero treatment effect, pE — pc  and 6  = 0. The likelihood is 
given by
m
rnE\(n ,  ^
Se fc ( 1.6)
where the random variable f E follows a hypergeometric distribution with parameters n, 
nE an d /. Upon taking the derivatives of equation (1.5) with respect to 6 , using the 
quotient rule, we get
L\9)  = J iEJ fc
f se -0/e
\JCJ
m i n ( /  , n E )
^  Vii'=max(0,/-nc ) \ J
(  n S \(  n ,^
nv
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E
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E
7 = m a x ( 0 , / - n c ) \J y f - j .
(1.7)
Evaluating the derivative of the likelihood in equation (1.7) under the null, we get
a
L\ 0)  =  - .Si\JEJ
( nc \  
\ f c j
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where the expected number of failures on experimental treatment is given by fn E/n. By 
definition, the score statistic is given by the first derivative of the log likelihood 
evaluated at 6  = 0: Z = £ '(0).
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Using the chain rule, Z = L '(0)/L(0)and using equations (1.6) and (1.8), the score 
statistic
z = - f E+ — '
" (1.9)
which is the difference between the expected number of events under the null 
hypothesis, given the proportion of subjects on E, and the observed number of events 
on E. Simply stated, Z is given by the expected failures minus the observed failures on 
E. Its variance is given by V = - i  "(0), which is then given by the quotient rule as
L(0)L"(0) - { L \ 0)}:
2 . Upon differentiating the log likelihood for the second time, and{ m y
evaluating the expression under the null, the Fisher’s information is expressed as
V =
nEncfs
"  ^  ^  (1.10) 
Both equations (1.9) and (1.10) are fundamental to this research and therefore will be 
recalled or re-expressed accordingly in subsequent chapters.
The derivation of the two logrank statistics Z and V have been shown above. 
These expressions are useful in the analysis of univariate data. In the case of bivariate 
data of two endpoints, the covariance between the two score statistics is needed. The 
derivation of such covariance for a binary data is given in Section 2.2.
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1.4.2. Z and V  for Survival Data
In this section, univariate survival data are considered. Suppose events are observed at 
times ta where a = 1, 2, . . . ,  m and the number of patients at risk of an event (at time ta) 
is ra. An event is counted as a failure, and the total number of failures at each time is 
denoted by oa\ the total number of successes is then given by ra ~ oa. The outcomes at 
each failure time ta can be tabulated as shown in Table 1.2; note that the form is 
identical to Table 1.1 earlier, but specific to survival at time ta.
Table 1.2: A 2x2 contingency table of univariate survival responses at time ta.
Response Experimental Control Total
Failed at t a °  aE ° a C o a
Survived beyond t a r  aE ~ °  aE r  aC ~ °  aC r a - o a
Total r  aE r  aC r a
Now let the discrete hazard function, hG(ta.) = P(TG e (ta*,ta*+l) \TG >ta*), a -  0, ...,
m+1, to = 0, where tm+l =00, and Tq is the survival time of a subject on treatment G,
where G = E, C. The log-odds ratio of failing during (V ’^*+i) > given survival past ta 
for E  relative to C is given by
' hE(ta) ( \ -h c (ta)) |
0 a = -  log hc {ta) { \ - h E{ta))\
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From equation (1.9), the score statistic is Za -  -  oqe + (oaraElra)> which can be 
expressed as
7  -  raE°aC  ~  raC°aE  
a ’
r “  (1.12) 
and from equation (1.10), Fisher’s information is now given by
y    raCraEOMa-°a) O '13)
0 ra\ r a - 1)
In the next section, we will see that equation (1.11) corresponds to the 
proportional hazards model, and equations (1.12) and (1.13) are summed over 
multiple time points. As mentioned earlier, the assumption that Za ~N {6 aVa, Va) for 
large Va and small 6 a, is very useful and is continually referred to within this thesis. 
Based on this fundamental assumption, the derivation of Z and V using several 
methods for survival data, are described also in Chapter 3. Further in Chapter 4, the 
derivation of the covariance between two score statistics is described.
1.5. Proportional Hazards
In Table 1.2, the numbers of failures and successes were counted at defined event 
times. In this section, the assumption of proportional hazards is described, while the 
logrank test which considers all time points with an event is described in Section 1.6.
Suppose there is a finer grid which includes all the observed failure times 
(regardless of an event occurring). Now we may have intervals with zero failure; oe -  
oc = o = 0 and these intervals do not contribute anything to Za and Va. The hazard
function is now, hG (ta) = P(TG e (ta, ta + St) I TG>tJ and as St —> 0, hG (ta) ~ SthG (ta).
From equation (1.11), 6  is now given by
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The proportional hazards assumption is expressed as,
0  = — log hE(t) j 
hc (t) I
• J (1.14)
for all r > 0 and implies that hE(t) = exp(-6 )hc(t) . The importance of this assumption is
that the logrank test is efficient for the detection of a proportional hazards alternative, 
which is illustrated in Section 1.6.
The proportional hazards assumption is also central to the widely known Cox’s 
model (1972). Cox’s paper launched an explosion of statistical and applied research 
on the effects of individual patient characteristics on the survival process, with 
obvious extension to prognosis (Armitage & Gehan, 1974). Cox’s method does not 
require any knowledge or assumption of the survival time distribution, and hence it is 
non-parametric with respect to time. Perhaps this flexibility is the primary reason for 
its popularity: the paper has been cited over 25,000 times as of June 2011. A detailed 
description of this model is covered in Section 3.1.1.
1.6. Logrank Test
The logrank test (Peto and Peto, 1972) is a non-parametric test to compare two 
samples of right-censored survival data. It is based on the assumptions that censoring 
is unrelated to prognosis, and that the survival probabilities are the same regardless of 
when a subject was recruited. Deviations from these assumptions matter most if they 
occur differentially in the groups being compared, for example, if censoring is more 
likely in one group than another. In summary, the logrank test statistic is constructed 
by computing the observed and expected number of events in one of the groups at 
each observed event time and then summing over all time points where there is an 
event, which is then divided by the square root of the cumulative variance.
Suppose two treatments are being compared, namely control and experimental. 
Since the intention of the experimental treatment is to reduce hazard, a positive 6  
indicates its superiority. Using equation (1.2), the survivor function for the
experimental group is given by, SE(t) = e x p J o (w)z/m| , and similarly for the control
group. Based on their relationships with treatment advantage and the assumption of 
proportional hazards,
- 0
S£(0 = expj-fV \(w )dw | = expjf'-hc(u)du\ = {5^(0}' .
1 1 L 1 JJ (U5)
Taking logs of equation (1.15), it follows that log{S£(r)} =<T*log{Sc(0} • 
Reversing the sign and taking logs again, gives an expression for the log hazard ratio, 
6  in terms of survivor functions,
0  = -lo g  {-log SE(t)} + log {-log 5C(0} • (1-16)
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For illustration of the logrank test, the example of survival data with m events 
(assuming one event at each time) from Section 1.4.2 is considered here. Suppose
there is a common treatment advantage given by the log hazard ratio in equation
(1.14), or equivalently equation (1.16), such that 0\ = ... 6 m -  0. Using equations (1.12) 
and (1.13), the overall score statistic Z and its null variance V are given by summing 
the Za and Va values over all time points, and respectively taking the forms,
7  =  V 7  _ ^ r a E 0 a C - r a C ° a E/  j a /  j
0=1 r“ (1.17)
and
T/=YV = ' y r^ raC°a(ra ~ ° g )
L a V* L i  2( _ n  ‘
a~ 1 a=1 'a \’a ' (1 18)
As noted in Section 1.4, the Z and V  are known also as the logrank statistics,
and the test based on them is called the logrank test or the score test. Similar 
assumption applies here: Z ~ N{9V, V) when 6  is small and V  is large. To test the null 
hypothesis that 6  = 0, the value of z N v  can be compared with the critical value of the 
standard normal distribution N(0, 1), or equivalently comparing Z2/V  with the critical 
value of the chi-squared distribution y£\. This is the popular logrank test which is 
commonly used to test the null hypothesis that there is no difference between the 
populations in the probability of an event over all time points.
The logrank test is most likely to detect a difference between groups when the
risk of an event is consistently greater for one group than another. It is efficient for
alternatives satisfying proportional hazards, but valid under the null with no further
assumption. However, it is unlikely to detect a difference when survival curves cross:
non-proportional hazards ratio. Since the logrank test is purely a test of significance, it
cannot provide an estimate of the size of the difference between the groups or a
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confidence interval. For these, we need to make some assumptions about the data. 
Common survival methods often use the assumption of proportional hazards and then 
estimate the ratio, as described in Section 1.5.
In many clinical trials, there exist factors associated with each patient which 
are anticipated to influence the patient response. For example, in multi-centre trials in 
which two treatment regimes are to be compared in terms of their effects on the 
survival times of cancer patients. The survival data are recorded for each centre and 
logically stratified by centre, with each centre termed a stratum. Instead of taking the 
individual log rank test for each stratum separately, a more realistic summary of the 
treatment effect over all strata is often necessary. This is achieved by a stratified 
logrank test which combines information about the treatment effect in each stratum. 
From above, denote the logrank statistic for the sth stratum as Zs, and its variance as
Vs. The stratified logrank test is then based on the statistic (]^]=lZs)2/ which
has the chi-squared distribution i- Other variables often requiring stratification are 
gender, age group and a classification of diseases such as late stage or early stage for 
cancer studies.
In general, stratification allows a less restrictive assumption whereby the 
hazards need not be proportional between all strata (for example: centres or events), 
but more realistically the hazards are assumed to be proportional within each stratum. 
It is worth noting that the stratified logrank test is equivalent to the test of treatment 
effect in a stratified proportional hazards model when treatment is the only factor 
being fitted. This topic of stratification is further discussed in Chapter 4.
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1.7. Sample Size Calculation
In the design of a clinical trial, one fundamental aspect is its sample size: the number 
of patients required to detect a clinically relevant difference reliably. Apart from 
making the main purpose of the trial clear, it is also important to identify the principal 
measure of outcome, type of data analysis, type of results anticipated with standard 
treatment, and the magnitude of treatment advantage to detect and its degree of 
certainty (Pocock, 1983). Based on current knowledge as well as previous trials, the 
magnitude of treatment advantage, sometimes referred to as the ‘reference 
improvement’ and denoted as O r, can be set.
In any trial, there exist two possible errors: type I error and type II error. The 
former consists in falsely detecting a significant difference when the treatments are 
really equally effective, that is when 0 = 0. Its probability of occurrence is commonly 
denoted by a, representing the risk of a false-positive result. A type II error arises 
when the trial fails to detect, as significant, a difference when there really is such a 
treatment difference of 0 = O r. The probability of a type II error represents the risk of a 
false-negative result, and is commonly denoted by p. The ‘power’ to detect the desired 
treatment advantage is often denoted by 1 -p , which represents the degree of certainty 
that O r, if present would be detected.
The result of a significance test is expressed as a ‘p-value’ (p), and a value of 
p  < 0.05 would indicate that such an extreme observed difference or greater could be 
expected to have arisen by chance alone less than 5% of the time, when the null 
hypothesis is true; thus it is likely that the treatment difference really is present. 
Meanwhile, ‘detecting a difference’ is usually taken to mean ‘obtaining a statistically 
significant difference with p  < 0.05 ’ (Machin, 1997).
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In determining sample size and in the analysis of results, there exist two 
options for significance levels: one-sided and two-sided. The former seeks to quantify 
the evidence that the experimental treatment is better than control, with no interest in a 
difference in the other direction. The two-sided equivalent is considered a justifiable 
safeguard against prejudging the direction of treatment difference (Pocock, 1983). The 
p-value for a one-sided test is therefore half that for a two-sided test. For example, the 
type I error for the former might typically be set so that p  < 0.025 (one-sided), while 
for the latter p  < 0.05 (two-sided) would be required. In this thesis, both types of test 
are employed for illustration and convenience purposes.
The design of a clinical trial is dependent on the relationship between sample 
size, n, and information, V. It is logical that more subjects give more information 
about the unknown parameter, such that the relationship between n and V is directly 
proportional: V = bn where b is a constant. Meanwhile, for a two-sided type I error, 
the amount of information is given by a well-known expression (Whitehead, 1997),
where uy is the upper lOOj, percentage point of the standard normal distribution: 
O (uy) - I - y , and Or is the treatment advantage at the required power. The method of
sample size calculation for a clinical trial is based on a power calculation. By 
specifying the desired power to detect a certain amount of treatment effect at the 
targeted significance level, the required information, V, can be obtained. The 
relationship between V and n can be quantified by a constant value, b, which will then 
lead to the sample size needed for the trial: n = VIb. The value of b can be determined 
from the approximation of V in terms of model parameters and sample size n; usually 
the result V <x n is found. For survival data, generally V = e/4 for 1:1 treatment
(1.19)
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allocation, where e is the total number of events, but interval-censoring leads to the 
relationship V oc n as usual. Equation (1.19) is fundamental to a design study and is 
referred to throughout this thesis.
This chapter has introduced the basic concepts of survival analysis that are 
used later in this thesis, described some of the important models and highlighted the 
difficulties in dealing with interval-censored survival data. In describing the 
proportional hazards model, the basic likelihood function was introduced in deriving 
the logrank statistic, and its relationship to the logrank test has been described. The 
principles governing sample size calculation too, were explained as part of the crucial 
requirement in clinical trials.
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Chapter 2. Global Test Methodology
This chapter presents the fundamental theory and application of global test 
methodology which will be used to combine multiple survival endpoints in later 
chapters. The global test methodology is first demonstrated for binary data in this 
chapter. Section 2.1 begins with an introduction to the global test approach in the 
evaluation of treatment efficacy. The established method of combining multiple 
binary endpoints is described and illustrated in Section 2.2 using a real data set from 
previous clinical trials involving stroke patients.
A study design of a clinical trial is described with illustrations of multiple 
stroke scales deployed. Section 2.4 presents the results of simulations conducted. The 
purpose of this investigation is two-fold: it serves as a foundation on which the case of 
interval-censored survival data will be built, and also forms a basis for comparison 
with results to be presented in that case. Finally, a discussion on the applicability of 
the method in general is provided.
2.1. Introduction to Global Test (Binary Data)
In clinical trials, the primary objective is often to evaluate the relative efficacy of two 
or more treatments. This may involve multiple assessment tools employed on the 
same group of patients, with each tool measuring certain aspects o f each patient’s 
condition. For the same patient, the outcomes on each tool or measurement scale are 
usually correlated with those on the other scales. The conventional method of analysis 
to evaluate treatment efficacy is one that controls the risk of detecting a significant 
difference when the treatments are really equally effective, that is a type I error, while 
maximising the power to detect a significant difference when there really is a 
difference. To find such a method is a challenging task especially when combining
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outcomes that are correlated. O’Brien (1984) and Pocock, Geller and Tsiatis (1987) 
have combined multiple binary endpoints and reported that global tests may increase 
the power to detect differences between groups, but the appropriateness of their use 
should be carefully considered. Use of a global test as a primary analysis for binary 
outcomes, accompanied by secondary tests of individual outcomes was implemented 
in the NINDS t-PA Stroke Trial (Tilley et al., 1996). The success of this trial has 
increased awareness and acceptance of the approach within stroke research, as is 
evident by its adoption for the International Citicoline Trial in acUte Stroke (ICTUS) 
documented by Davalos (2007).
The existence of a variety of stroke scales poses a statistical opportunity in 
analysing the clinical trial, as each scale is correlated with the others and none 
captures all o f the information on a patient’s condition. Therefore, the multiple scales 
employed in a trial may be analysed in order to yield the most information. The 
method of combining the stroke scales works well for ordinary data analysis and can 
be adopted in meta-analysis and interim analyses of such trials. This methodology, 
also termed a ‘global test’ is useful when the outcome, such as clinical recovery from 
stroke, is difficult to measure and a combination of correlated outcomes (each 
measuring recovery from stroke) would be informative (Tilley et al., 1996). The 
global test statistic assumes a common treatment effect in terms of magnitude and 
direction on all outcomes. If the assumption is met, the power of the global test is 
equal to, or greater than, that of the individual outcomes.
In this chapter, the investigation is based on the data from four trials of 
citicoline by Davalos et al. (2002) that motivated the ICTUS trial. The outcome on 
each scale is categorized as a success for Barthel index (BI) > 95 (favourable 
outcome), modified Rankin scale (mRS) < 1 (no symptoms or no significant
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disability) and National Institutes of Health Stroke Scale (NIHSS) < 1 (common or 
minor impact) as measured after 12 weeks from randomization. Previously, Bolland et 
al. (2009) concluded for larger samples that global tests gave accurate type I error 
rates and satisfactory power, even after the adjustment for prognostic factors. This 
chapter now investigates the simpler setting without any covariates, and also the 
effect, on the power, of deviation from the assumption of a common log-odds ratio. 
First, the underlying theories and assumptions are to be described.
2.1.1. Global Z and V  Approach
The basic definitions of the score statistic Z and Fisher’s information V were given in 
Section 1.4. These statistics are now described within the context of the global test 
approach. Suppose that each patient is measured on m stroke scales and subscript u is 
used to indicate the quantities associated with the wth of the stroke scales, where u = 1, 
2, ..., m. The score statistics Z„ are distributed approximately as N(0uVu, Vu). Let Zf 
denote the sum of the score statistics and similarly V* the sum of its null variances. 
The global test statistic, which is the combination of all Zu values on each uth scale, Z+ 
= Z\ + Z2 + ... + Zm is deployed. However, due to the correlation among the scales, the 
variance of Zf is no longer equal to the sum of the information, that is var(Z+) ^  V
where V* = V\ + V2 + ......+ Vm. A correction factor of twice the sum of the covariances
between uth and vth scales (when u < v) needs to be considered as var(Z+) = V* +
m
2( ^ C uv) , where Cuv = cov(ZM, Zy), u, v = 1, 2,..., m.
H<V
The global test statistics are Z* = ZfLf/var(Zf) and V* = Vrf2/var(Z+) such that
the expected value of Z* is given by
E(Z*) = E(Z+Ff/var(Zf)) = E(Zf)Vrf/var(Zf) = 6 V* Ff/var(Zf) = 6 V*.
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Consequently, the variance of Z* is given by
var(Z*) = var(ZfVf/var(Zf)) = var(Z+)(Vrf/var(Zf))2 = \^ 2/var(Zf), 
which equals the global information, V*. Assuming the log-odds ratios 9U are all equal 
to 9, Z* is distributed approximately as N(9V*, V*). Under the null hypothesis of zero 
treatment effect on any scale, 6 l = 92 = ... = 9m = 0, thus Zu ~ N(0, Vu) and similarly, 
Z*~ N{0, V*).
A global score test can be based on comparing the quantity Z*2/V* with the 
critical value of the chi-squared distribution on 1 degree of freedom. Under the 
alternative hypothesis, when the log-odds ratios 9 \ = 9 2 = ... = 9 m = 9  ^  0, then the 
common log-odds ratio 9 represents the global log-odds ratio of success for 
experimental treatment relative to control. The global test is always valid under the 
null hypothesis (9U = 0) and is efficient for an alternative hypothesis in which the log- 
odds ratios 9U are all equal. Since an assumption of equality of the 9U is deployed in 
this study design, any deviation from it may degrade the power of the test. An 
illustration of this global test methodology using a real data set is given in the 
subsequent sections.
2.2. Combining Multiple Binary Outcomes
In Section 1.4.1, a 2 x 2 table for a single binary response has been described. This 
section extends the application of the derived quantities to binary outcomes evaluated 
on multiple stroke scales. The covariance between the score statistics which is 
required in combining analyses of bivariate binary data is also derived. The possible 
outcomes on an individual stroke scale such as BI, mRS or NIHSS, for both citicoline 
and placebo can be summarized in a 2 x 2 contingency table such as that in Table 1.1 
on Page 18. Based on the conditional likelihood, Z and V are respectively given by
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equations (1.9) and (1.10), except that Z is now expressed in terms of S ’s for 
successes, as is more natural for many forms of binary data,
z  jncSE- n ESc ) (2.1)
n
Suppose that outcomes on m stroke scales are available from each patient. The 
total number of patients is denoted by n** where m* = he* + nc*. A subscript u is added 
to all quantities associated with the uth of the stroke scales, where u = 1,2, ..., m. For 
combined outcomes on two scales: m = 2, a table can be constructed as shown in 
Table 2.1, where 0 and 1 respectively indicate success and failure according to the 
scales, while Qe 01) denotes, for example, the number of counts for subjects on E  with 
success according to uth and failure according to vth scales.
Table 2.1: Counts of subjects for combined binary outcomes on two scales.
Scale u Scale v E C Total
0 0 n  (00) U e Q c m
e > (0°)
0 1 Q s m Q c(m> e . <0,)
1 0 Q e(W) Q c (m Q m
1 1 G e(,1) 2 c (ll> £ . (U)
Total ft  E* ft c* fl **
It is to be noted that the number of double successes is given by <2*(°°\ while 
the number of successes on scale u is given by <2*(00) + Q*°X)- Based on the notation in 
Table 2.1, the binary score statistic Zu is given by
mm m» nFA<Xm +<Xm )z u = (QEm  + QEm ) -  - ^
ft**
and similarly
It is to be noted that the binary score statistic in equation (2.2) is simply given 
by the difference between the observed successes and the expected successes. 
Conditional on the margins of Table 2.1, the covariance between the two score 
statistics is given by
U^V
= var
cov(Z„,Zv) =  c o v { ( Q £ <. .  . . .  l^ <00,+ e £(OI)) .( e E<“ 1+ e £(1(,,)}
■ (a r )+■cov (q ™ , ) + cov (e /» > . e E(10)) + cov (q e
(2.3)
To find the variance and covariances in equation (2.3), further notation is necessary. 
Let N g denote the vector of category counts (nGu ..., nGay  for G = E, C, * and q, r = 1, 
..., a. The conditional density of N e, given TV* is expressed as
\n*
f ( n E\N,)  = ^ 4 \ U E a J
n.** ^
\ n E* )
(2.4)
where n** = he* + nG*. It follows that E{riEq IN*)= tiE* n*q/n** and E{(nEq(riEq-1) IN*} = 
«£*(«£*-l)n*q(n*q-l) / {(n **(ft**-l)}, such that var (yiEq) — tiE*ttc*ti*q(ti**~ ti*q ) l{{n 
1)}, as for hypergeometric sampling in a 2 x 2 table. Using similar arguments, 
E(nEqnEr) = nE*(nE*-l)(n*gn*v)/{(n **(77**-l)} and CO v if lE q i  H-Er) ~ -tlE*tlC *fl*qft*r/
1)}. Putting these expressions back into equation (2.3), we get,
C.
Tt ** (fT** 1)
nE*nc* f  Q*m
- { a (00)(n- -  g .(00)) -  Q*m o r  -  a m Q*(m) -  a m o r }
(«** - 1) «**
re.<00)+e.<0,>)fQ.m + Q,m ]
 ^ H** y  ^ H** j
(2.5)
It is to be noted that Q*m  is the total count of "double ” successes according to both 
m* and Vth scales over both treatments, now denoted by Suv, while the total number of 
patients n** can be represented by the conventional n, for simplicity. Similarly, the
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total number of patients succeeding according to scale Z u is denoted by Su which is 
given by the expression <2*(00) + <2*(01) and likewise, Sv for the quantity according to 
scale Z v. Therefore, the covariance between two binary score statistics Zu and Zv is 
written as
Cm = cov(Z ,Zv) = - M e -  W "  -  S:ISJ. (2.6)
n (tt-1)
This equation follows from the conditional likelihood approach, resulting in a 
denominator of n2(n— 1), as derived by Whitehead et al. (2010), while that from the 
unconditional approach leads to a denominator of n3, as in Pocock et al. (1987).
The general expressions for m scales were given in Section 2.1.1. Specific for 
the case of m = 2, the global test statistic Z* = Zj + Z2, while V* = V\ + V2, and var(Zf) 
= V* + 2C12, where Cuv = cov(ZM, Zv), u, v = 1,2. Furthermore, for three scales, m = 3, 
hence Z*- = Zi + Z2 + Z3, V4- = Vi + F2 + V3 and var(Z") = V* + 2(C,2 + C23 + Ci3), 
where Cuv = cov(ZM, Zv), «, v = 1, 2, 3. The expressions for the Z’s, V s  and C’s can be 
used to give the global score statistics Z* and the information F* needed to conduct a 
global score test on any given m scales of stroke outcomes.
2.2.1. Analysis of Data from Trials of Citicoline
A previous study by Davalos et al. (2002) involved 1372 patients with 789 
randomized to citicoline and 583 to placebo. The primary analysis was a global test 
for multiple outcomes of patients treated with citicoline for 6 weeks, and the efficacy 
of treatment was measured on Barthel index, modified Rankin scale and NIH stroke 
scale at 12 weeks after randomization. Bolland et al. (2009) evaluated a sequential 
global test design and concluded that the global score test can be used, even with 
adjustment for multiple covariates. In their study, treatment comparisons on multiple
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scales were conducted using similar expressions as given earlier. The trial was 
designed to have a power of 0.80 to detect significance at the level 0.05 (two-sided) if 
all three scales have a true log-odds ratio equal to 9  = log (1.26) = 0.231 which then 
led to fixing the power of ICTUS for the same odds-ratio value. A summary of the 
results is presented in Table 2.2.
Table 2.2: Summary of successes on individual and multiple scales from a meta­





Success on scale (s): 
(Proportions of success on scale(s))





283 325 325 
(0.359) (0.412) (0.412) 
186 223 217 
(0.319) (0.383) (0.372)
165 279 149 
(0.209) (0.354) (0.189) 







*BI_mRS denotes success on both the BI and mRS scales.
In Table 2.2, the numbers of successes on each individual and combined scales 
are tabulated from the original data sets used by Davalos et al. (2002) and Bolland et 
al. (2009). Columns 3 to 5 present counts (and proportions) of successes on each 
individual scale, columns 6 to 8 counts of patients who succeeded on both of the two 
scales mentioned and column 9 counts of patients who succeeded on all three scales. 
With pE and pc  denoting the probabilities of success on citicoline (experimental) and 
placebo (control) respectively, the advantage of citicoline relative to placebo can be
expressed as the log-odds ratio, 0 = \og{pE( l -  pc ) I Pc Q-~ PE)} . similar to equation
(1.4) earlier. For each individual scale, the corresponding log-odds ratio is calculated:
0\ = 0.178, 6 2  = 0.123 and 63 = 0.166. Note that these 6 U values are not equal, but are
close to each other. From equation (2.2), the values of Z\y Z2, and Z3 are obtained,
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leading to Z* = 20.335, and similarly for the V counterparts, resulting in V* = 
131.704. The calculated p-value is 0.038 indicating that the treatment difference is 
statistically significant at the 5% level (two-sided).
2.3. Sample Size for a Clinical Trial
The basic principles for sample size determination as described in Section 1.7 apply 
here. Say the probability of success on u h scale is pu, where u = I, the information 
needed can be estimated as follows. Put wu = pu( l -p u), V  = V\ ~ (nEnc / n)w\. Since 
V* = Vrf2/var(Z+) and var(Z?) = V* = V\, therefore T* = V\ ~ {npric / n)w\. For equal 
sample sizes, riE = nc = nil, then V* = lA{nw\) so that b = Va{w\). For m scales, V* = V\ 
+ V2 + ....+ Vm ~ (riEfic / n)(w\ + W2 + ...+ w,„). Each covariance, Cuv can be 
approximated by {nEnc / n)cuv where cuv = puv -  pup v and puv denotes the overall 
probability of simultaneous success on both wth and vth scales. The required V'* and b 
could be derived more generally first, before specialising to the binary case, and will 
be given later. From what was shown earlier, since F* = Vf2/var(Zf) and var(Z+) = V
m
+ 2( Z C«v)»then
u < v
and V -  bn where
1 f  JUL. [ ( ( ^*^)
V«=l / «<v J4'
Suppose all the binary responses on the m scales were independent, then cuv = 
0 for all u and v, and hence V* ~ {ngnc In) (wi + W2 + ....+ wm), such that the quantity 
of information provided by the global test would be represented by the sum of those
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f  m ^
provided by all m scales. This can be written as y* « (nEnc / n) ^ w u , where u = 1,
V « = 1 )
2, m scales. On the other hand, if all three responses were measuring exactly the 
same phenomenon, then the values of wu and cuv would lead to a single common value,
w, for whatever value of m, and hence V*~ (ngnc fn)w, for a test based on any of the m
scales. The advantage of using a global test should reside somewhere between these 
two extreme situations.
The expressions for V* and b are now given for two and three scales, as they 
will be required in the following investigations. For the case of two scales, m -  2, the 
information V* and b can be estimated as
V* ~ (ngnc /n)(w\ + W2)2{(wi + W2) + 2 (ci2 ) } ’1
and b = xA(w\ + W2)2{(wi + W2) + 2 (ci2)} 1 (2.9)
while for three scales, m = 3,
V* ~  (nEnc !ri)(w\ +  W2 +  w>3)2{(w i + w 2+ W3) + 2(cu+ C23 +  C13)}’1
2 1 and b =lA(w\ + w2 + W3) {(wi + w2 + W3) + 2 (ci2 + C23 + C13)}' . (2.10)
Certain assumptions are made in the sample size calculation presented here.
Firstly, the average of estimates (of the probabilities of success for patients on
citicoline and placebo) from Bolland et al. (2009) are used as the true probabilities of
success for patients on placebo, puc on wth scale where individual success probabilities
are taken to be p ]C = 0.347, p2c = 0.207 and p 3c = 0.195, and the double success
probabilities are taken as /?i2c = 0.200, p 23c = 0.147 and p u c  = 0.175. Under the null
hypothesis of zero treatment effect, the same values are deployed for citicoline. Say
the alternative hypothesis is based on the Or value in the same study, which is 0R =
0.231 with an assumption of equality 8 l = 6 2 = 03 = 0.231. Type I error is set as a/2 =
0.025 and the power of the test (l-ff)  is aimed at 0.90; an increase in power compared
to 0.80 in the earlier study by Bolland et al. (2009).
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For each individual scale, the average success probability is p u =  ( p uc  +  p ue ) I 2 ,  
where p u c  is the probability of success for patients on placebo according to uth scale, 
and that for citicoline, p uE, is derived from the log-odds ratio assuming 6 = 0.231. The 
derived values are p\ = 0.374, pi = 0.227, and /?3 = 0.215. For equal sample sizes for 
each treatment arm, n E =  n c  = n i l , V a  { n p u (  1- p u) } / 4. Since V* = {{Uoj2 + ufi)/0R} \  
where ua/2 = wo.25 = 1.960 and up = wo.10 = 1.282, and Or = 0.231, the sample size n  can 
then be calculated for each individual scale as displayed in Table 2.3.
Table 2.3: Summary of the success probabilities, calculated at 0 — 0.231 for individual 
scales, with their corresponding sample sizes.
Scale P u C P uE P u w u n
BI 0.347 0.401 0.374 0.234 3366
mRS 0.207 0.247 0.227 0.175 4490
NIHSS 0.195 0.234 0.215 0.169 4668
For two scales, computation of b involves covariance, cl(V as described in 
equation (2.9). In order to predict cuv, we need the average double success 
probabilities given by puv = (puvc+PuvE)/2. While puvC for placebo is given, its citicoline 
counterpart, puvE needs to be determined. One way is to assume the same value of the 
correlation coefficient for both placebo and citicoline. This correlation coefficient, p, 
describes the association between both scales that measure different variables, which 
can be computed as
P  = iPm -  P.P . ) 1 Jp .d -P JP vO - ~ A.)- (2-H )
Taking the individual success probabilities for placebo, puC as per Table 2.3, 
and the double success probabilities for placebo as p\2c — 0.200, p u c  = 0.147 and p\zc 
= 0.175, we get p n  = 0.665, p 23 = 0.664 and p n = 0.569 in this case. These values 
indicate that each scale adds information to the others. If the value of p is 1, then one
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scale provides exactly the same information as the other and the power would equal 
that of a single test. The closer p is to 1, the higher the correlation, which may lead to 
reduction in the advantage from combining scales. By preserving the correlation p, for 
example on BI and mRS scales, p n  -  0.665, the corresponding double success 
probability for citicoline, p\2E can be found by rearranging equation (2 . 1 1 ),
P \ 2 E  ~ p \ 2  {pjP l E ^  ~ P l E ^ P l E ^  ~ Pie)) (P\ePie)= 0.240,
and the average double success probability, p n  = 0.220. From Table 2.3, w, = 0.234, 
wi = 0.175, and thus cn  = 0.1351. Using equation (2.9), we get bn  = 0.0616. A similar 
procedure is followed for the other combined scales, giving C23 = 0.1142, cn  = 0.1136, 
£23 = 0.0517 and b 1 3 =  0.0644. These values of b are required to determine the sample 
sizes.
Table 2.4: Summary of the success probabilities {0 = 0.231), correlations and the 
corresponding values of cuv and buv for two-scale.
Scales P  uvC P  uvE P u v P  uv €  uv 0  uv
BI_mRS 0 . 2 0 0 0.240 0 . 2 2 0 0.665 0.1351 0.0616
mRS_NIHSS 0.147 0.179 0.163 0.664 0.1142 0.0517
BLNMSS 0.175 0 .2 1 2 0.194 0.569 0.1136 0.0644
As per equation (1.19) earlier, the global sample size, n, can then be calculated 
from the information required, V* ~ bn whereby V* = {(««/2 + up)!9R}2 when Z* is 
approximately distributed as A(^F*, V*), and Or  = log(1.26) = 0.231, leading to V * = 
196.96. The sample size for a fixed sample study on combining BI and mRS scales 
(denoted as BI_mRS in Table 2.4) is then nn  = V*/b]2 = 3198. Similar calculations are 
repeated for each two-scale combination. Finally, for m = 3, using b = 0.0641 from 
equation (2.10), the required sample size is 3074 in order to achieve a power of 0.90 
to detect significance at a level of 0.05 (two-sided), if all three scales have a true log-
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odds ratio equal to 0 -  0.231. The resulting values of sample sizes n for individual and 
combined scales (m = 2, 3) are displayed in Table 2.5.
Table 2.5: Summary of the success probabilities calculated at 0 — 0.231 for individual 
and combined scales, with their corresponding sample sizes, n.
Scale(s) P u C P  uE P u n
BI 0.347 0.401 0.374 3366
mRS 0.207 0.247 0.227 4490
NIHSS 0.195 0.234 0.215 4668
BI_mRS 0.200 0.240 0.220 3198
mRS_NIHSS 0.147 0.179 0.163 3810
BLNIHSS 0.175 0.212 0.194 3060
BI_mRS_NIHSS 0.147 0.179 0.163 3074
N.B. The values of puc ore extracted from Bolland et a l (2009).
As displayed in Table 2.5, the required sample size is reduced for the 
combined scales, indicating the usefulness of the global test approach in minimizing 
patient recruitment for a clinical trial. The fundamental relationship between V and n 
(hence O r )  is applicable throughout the designing of clinical trials in subsequent 
chapters which reference to this section.
2.4. Simulation and Results
To investigate the accuracy of the sample sizes derived earlier, a simulation study is 
conducted to verify the type I error rate and the power of the test to detect treatment 
effect at the 2.5% (one-sided) significance level. A power of 0.90 is targeted in this 
simulation. It is to be recalled from the previous section that Bolland et al. (2009) had 
set type I error rate at 5% (two-sided) and power of 0.80 in their study. The data sets 
are generated from a random uniform distribution, E/~(0, 1) from which the binary 
outcomes of a clinical trial are obtained. The proportion of successes is set by
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specifying U < pu accordingly in the SAS codes, where /?u is the average success 
probability for patients on uth scale. Under the null hypothesis of no treatment effect, 
the same success probabilities are used, p U£  = p u c ,  for example on the BI scale, p UE  = 
p u c  = 0.347. Under the alternative hypothesis, p UE > p u c  and the values shown in Table 
2.5 are used; the proportion of successes on E  needs to be included in the SAS codes 
accordingly since it is different than that on C.
Investigation begins with data for the individual fixed sample sizes for the 
targeted power to detect the desired significance level and simulated under both the 
null and alternative hypotheses. For each data set, simulations of 20,000 replicates are 
conducted to verify the type I error and the power of the test, with results shown in 
Table 2.6 below. Under the null hypothesis, Z is distributed approximately as N(0, V), 
while 0(ZHV) follows a uniform distribution. Hence, the p-value which is given by 
1 - 0(ZNV)  also follows U (0, 1). Under the null, the average p-value should be very 
close to 0.5 as the mean for U (0, 1) equals Vi. The proportion of p-values < 0.025 
gives an estimate of the type I error rate which represents the risk of a false-positive 
finding that is the probability of rejecting the null hypothesis when the treatments on 
both arms are indeed equal. Under the alternative hypothesis, the average p-value < 
0.025 illustrates the power of the test; that is the degree of certainty that the treatment 
difference, 6 , if present, would be detected.
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Table 2.6: Simulation results under the null and alternative hypotheses for individual 
scales, each with a different sample size, n.
0 Scale n p-value p-value <0.025 within 95% PI?
0 BI 3366 0.497 0.029 No
0 mRS 4490 0.500 0.025 Yes
0 NIHSS 4668 0.501 0.025 Yes
0.231 BI 3366 0.011 0.898 Yes
0.231 mRS 4490 0.012 0.892 No
0.231 NIHSS 4668 0.011 0.899 Yes
N.B. Texts in bold highlight out-of-limit situations.
As illustrated in Table 2.6, under the null hypothesis, type I error rates are 
found to be within the 95% probability interval of (0.022, 0.028), except for that of the 
BI scale which marginally exceeds the upper limit by 0.001. This implies that the type 
I error rate when using BI is not exactly 0.025, as it is indeed an asymptotic result, 
whereby in this case, the actual a is perhaps slightly elevated. It is also noted that the 
95% PI itself is approximate. Quite possibly, the proportion of p-value < 0.025 = 
0.029 (for BI) is simply a chance result. Under the alternative, where 6  = 0.231, the p- 
value for mRS lies slightly outside the 95% probability interval of (0.894, 0.906) 
based on the power target of 0.90. The results also show that large sample sizes are 
needed to achieve the desired power to detect significant treatment advantage if a 
single scale is being used.
For the combined scales, the individual and double success probabilities are 
now used to construct the appropriate 2 x 2  tables for each pair of scales. As usual, 
under the null hypothesis of no treatment difference, the same success probabilities 
are deployed on each treatment arm. The individual success probabilities are p\E — pic 
= 0.347, P 2E =  P 2C = 0.207, p i E -  P i c  = 0.195, while the double success probabilities
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for placebo and citicoline are as displayed in Table 2.4 earlier. With knowledge of 
these values, a 2 x 2 contingency table of outcomes for two scales u, v, can be 
constructed as shown in the example for placebo on combined BI_mRS scales in 
Table 2.7.







Failure 0.646 0.007 0.653
Success 0.147 0.200 0.347
Total 0.793 0.207 1.000
Four categories are formed, SS = success on both scales, SF = success on uth 
scale, but failure on vth scale, FS = failure on uth scale, but success on vth scale, and FF 
= failure on both scales. From earlier, the double success probability for patients on 
placebo according to both BI and mRS scales, p u c  = 0.200, is represented by the 
probability for SS. Given that the total success probabilities for patients on placebo 
according to the BI scale, p \C = 0.347 (last column, 2nd row), the probability for 
success on BI but failure on mRS, represented by SF, can be computed by p \c ~ p u c  = 
0.347 -  0.200 = 0.147. Similarly, the probability for FS can be calculated from Table 
2.7. The desired treatment advantage of 0 = 0.231 is then introduced by imposing the 
success probabilities for patients on citicoline (p\E -  0.240, pie = 0.179, Pze-  0.212, 
as in Table 2.4) to the same data sets. The method used to calculate these by 
preserving the correlation coefficient, has earlier been explained in Section 2.3. The 
case under the alternative hypothesis is illustrated in Table 2.8.
46







Failure 0.592 0.007 0.599
Success 0.161 0.240 0.401
Total 0.793 0.247 1.000
Similar contingency tables are constructed for each combination of two scales 
under both the null and alternative hypotheses, and then simulation is run accordingly. 
The same process is extended to the combined three-scale, with 8 categories of 
probabilities. These are SSS = triple successes, SSF, SFS, FSS = double successes, 
SFF, FSF, FFS = single successes, and FFF = triple failures. Say SSF denotes 
successes on both BI and mRS scales, but failure on NIHSS scale. The total of success 
probabilities for patients on placebo according to the BI scale, calculated as p i c  =  
0.347, represents the summation of probabilities for SSS, SSF, SFS, and SFF. With the 
known double success probabilities, p u c ,  P 2 3 C, and p u c ,  each category can be 
assigned with the correct probability, as shown in Table 2.9.
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Table 2.9: The probability for each combined outcome for patients on citicoline and 
placebo, under the alternative ( 6  = 0.231).









Table 2.9 shows the probabilities of outcomes on combined scales for patients 
on citicoline and placebo under the alternative hypothesis: Hi: 6  = 0.231. Under the 
null, the probabilities of outcome for patients on citicoline are taken as those values 
for patients on placebo. Based on these probabilities, the outcomes on each scale can 
be simulated, and the required statistics and p-values can then be computed. The 
corresponding results for all the combined scales are displayed in Table 2.10.
Table 2.10: Simulation results for all two-scale and three-scale combinations under the
null and alternative hypotheses.
e u=e Combined scales n p-value p-value < 0.025
0 BI_mRS 3198 0.494 0.028
0 mRS_NMSS 3810 0.498 0.024
0 BI_NIHSS 3060 0.497 0.024
0 BI-mRS-NMSS 3074 0.497 0.024
0.231 BI_mRS 3198 0.011 0.894
0.231 mRS_NIHSS 3810 0.011 0.894
0.231 BI_NMSS 3060 0.011 0.898
0.231 BI-mRS-NIHSS 3074 0.011 0.900
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Table 2.10 shows that the type I error rates are well within the 95% probability 
interval of (0.022, 0.028) under the null and similarly for the power of the test. 
Comparing with the power for each individual scale earlier (Table 2.6), it is evident 
that the combined scales yield higher power than those using an individual scale. 
Equivalent power can be achieved on combined scales with smaller sample sizes than 
that achieved on individual scales. For example, to give a power of 0.898, the required 
sample size for combined BI_NIHSS is 3060 (Table 2.10), whereas a sample size of 
4668 on a single NIHSS is required (Table 2.6). Furthermore, the global test on 
combined three scales yields the highest power; 0.90 which is the set target for this 
study, attainable with a reasonably small sample size of 3074. It is to be noted that the 
slightly smaller sample size for BI_NIHSS (n = 3060), compared to the global sample 
size {n = 3074), could be a peculiarity of this particular data set.
Another simulation, fixing the same sample size (n = 3000) on each individual 
and combined scales also proves the advantage of the global test over any single test 
as shown in Table 2.11 below. Consistent with earlier results, the combined all-three- 
scale procedure again gives the highest power of test of all.
Table 2.11: Summary of simulation results showing the power for each individual and 
combined scales under the alternative, with sample size n = 3000.







0.231 BI_mRS_NIHS S 0.892
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To investigate the effect of any deviation from the assumption of log-odds 
ratio equality (8U values are all equal), simulation is extended for situations in which 6\ 
+ 02 + @3, with results summarized in Table 2.12. It is to be noted that this table 
contains the results for the cases of two-scale and three-scale and “N/A” indicates that 
the individual scale is not applicable.
Table 2.12: Summary of the p-values and powers from the simulations using unequal 








p-value p-value < 0.025
1 0.231 0.116 N/A 0.040 0.703
2 N/A 0.116 0 0.298 0.115
3 0.231 N/A 0 0.090 0.477
4 0.231 0.116 0 0.100 0.441
5 0.231 0.462 N/A 0.001 0.996
6 N/A 0.462 0.116 0.004 0.967
7 0.231 N/A 0.116 0.036 0.720
8 0.231 0.462 0.116 0.000 1.000
For Cases 1 to 4, the log-odds ratios are set such that 62 = where 0\ =
0.231, and 63  = 0. As anticipated, the power of test (last column) deteriorates upon 
departure from the equality assumption for log-odds ratio 0U. Only Case 1 shows quite 
a high power of 70.3%, largely offset by the unaltered treatment advantage on the BI 
scale. In Case 2, the power of the test suffers the most due to the absence of any 
treatment effect on the NIHSS scale which cannot be salvaged by only half of the 
desired log-odds ratio on the mRS scale. The effect of no treatment advantage on the 
NIHSS scale ( 8 3  = 0) is clearly illustrated in Cases 3 and 4 as the powers are both 
below 50% for this study.
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To investigate further whether a reduction in treatment advantage on one scale 
could be recovered by an increase on another, Cases 5 to 6  follow with 0\ = 0.231, 02 
= 2x0 \,  and 02 = Vi x 6\. Case 6  demonstrates that half of the treatment effect on one 
scale can be compensated for by a double on the other to achieve the desired power. 
On all three scales, the power of the test further improves as shown in Case 8 . This 
serves as an additional confirmatory result to emphasize the importance of adherence 
to the equality assumption in the global test approach.
It is worth mentioning that Bolland et al. (2009) suggested, for the case where 
6 U values are not equal, the power can be approximated by taking 0  to be a weighted 
average: 6W = (9\W\ + 62w2+ 62w2)l(w\ + w2 + w2), where wu = pu( \ - p u), as defined in 
Section 2.3. Using equation (1.19), V* = {(Uoj2 + u^)/6r}2, up can be found from the 
standard normal distribution table and so it is l- f i  which gives the power. Using this 
approximation method for Cases 4 and 8  above, the powers are respectively 43.7% 
and 97.8%. Both values are very close to those displayed in Table 2.12, which are 
44.1% and 100%. Hence, the approximation method works well for the cases explored 
here.
2.5. Discussion
The method of combining binary assessments has achieved the intended type I error 
rate under the null hypothesis of zero treatment advantage, and yielded improved 
power under the alternative hypothesis of equal log-odds ratio, 9 = 0.231, compared to 
that for individual scales or even the two-scale combinations. The fundamental 
equations in Section 2.3 simplify the procedure for deriving sample size and power for 
a clinical trial. This illustrates the benefit of the global test approach for the 
correlations established between BI, mRS and NIHSS.
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The global test assumes a common treatment advantage, whereby a treatment 
has the same direction and size of effect on all outcomes. If the assumption is not 
valid, such that some outcomes for the experimental show benefits and others 
disadvantages, the power of the test is reduced. This is indeed a desirable feature in 
such clinical trials which demand consistent and persuasive evidence among the 
outcome measures. The basic requirement of this global test method is that the 
treatment advantage on each component scale can be summarized in terms of a score 
statistic Z, which is approximately normally distributed with the mean 6 V and 
variance V. Many types of responses satisfy this requirement, including survival data 
under proportional hazards. Thus, there is huge potential for the application of this 
global test approach. The simulations conducted have shown evidence for large 
samples that global tests based on the score method yielded satisfactory type I error 
rates and accurate power in this binary assessment.
To conclude, the overall result in this chapter justifies further investigation into 
survival data and combination of responses to explore the capability of this promising 
method. Using similar methodology, Whitehead et al. (2010) have developed a global 
score test for binary and ordinal endpoints, which centred on the derivation of the 
correlation between two score statistics. In Chapter 4, the global score test 
methodology is extended to bivariate interval-censored survival data.
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Chapter 3. Methods for Interval-censored Survival Data
Interval-censored survival data were earlier introduced in Section 1.3. Such data may 
arise from the grouping of continuous survival data or genuinely discrete data. The 
aim of this chapter is to identify within a few derived models, the model that yields 
the best approximations to the score statistic Z, and Fisher’s information V\ the 
selected model will be used in subsequent work.
Section 3.1 begins with an overview of the modelling of survival data. The 
very basic form of Cox’s proportional hazards model is described, followed by the 
application of the proportional hazards model in the context of interval-censored 
survival data. Two familiar models, namely log-odds ratio and complementary log-log 
transformation are explored; Z and V are derived from each model, and each leads to a 
different version depending on approximations made concerning information. 
Therefore, it is necessary to examine whether these variations are important before 
deciding on the model of choice. The resulting equations are then applied to a real 
interval-censored survival data set in Section 3.2.
A study design is formulated in Section 3.3 and simulation is performed to 
evaluate the accuracy of each method under the assumption of proportional hazards, 
and to investigate the effect of any deviation from it on the accuracy in Section 3.4. A 
discussion is given in the last section.
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3.1. Modelling of Survival Data
The modelling of survival data needs considerable attention to the underlying 
distribution as well as to the censoring mechanism. While the non-parametric 
methods, such as the logrank test (Section 1.6 ), can be useful in a simple comparison 
between two or more groups of survival times, they may not be suitable for more 
complex data. For example, often in a clinical trial to evaluate treatment advantage, 
other variables such as gender, smoking status and physiological measurements are 
recorded as well as the survival times. In such a situation where these explanatory 
variables must be included in the analysis, a statistical modelling approach renders 
solutions.
As survival analysis is mainly centred on the hazard of death (or event) at any 
time after a study has begun, the hazard function itself needs to be modelled. Although 
hazard models are distinct from linear models, many principles of the latter are 
applicable to the modelling of survival data. In general, such is performed to identify 
which of the explanatory variables affect the hazard function and consequently to 
estimate the hazard function. Such knowledge is useful in evaluating treatment 
efficacy since the survivor function can then be obtained from the hazard function: 
their unique relationship has been described in Section 1.1.2.
The famous Cox’s proportional hazards regression model is now described in 
greater detail than in Section 1.5. Cox's model is first explained in the situation where 
each survival time is distinct, before considering the case where two or more survival 
times might be tied at the same value. The latter case which involves tied failures or 
ties is relevant to interval-censored data. The log-odds ratio and complementary log- 
log transformation are then employed in the derivation of Z  and V. It is to be noted
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that the scope here is limited to fixed covariates, such as treatment group, which do 
not vary over time.
3.1.1. Cox’s Proportional Hazards Regression Model
Cox’s proportional hazards regression model (hereafter Cox’s PH) is very popular for 
many reasons, as already documented in many texts. Two key concepts of Cox’s PH 
model are the proportional hazards model and the estimation procedure using 
maximum partial likelihood, which are described in this section. The former is a direct 
generalization of the Weibull and Gompertz models while the latter is genuinely a 
novel approach in statistics. The Cox's PH assumes a parametric form for the effects 
of the explanatory variables, but it allows an unspecified form for the underlying 
survivor function, hence it is a semi-parametric model.
In the following example, the comparison of two survival curves is expressed 
in the form of a proportional hazards model. This approach is essentially the same as 
the log-rank test when there is only one covariate: a treatment indicator. In fact, if 
there are no ties in the survival times or when Cox’s discrete approach to ties is 
applied, the likelihood score test in Cox’s regression analysis is identical to the log- 
rank test. The advantage of Cox’s regression approach is its ability to adjust for the 
other variables by including them in the model, as will be shown later.
Consider a group of individuals randomized to treatments E and C, and their 
hazards of failure at time t which are given by hE(t) and hc(t) respectively. As
described in Section 1.5, the hazard for an individual on E  is taken to be proportional 
to the hazard for a patient on C, at time t. For any t > 0, this proportional hazards 
model can be expressed as
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hE(t) = i//hc(t), (3.1)
where y/ is a constant known as the relative hazard or hazard ratio. This is the true 
meaning of proportional hazards. The assumption of proportional hazards implies that 
the survivor functions for individuals on E  and C do not cross.
More generally, suppose there are n individuals randomized between E and C, 
i — 1, ..., n. The hazard for individual i at time t, denoted by h{t) , is simply expressed 
as the product of a baseline hazard function, h0(t) and the constant hazard ratio y/[. 
Since the hazard ratio cannot be negative, it can be written as y/.t = exp77, such that any 
value of the parameter r}t always gives a positive value of y / r  To consider the 
different treatments, enter an indicator variable X  with a value 1 if an individual is on 
E  and 0 otherwise. Denoting by xt for the value of X  for the i h individual and
Tji = /3xn the hazard function can be written as
Note that the baseline hazard function, hQ(t) is left unspecified apart from being a non­
negative function; it can be envisaged as the hazard of individuals with x(.= 0 .
Equation (3.2) implies two conditions: (i) the value of any covariate is measured at a 
fixed point in time, for example, at the beginning of the study, and (ii) the effect of 
each covariate is constant throughout the individual’s survival. The above model can 
be re-written by taking logarithms of both sides of equation (3.2) giving
where a(t) = log1\(t) . This baseline hazard can be specified to cater for any function: 




describe the Gompertz and Weibull models respectively. Such a specification, 
however, may be redundant as the hazard for any individual is a fixed proportion of 
the hazard for any other individual. For example, in a clinical trial comparing 
treatment advantage of experimental over control, the hazard for a patient on E is 
proportional to that for another patient on C. In the Cox’s model, no form is specified 
for the baseline hazard.
In reality, the hazard of failure at a given time often depends on many 
variables which are termed explanatory variables. The above expression can be 
generalized to suit this situation accordingly. Suppose there are k explanatory 
variables with all values recorded at baseline when a patient enters the study: 
xl9x2 t..fxk . Let these values be denoted by the vector x  = so that the
hazard function of the individual i can be expressed as
hi(t) = h0(t)exp(Tfi). (3.4)
This is indeed the product of the baseline hazard function and the exponential of a 
linear function of a set of k fixed covariates x(. with coefficient fi where the constant, 
V ,= A x n +...+fikx lk. In medical contexts, this constant is also known as the risk 
score or prognostic index. Applying equation (3.2) to two individuals i and j, then 
their hazard ratio is simply
jyL exp{A (*« - x f l )  + -  + M x ik “ **)}•
(3.5)
since the baseline hazard for one individual cancels out with that of the other, hence
giving a constant hazard ratio over time. It is to be noticed that the linear combination
of the explanatory variables resembles a linear model, hence making this approach
semi-parametric. It is assumed that these explanatory variables act multiplicatively on
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the hazard, and conditionally on the covariates x. and X j ; the failure times of
individuals i and j  are independent. The key point is that the baseline hazard need not 
be specified in order to obtain meaningful interpretation of the coefficients being 
estimated. The P coefficients can be estimated using the method of maximum 
likelihood which will be covered next.
The basic expression for likelihood has been introduced in Section 1.4; partial 
likelihood is now described in the context of Cox’s estimation method (Cox, 1975). 
The partial or conditional likelihood approach enables the P coefficients of the PH 
model to be estimated without having to specify the baseline hazard, as earlier 
mentioned. To construct the partial likelihood function, it is assumed that the intervals 
between the successive failure times, where there are no failures occurring, do not 
contribute any information about the effect of the explanatory variables on the hazard 
of failure.
Suppose we have a data set comprising n patients, Pjt\, Pjt2, Pj,n who failed 
at each time tj and those censored between any two times tjand tj+] , j  = 1, 2 , . . . . ,  m.
The probability that the individual i fails at time tj is conditional on tj being included 
in the set of m failure times. Since the failure times are assumed to be independent, the 
partial likelihood is a product of the partial likelihoods, one at each time point, 
denoted by £ ,( /? ) , which is the probability of patients Pjti ,  Pj>2, Pj,n failing at time
tj given p  and how many failed, and who were at risk of failing at time tj. This
quantity can be written as
m
L(/3) = Y l LJ(/3).
M (3.6)
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Suppose only one patient fails at each tj, denoted by i f h and let R(tj) denote the
risk set at time tj, which consists of all the patients who are at risk of failing at time tj.
The partial likelihood over all failure times, is written as
jr q\ _ TT W e x p O f r )
m  z
leRUj)
where the individuals who are at risk of failure at time tj, are indexed by /. Since the 
baseline hazards cancel out, the partial likelihood for m events can be generalized as
e*p( Vij)
j-i Z exP^>' ,,
l eR( t j )  W - O ;
U P )  = n
It is to be noted that the baseline hazard is not required for model fitting, thanks to 
elimination by conditioning. The name “partial likelihood” implies that only part of 
the data is directly used in its construction; the probabilities for subjects experiencing 
an event are considered, while those for censored subjects are taken into account only 
when summing over the risk sets at event times that occur before the subjects being 
censored, as shown in equation (3.8).
In a conventional conditional likelihood, the probability of observing all of the 
data, conditional on a single set of ancillary data, is considered. Instead, for partial 
likelihood, only part of the data is used and the conditioning is progressive, 
considering each failure time separately and conditioning on the risk set associated 
with that particular time. This simply means that we only make use of the identity of 
the patient who failed amongst all those who were at risk at any failure time, whereas 
the actual failure times are not used. Nevertheless, the partial likelihood is treated in 
the same manner as an ordinary likelihood, and the general MLE theory still applies. 
This provides an asymptotic distribution for the maximizing value of /?, and provides 
also a hypothesis testing and confidence interval framework (Cox and Hinkley, 1974).
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So far, only unique failure times have been considered, but in reality several 
patients may fail at the same time. These tied failures occur in part because survival 
times are recorded coarsely, perhaps to the nearest day. On the other hand, interval 
censored survival data (Section 1.3) arise from a slightly different formulation, 
whereby a coarse but precise representation of the data in time intervals, is given. 
Interval censored survival data often involve tied failures or ties within the failure 
time intervals. In order to incorporate these ties, the failure set at time tj (comprising 
all Oj patients who failed at that time) and the set of all groups of oj patients who might 
have failed at time tj is included. Denoting these sets by D(tj) and R(tj) respectively, in 
Cox’s method for ties, the partial likelihood can now be re-written as
n expc»7«)m
u j } ) = Y l ^ f= ------— ,
>1 x n exp(7.) ( }
GeR( t j ) veG( t j )
where G{tj) is the group of Oj patients who might have failed at time tj. Suppose 
patients Pi and P2 failed at time tj, while patient P3 is also at risk of failing. The 
likelihood considering Cox’s method for handling ties is then given by
L ( «, = ______________exp(fr)exp(72)______________
CftV exp(7/1)exp(772) + exp(^)exp(7 3) + exp(^2)exp(^3)
Cox’s method as outlined above is accurate but can be computationally slow; hence 
approximation methods have emerged as offering more viable options. In general, ties 
are dealt with by considering the event times separately, such that o subjects fail at o 
separate times. Using equation (3.9), the product is now realized over the patients who 
failed, instead of over the failure times.
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How the risk sets are defined for these separate event times is what 
distinguishes one method from another. For example, in the case of the failure time tj 
above, Breslow’s method considers two separate event times whereby Pi, P2 and P3 
are at risk, Pi failed and then P2 failed for the same risk set. The likelihood can be 
expressed as
It is to be noticed that the denominator for the Breslow’s method for handling tied 
observations is slightly different from that for the Cox’s method. The former method 
is a default in SAS which will be used in analyses performed in Chapter 6.
A common goal in clinical trials is to compare two treatment groups by 
evaluating the treatment advantage, 6 . Relating to the likelihood in equation (1.5), 
the partial likelihood can be expressed as
where Oj is the total number of failures and rjG is the total number of patients on 
treatment G at risk of / h event, G = E, C, and q is an index denoting the various 
possible values of the random variable ojE. By differentiating the logarithm of 
equation (3.10) and using equation (1.5), it can be shown that the efficient score is
where oE is the total number of failed patients on E\ a positive value of Z indicates that 
treatment E  is better than C. Upon differentiating a second time, we get
H P ) exp(?71)exp(^2)Breslow
{ ex p ^ ) + exp(*72) + e x p ^ )} 2
min( Oj,rJE)
<?=max(0 , Oj - r j C) \ ° j  4 )  V<? J
(3.10)
(3.11)
which is indeed identical to equation (1.18), the Fisher’s information as described in 
Section 1.6. The proportional hazards model, with Cox’s method for ties yields the 
logrank test as its associated score test.
As demonstrated above, the ordering or ranking of event time tj is used, but not 
its magnitude. Hence any monotonic transformation of the event times will neither
change the coefficient estimates ft nor alter the conclusion of the analysis. Since the 
baseline hazard is a nuisance parameter, it seems logical that there is not much 
information beyond the ranking information regardless of its underlying function. 
Indeed, it has been reported that for a wide range of hazard functions, Cox’s partial 
likelihood yields inferences that are asymptotically equivalent to those obtained from 
the full likelihood based on all the data (Efron, 1977).
Partial likelihood estimates still retain two standard properties of ML 
estimates: consistency and asymptotic normality. This means that in large samples, 
they are approximately unbiased and their sampling distribution is approximately 
normal. Their standard errors are, however, larger than those for estimates using the 
full likelihood; but the robustness gained from the simplification of employing the 
partial likelihood method of estimation may outweigh this shortcoming.
Although its formulation appears rather complicated, Cox’s PH regression 
model is available in many standard software packages. For example, SAS/STAT 
deploys it as PROC PHREG with a simple basic coding such as: “PROC PHREG 
DATA=DEATH; MODEL TIME*STATUS(0)=TREAT; RUN; ”. This coding will fit 
a model of data set (DEATH) with only one covariate of treatment (TREAT) and two 
variables (TIME, STATUS). The MODEL statement specifies the variables that 
define the survival time (TIME), the censoring variable (STATUS: (0, 1} where 0
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typically means censored), and the explanatory variables (TREAT). Further 
description and samples of typical output are given in Chapter 6.
The merits of the proportional hazards model and the estimation method have 
probably over-shadowed the other aspects of Cox’s regression model. Among other 
attractive features o f Cox’s regression model are: (i) facility to incorporate time- 
dependent covariates, (ii) admissibility of stratified analysis that is effective in 
controlling nuisance variables, (iii) adjustability when a subject is not at risk of an 
event, and (iv) readiness to accommodate both discrete and continuous measurement 
of event times (Allison, 2001).
All in all, Cox’s PH regression model has opened doors to many possibilities 
and thus numerous methods have built on it since its introduction. Examples of new 
extensions to the original Cox’s model include the analysis of residuals, time- 
dependent coefficients, multiple or correlated observations, multiple time scales, time- 
dependent strata, and estimation of underlying hazard functions (Therneau and 
Grambsch, 2000). One drawback of the popular Cox’s model is that the assumption of 
proportional hazards may be violated in the presence of heterogeneity which affects 
the hazard ratio (Hougaard, 2000). Wei et al. (1989) proposed the well-known Wei, 
Lin and Weissfeld (WLW) model which assumes that the marginal distributions of the 
multiple events time follow Cox’s models; this method is later described in Chapter 6.
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3.1.2. Modelling Interval-censored Survival Data
In Section 1.3, various types of interval-censored data have been described. From this 
section onwards, only the case of fixed intervals for all subjects is considered. For 
illustration purposes, interval-censored survival responses can be summarized as in 
Table 3.1. This research is developed partly on the basis of previous work by 
Whitehead and Thomas (1997), which concerns trial design for data of interval- 
censored nature.
Table 3.1: Statistics for a parallel group study with interval-censored survival
responses (Whitehead, 1997).
Treatment Experimental Control Overall
Number of events e  E e
Number of events in the interval
( 0 , t j ) °  I E °  1C O l
( t  1> t  2 ) ° 2 E ° 2 C o 2
( t  k-i> t k )
Number of patients being followed- 
up for time t
° k E <>kC Ok
11 r  I E r  1C r  I
12 r  2E r  2C
t  k r  kE r  kC ? k
In viewing Table 3.1, suppose patients who have been cured of ulcers are 
recruited into a clinical trial to compare two treatments for suppressing recurrence and 
that endoscopies are performed at defined times, t h  . . . . ,  t k. A positive result indicates 
ulcer recurrence and is considered as an event within that time interval. The exact
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times of events are not known since the events could have happened at any time 
during the interval between the last visit when the patient was determined to be 
negative for the outcome and the first visit with positive outcome.
In the trial, say e events are observed, for a total of r patients who are recruited 
over time t, randomized to experimental and control treatments giving ye and yq 
respectively. The patients are observed at fixed intervals between ti.\ and t\, i — 1 ,2 ,.., 
k, and the number of events occurred, oi in the intervals is recorded, as shown above. 
The number of patients on experimental and control treatments who are at risk during 
each interval, r,■£ and y,c respectively are recorded, and their summation gives the total 
number of patients at risk for that interval, n. Note that the number of successes, that 
is no recurrence, is given by r* -o t. If an event has occurred for the patient, the 
associated failure time is recorded, and there are no further examinations. Meanwhile, 
patients may withdraw from the study or not have had any occurrence until the end of 
the study, thus their data are censored.
Interval-censored survival data can also be considered as a series of familiar 2 
x 2 tables, one for each of the intervals (rM, ti) under study as shown in Table 3.2. It is 
to be noted that this table is similar to Table 1.2, but particular to a defined interval.
Table 3.2: A 2 x 2 contingency table for survival responses at a defined interval for
experimental and control groups.
Responses during interval t ,•) Experimental Control Total
Number of events (Failure) ° i E ° i C Oi
Number of patients survived (Success) r  iE ~  °  iE f i c  ~ o iC - o t
Total r iE ? i c f i
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The number of events that occurred during any interval , ti) is recorded as 
OiE and Oic for patients on experimental and control treatments respectively. Given that 
the total number of patients in the interval is r,-, the total number of successes is simply 
rj -  Oi, and similarly for those on experimental and control. The k distinct 2 x 2  tables 
are assumed to have a common value for treatment effect 6, measuring the advantage 
of experimental over control, regardless of the failure pattern. Hence, under the null 
where H o :0 = O, p-values are guaranteed to be valid.
The logrank test for interval-censored data is a special case of the Mantel- 
Haenszel test (Mantel, 1966) for combining 2 x 2  tables and the two are often used 
interchangeably. As already described in Section 1.6, the efficient score Z is the sum 
of Zj’s from 2 x 2  tables, Z = ^ Z . , and similarly, V = . However, the derivation
i i
of V is not quite straightforward due to the presence of nuisance parameters. Such 
parameters are not of immediate interest but need to be accounted for in analysis of 
the parameter of interest, 6. An example of the parameterization is introduced in 
Section 3.1.3 and illustrated further in Section 3.1.4.
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3.1.3. Methods Using Log -Odds ratio Transformation
A model using a logit link function expresses the log-odds of failure as a linear 
function of regression parameters. Suppose ptE and pic denote the probabilities of 
occurrence for experimental and control respectively, and that ptE can be estimated by
(° ie  I  ^  f° r the /th interval, i  = 1, 2, . . . ,  k .  Similar expressions can be derived for p,c 
accordingly. For independent Bernoulli random variables oie and otc with parameters 
PiE and pic respectively, the likelihood functions for experimental and control are 
given by
L (p iE) = PiE° 'H l - p iE)n
L(piC) = Pi^ a - p iCy c-°«. (313)
Therefore, the log likelihood functions for each component are derived as,
P ie ) = °m  log P ie + f e  “  °ii;)log (1 ~  P ie )
£(Pic) =  0iCl°g Pic  +  ( ri C - ° , c ) l°S , ( l -P ic )-  (3 14)
Based on the log-odds ratio approach, the advantage of experimental relative
to control can be expressed as 0 = -\og\Jip iE{ \ -  p iC)} / {piC{ \ -  p iE)]],  as given in
Section 1.4.1 earlier. In Table 3.2, there were two parameters concerning the 
probabilities of failures in the two groups (piE and p iC), conditional on surviving up to 
that time interval. Each of these probabilities can be re-expressed in terms of 6, but to 
complete the parameterisation, a second parameter is required. This second parameter 
could be one of the treatment-specific probabilities, or the sum of the logit 
probabilities or the baseline hazards which may be strata-specific; regardless of the 
form, it is called the nuisance parameter. In order to derive Z and V, parameterization
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of the nuisance parameter is necessary. For example, let the nuisance parameter fa for
(  „ \  f  \
all i, be expressed as fa = -  log PiE
l ~ P i E
log Pic
1 ~ P i C
For survival responses of the patients such as in Table 3.2, the efficient score 
for 0 based on log-odds ratio, Zor can be derived by the unconditional profile 
likelihood approach, giving
7 - S r r> E ° > C - riC°iE <3-15)^OR ~
/=i rt
for k intervals, and the Fisher’s information is,
v  Y ' i c W 'I - o , )  (3 J 6 >
OR Z j  3
W Ti
It is to be noted that equations (3.15) and (3.16) are similar to equations (1.17) and 
(1.18) earlier; they are displayed here as a reminder. Both equations (3.15) and (3.16) 
are used as the first method to derive Z and V respectively (Method 1). Conditioning 
of the procedure with regard to the totals of <?,• events and r,-Oi successes can be 
applied to eliminate the nuisance parameters; this is referred to as Method 2. Based on 
this conditional likelihood, the efficient score, Z is similar to equation (3.15) while the 
Fisher’s information, VoR(C) is given by (Whitehead, 1997):
v  _ S p riCriE°Ml ( 3 J 7 )
“ <C) h 1)
When events are few relative to the numbers surviving in each interval, riE/ri ~ 
nE/n = R/(R+l) where nE is the number of patients on experimental and n is the total
number of patients in the study. Similarly, n d n  ~ nc/n = l/(/?+l). Therefore, the
amount of information can be approximated by Re/(R+1) , where e is the total number 
of events observed. In the case of equal treatment allocation, R =1, V * e/4 as
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mentioned in Section 1.7 earlier. However, this approximation is unreliable if the 
number of events is large relative to the number of survivors.
In the case of the logrank test, only the relative ordering of survival time is 
used instead of the actual times, thus no assumption is required for the individual 
survival distribution. In general, when 6 is small for large sample sizes, Z is normally 
distributed with mean 6V  and variance V and the maximum likelihood of 6 can be 
approximated by 6  = Z I V .
The logit model above presumes that events can occur only at discrete points 
in time. For most applications, however, ties occur because event times are measured 
coarsely at defined intervals. Aside from the implausibility of the logit model for such 
data, the model suffers from a lack of invariance to the length of the time interval. For 
example, switching from person-months to person-years changes the model in a 
fundamental way, so that coefficients are not directly comparable across intervals of 
different length (Allison, 2001). An alternative model is complementary log-log link 
which is described next.
3.1.4. Methods Using Complementary Log-Log Transformation
A model using a complementary log-log (cloglog) link function expresses the log
negative log survival probability, -  log(- log as a linear function of regression
parameters. Like the logit function, the complementary log-log function takes a
quantity that varies between 0 and 1 and associates it with a quantity that varies
between minus and plus infinity. Unlike the logit function, however, the
complementary log-log function is asymmetrical. For example, after taking the logit
transformation, a change in probability from 0.25 to 0.50 is the same as one from 0.50
to 0.75 {0 = 1.10). On the complementary log-log scale, however, the difference
between probabilities of 0.25 and 0.50 {6 = 0.88) is larger than the difference between
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0.50 and 0.75 {6 -  0.69). This difference has an important practical implication in 
situations where the magnitudes being compared matter too, not just the difference 
between them.
From Section 1.6, treatment advantage can be expressed in terms of survival 
functions: 0 = -log{ -logS £(r)} + l°g{- l°g^c(0}• F°r interval-censored survival data 
(illustrated in Table 3.2), equation (1.16) can be written as
for all i, and therefore, the log hazard ratio is
- l o g !  s e (o + log - l o g !
■ScOm )M h J .
Alternatively, it can also be expressed in terms of ptE and p iE, the probability of 
occurrence within interval (r„ U.\), for subjects on E  and C respectively. The 
probability of occurrence for patients on the experimental during the interval (?/, f/.j), 
pEi is given by the number failed at u conditional on surviving at tiA\ p iE = [1- 
(5fi(f,-)/5£Ui.i)}] and similarly for the control group. Upon re-parameterization by these 
probabilities,
e = —log {—iog(i -  plc)}+ log {-iog(i -  pic)} (3-18)
^ = -  log {-log(l -  P,£)} -  log {- log(l -  p,c)}, (3-19)
for all i. From equations (3.18) and (3.19), the probability of occurrence for 
experimental can be given by piE = l - e x p [ - e x p { - | ( $  + 0)}] and similarly for
control, ptc = l- e x p [ -e x p { ~ j ($  -# ) } ] •  Under the null, 0 = 0 and the maximum
likelihood estimate, , of $  is given when ^ ( ^ 0) —0, hence giving
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exP (~ v )  = “ 'ogO “  ~ ) = %■2 r
(3.20)
From equation (3.14), the full log likelihood in terms of fa and 0, can now be 
expressed as,
i{fa,0) = oiE\og 
+oiC log
(3.21)
l-e x p (-e x p (- (^ —^))) - ( r ic- o lc)ex p ( - ( ^ y ^ ) ) .
Differentiating equation (3.21) with respect to 0 and fa respectively, we get 
l e -  G + H  and i . - G - H , where
exp ( - ( ^ - ^ ) )  exp(- e x p ( - (^ -^ ) ) )
G =  1... ^  ^ ..^...■?, +  -0|g)exp(-(
fa+0
1 -  e x p (-e x p (-(^ -^ ) ))
)),
and H - ° iC
exp( (^  2 ))exp( exp( (^  ^ *)))]
2 1 exp( exp( (^' )))
(Jkl3cl exp(- (^ ) ) .  
2 2
Under the null, 0 = 0, and taking iA fa) = 0, we get exp(-^-) = -lo g (l--^ -) = qrn r;
Substituting this expression back in to ^ ,  the efficient score can be obtained from
w 0),
± q t , , (3.22)
ZcL = L j \ riE0i c - ric°iEb
Upon taking the second derivatives, the Fisher’s information can be given by 
y  = and without conditioning on the margins, we get
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VcL^ s l S n p K +\
i 4 o,
-q-ir. - o .M e  -Qic)n 
4o.2
+
, [ rl ( ° lE - ° IC) - ° , ( ri F . - r, c ) ]4 o,
(3.23)
The unconditional Z and V given by equations (3.22) and (3.23) respectively, form 
Method 3. Similarly under the null hypothesis, but conditional on the margins, and
t(¥ ==t t d = K ~L,  where K =  q‘ ^  °l\ iE and L  = ^  ^  0i\ iC,
4oj 4 ot
4KL  ^ q?{r ,-o ,)r iEr,c (3-24)
C U C )  Z s K  +  L  2 j  0jJ.
The conditional expressions for Z and V are given by equations (3.22) and (3.24) 
respectively, form Method 4. Under the null hypothesis that failures are independent 
of treatment (Ho: 6 = 0), then conditional on Oi = the random variable oiE follows 
the hypergeometric distribution. This leads to an alternative expression for V, with a 
slight difference in the denominator,
v  (3'25)
V CL ( H )  2 a  /  i \i 0 t(rt - 1)
Both equations (3.22) and (3.25) respectively are conditional expressions for Z and V, 
here called Method 5. All these five methods are summarized and compared in the 
next section.
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3.1.5. Summary of Methods
It is apparent that the statistics derived from the complementary log-log approach 
(cloglog link) are in the form of a multiplier to those derived from the log-odds ratio 
approach (logit link). On comparing equations (3.15) to (3.22) for Z, and equations 
(3.17) to (3.25) for V, it appears that Z Cl  = (qin/o^ZoR, while V Cl  = (qin/oi)2V0 R- 
Notice that from equation (3.22), when the <?; are small relative to r„ then qt ~ Oi/rt. 
Substituting this approximation into equation (3.22) gives the same expression as in 
equation (3.15). Similarly, equation (3.25) is reduced to the form as in equation (3.17). 
This situation occurs only when there are few events in each interval, implying that in 
the case of finer intervals, the method of cloglog is approximately the same as that of 
log-odds ratio. However, when the intervals are coarse, the former method is more 
appropriate.
The resulting expressions for Z and V, as derived by the various methods 
described are summarized in Table 3.3. Methods 1 and 2 use the familiar likelihood 
function to derive both statistics based on the log-odds ratio, with the latter method 
taking the conditional likelihood approach resulting in r2{r -1) in the denominator for 
V. Since these two link functions often provide similar fits, the choice may depend 
upon whether inference should be in terms of odds ratios or discrete hazards ratios 
(TenHave, 1996) and should be based primarily on ease of interpretation (McCullagh, 
1980). For survival data, an inference based on the hazards ratios is an obvious choice.
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As explained earlier, Methods 3 to 5 take advantage of a more appropriate 
complementary log-log approach, which should be better suited for the case of 
interval-censored survival data. The statistics Z and V can be calculated for any single 
interval using equations in Table 3.3, while for k intervals, Z  = Z\ + Zi + ...+ Zk, and 
similarly V = V\ + V2 + ...+ V*. The applications of both logit and cloglog link using 

















































3.2. Application to Bone Marrow Transplant Data
In this section, the methods listed in Table 3.3 are applied to data from a trial reported 
by Storb et al. (1986) concerning leukaemia patients. The patients were randomized 
between immunosuppression with cyclosporine (control) or with cyclosporine and 
methotrexate (experimental): abbreviated as CSP and CSP + MTX respectively. At 
the beginning of recruitment, 17 and 24 patients were randomized to experimental and 
control treatments respectively. The aim of the trial was to investigate whether the 
addition of methotrexate would reduce the incidence of acute graft-versus-host- 
disease (GVHD) upon the bone marrow transplantation. The survival times of patients 
on CSP and CSP + MTX in days are listed below, where an asterisk indicates a 
censored observation.
CSP: 1*, 9, 9, 10, 11*, 13, 14, 18*, 19, 20, 21, 21, 21, 23, 24, 25, 29,
30, 33, 34, 34, 62,218*, 251*.
CSP + MTX: 7*, 10, 12, 15*, 21, 21*, 24, 25, 26*, 34, 69*, 89*, 167*, 201*,
205*, 237*, 257*.
The survival times are then split into three intervals with cut-off points at 
weeks 2, 3 and 4. The summary of occurrence of the acute GVHD during the defined 
intervals following transplantation is displayed in Table 3.4. As an example, interval 
(2, 3] indicates the third week after transplantation.
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Table 3.4: Summary of outcomes for bone marrow transplant trial (Storb et al, 1986), 
used as illustration of interval-censored survival data.




Success (r ,•-<?,•) 15 19 34
No. at risk (r ,) when t = 0 17 24 41
Failure (o ,)
Interval (2, 3] 
1 5 6
Success (r, - o ,  ) 13 12 25




Success (r ,• - o  ,•) 10 8 18
No. at risk (r ,•) when t -  3 12 11 23
During the first two weeks of observation for the experimental group, 2 had 
suffered acute GVHD (failure) while 1 died without suffering from acute GVHD, 
hence recorded as success along with 14 others who were still alive and free from 
acute GVHD. Notice that the number of patients on the experimental treatment 
remaining at risk during the third week was only 14, out of which one patient suffered 
from acute GVHD and another died without suffering acute GVHD. After a fourth 
week of follow-up, 1 of the remaining 12 patients (at risk) had died without suffering 
from acute GVHD, 2 had suffered from acute GVHD and 9 were still alive and free 
from the acute disease. Similar details can be read off from Table 3.4 for patients on 
the control treatment. Applying each of the five methods described above, Z, and Vj 
for each interval are calculated and the resultant sums of Z and V  are displayed in 
Table 3.5.
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Table 3.5: Summary of the cumulative score statistic, Z and information, V, using the 
five methods numbered 1 to 5 (Table 3.3).
Method Z V Z 2/V z N v p-value 0  = Z / V
1 3.22 3.58 2.895 1.701 0.089 0.899
2 3.22 3.70 2.801 1.674 0.094 0.870
3 3.58 4.44 2.882 1.698 0.090 0.806
4 3.58 4.42 2.896 1.702 0.089 0.810
5 3.58 4.56 2.802 1.674 0.094 0.784
As anticipated, the multiplier effect of qrlo being introduced by the
complementary log-log approach (Methods 3 to 5) yields higher values of Z compared 
to those based on the log-odds ratio (Methods 1 and 2). Comparing the values of V, 
the largest amount of information is given by Method 5, in which a hypergeometric 
distribution is assumed. Under the null hypothesis of no treatment effect, Z IV follows 
the chi-squared distribution on 1 degree of freedom. The 2 sided p-values are shown 
in Table 3.5, indicating positive outcomes for this exploratory trial where a 
significance level of 10% level (two-sided) was being sought. On comparing Methods 
2 and 5 which are both based on conditional likelihood, their p-values, and logrank 
test statistics are almost the same. Assuming d\ = 62  — @3 = 0, then the treatment 
advantage can be estimated by Q = Z / V .  It is observed that Method 5 gives the 
smallest estimate of treatment advantage compared to other methods. Nevertheless, 
this investigation gives a good indication as to the applicability of all five methods 
which are to be further compared on a bigger scale in Section 3.4.
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3.3. Power Specification of a Clinical Trial
With reference to Section 1.7 earlier, equation (1.19) can be applied in this study 
design. It is to be noted that in this chapter, r is used to denote sample size which is 
the same as the number at risk of an event at time 0. From equation (3.16) based on 
the logit link, Fisher’s information, V = rErco(r~o)/r3. In cases of equal sample size on 
each treatment arm, t e - v c -  r/2 and olr = p, where p  is the average probability of 
occurrence; therefore
y  _ °(r ~ 0) _ P<\~P)r (3.26)
Ar A
Using equation (3.24) based on the complementary log-log link, V = q2(r -  c^rgrdor, 
and with similar treatment allocation,
q 2( r - o ) r  {—log(l -  p )}2 (1 -  p)r (3.27)
Ao Ap
For the calculation of sample size, equation (1.19) can be used to find V, and then 
equation (3.27) to convert to r, the required sample size, given by
4V p /^{- \og (l-p )}2 p) . Both approaches can be used to calculate the required
sample size, but only the one based on the complementary log-log link is used in this 
design.
In this study, the determination of the sample size is based on commonly used 
error probabilities for clinical trials. The probability of type I error, a is chosen as 
0.025 (one-sided) and the probability of type II error, is targeted at 0.10, hence the 
power of the test (1 - fi) is 0.90. The probability of an event occurring under the 
control treatment, p c is fixed at 0.60, while its experimental counterpart, pE under the 
alternative is varied from 0.35 to 0.55 in 0.05 increments. Based on the
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complementary log-log approach, the reference improvement is given by 
0R — —l°g{—log(l — p£.)} + log{—log(l — pc)}. Taking the individual probabilities for control
and experimental groups, an average probability of occurrence is estimated by p  -  ( p c  
+ pe)I2 and the required sample size r is calculated as displayed in Table 3.6.
Table 3.6: Sample sizes, r, determined from the power calculation approach, for each
of the five methods.
Method P c P e P 0 R y* r
1 0.600 0.350 0.475 0.755 18.45 162
2 0.600 0.400 0.500 0.584 30.78 256
3 0.600 0.450 0.525 0.427 57.64 460
4 0.600 0.500 0.550 0.279 134.93 1036
5 0.600 0.550 0.575 0.138 555.18 4104
As anticipated, a bigger sample size r is needed to show significant results 
when the treatment advantage, Or  is smaller. The values in the above table are used in 
the simulation study described next.
3.4. Simulation and Results
To investigate the accuracy of the values derived in Table 3.5, a simulation study is
conducted to verify the type I error rate and the power of the test to detect treatment
advantage at the 2.5% (one-sided) significance level. The data sets of specified sample
sizes (Table 3.6) are generated from a binary distribution and randomized to control
and experimental groups based on equal treatment allocation. Under the null
hypothesis of no treatment effect, the same failure probabilities are applied for both
treatment groups, that is p c  = P e , while those values shown in Table 3.6 ( p E <  p c ) are
used for the case under the alternative hypothesis. A scenario of half the treatment
advantage is also simulated to evaluate the resulting effect on the power of the test.
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Investigation begins with data for the individual fixed sample sizes for the 
targeted power to detect the desired significance level and simulated under both the 
null and alternative hypotheses. For each data set, simulations of 20,000 replicates are 
conducted to verify the type I error and the power of the test, with results shown in 
Table 3.7 below. All methods are applied to the same data sets for their comparison 
purposes. Under the null, the average p-value (denoted by p_vo) should be very close 
to 0.5 as the mean for a distribution ~ U (0, 1) equals Vi, while the proportion of p- 
value < 0.025 (denoted by indo) is the type I error. Under the alternative hypothesis, 
the proportion of p-value < 0.025 (denoted by ind\) illustrates the power of the test: 
the degree of certainty that the treatment difference, 6, if present will be detected.
Table 3.7: Results for the average p-value and type I error using each of the five 
methods, simulated under the null for each sample size r.
r 0 Results Method 1 Method 2 Method 3 Method 4 Method 5
p_v o 0.499 0.499 0.499 0.499 0.499
162 0
indo 0.023 0.023 0.023 0.023 0.023
P -v 0 0.500 0.500 0.500 0.500 0.500
256 0
indo 0.026 0.026 0.026 0.026 0.026
P -v 0 0.500 0.500 0.500 0.500 0.500460 0
indo 0.025 0.025 0.025 0.025 0.025
P -v 0 0.501 0.501 0.501 0.501 0.501
1036 0
indo 0.029 0.029 0.029 0.029 0.029
p _ v 0 0.501 0.501 0.501 0.501 0.501
4104 0
indo 0.026 0.026 0.026 0.026 0.026
N.B. Text in bold highlights an out of limit situation.
As illustrated in Table 3.7, under the null hypothesis, type I error rates are 
found to be within the 95% probability interval of (0.022, 0.028), except for those of 
sample size 1036 when they slightly exceed the upper limit (0.029 in bold). Note that
the normal approximation of 0.025 in reality is not perfectly exact. All five methods 
give exactly the same average for p-values as well as for type I error rates at three 
decimal points significance. However, further checking reveals that not all the values 
of Z and V were identical; coincidentally the proportion of p-values < 0.025 happened 
to be exactly the same to 3 decimal places.
Table 3.8: Results for the average p-value and power using each of the five methods, 
simulated under the alternative for each sample size r.
r e = e R Results Method 1 Method 2 Method 3 Method 4 Method 5
p_v i 0.012 0.012 0.012 0.012 0.012
162 0.755
ind! 0.896 0.896 0.896 0.896 0.896
p_v i 0.011 0.011 0.011 0.011 0.011
256 0.584
ind ] 0.901 0.901 0.901 0.901 0.901
p_v i 0.011 0.011 0.011 0.011 0.011
460 0.427
ind i 0.899 0.895 0.905 0. 899 0.895
P-v l 0.010 0.010 0.010 0.010 0.0101036 0.279
ind i 0.902 0.902 0.902 0.902 0.902
p_v i 0.011 0.011 0.011 0.011 0.011
4104 0.138
ind j 0.900 0.900 0.900 0.900 0.900
N.B. Texts in bold highlight different values observed.
Under the alternative, where 6 = O r  (Table 3.8) for all sample sizes p-values < 
0.025 lie within the 95% probability interval of (0.894, 0.906) based on the power 
target of 0.90 specified for the complementary-log-log approach. Apparently, the 
probability intervals seem to be applicable also to the log-odds ratio counterpart 
(Methods 1 and 2). All approximation methods give the same values except for those 
highlighted in bold text, where Method 3 yields slightly higher power than Methods 1 
and 4, then followed by Methods 2 and 5. In the case of observing only half of the 
treatment advantage, the results are shown in Table 3.9.
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Table 3.9: Results for the average p-value and power using each of the five methods 
simulated under the alternative (half the treatment advantage), for each sample size, r .
r 0 = Vi0R Results Method 1 Method 2 Method 3 Method 4 Method 5
P -v 0.5 0.121 0.121 0.120 0.121 0.121162 0.377
ind Q^5 0.381 0.381 0.381 0.381 0.381
P-V 0.5 0.126 0.127 0.126 0.126 0.127256 0.292
ind 0.5 0.368 0.368 0.368 0.368 0.368
P-V 0.5 0.110 0.111 0.110 0.110 0.111460 0.214
ind 0 .5 0.421 0.419 0.423 0.421 0.419
P-V 0.5 0.123 0.124 0.123 0.123 0.1241036 0.14
ind 0.5 0.361 0.361 0.361 0.361 0.361
P-V 0.5 0.084 0.084 0.084 0.084 0.0844104 0.069
ind 0.5 0.494 0.494 0.494 0.494 0.494
N.B. Texts in bold highlight different values observed.
The results of all approximation methods achieve exactly the same power 
values, except for the case of the sample size 460 where values were slightly lower 
than those of Method 3. Halving the treatment advantage appears to reduce the power 
of the test to as low as 36% ( r  = 1036). While earlier results a t  0  =  0  and 6  = O r  failed 
to show any differences among the methods, however at 0  =  V i O r , it now appears that 
Method 1 always yields exactly the same result as for Method 4, and likewise for 
Methods 2 and 5. While Table 3.7 and Table 3.8 earlier show that all methods gave 
the same p-values, Table 3.9 reveals that the p-values actually do vary. Despite the 
fact of these methods being mathematically different, they tend to generate identical 
results for average p-value and type I error rate or the power of the test.
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3.5. Discussion
In conclusion, the simulation results have shown no appreciable difference between 
the approximation methods, despite small differences observed using real data sets 
earlier. All five methods have achieved the intended type I error rates under the null 
hypothesis, and yielded accurate powers under the alternative. The efficient score 
using the complementary log-log approach shows a multiplier of magnitude (qr/o) of 
that derived on the basis of the log-odds ratio. The Fisher’s information using the 
former approach has a multiplier of (qr/o)2 compared to that using the latter.
Essentially, interval-censoring can be regarded as a case of missing data. 
Independent or random censoring relates to the mechanism of missing completely at 
random (MCAR), while the most common assumption of non-informative censoring 
corresponds to missing at random (MAR). Meanwhile informative censoring is due to 
the non-ignorable mechanism of missingness. Coarsening at random (Heitjan and 
Rubin, 1991) is another topic that is closely related to interval censoring. 
Consequently, the imposed stratification allows different proportional hazards within 
intervals, thus making interval-censored data less rigid than the continuous data.
At present, methods of estimation for interval-censored data are readily 
available to handle cases where data are independent (Section 1.3). However, methods 
for correlated interval-censored data are not well developed. Statistical methods for 
the analysis of covariate effects on interval-censored discrete survival data are needed 
since these data frequently arise in clinical trials and other biomedical studies 
involving periodic monitoring of patients for multiple outcomes. This comparison of 
methods in the derivation of Z and V sets the foundation for further work in the 
estimation of the correlation between two score statistics for interval-censored 
survival data using the complementary log-log approach (Method 5).
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Chapter 4. The Correlation between Two Score Statistics
The main objectives of this chapter are to derive an estimator for the correlation 
between two score statistics arising from interval-censored survival data in the 
absence of covariates, and illustrate its applications to real data. The theories 
described in the earlier chapters which form the building blocks of this study, are now 
put together in this core chapter.
To begin with, a description of bivariate survival data relating to correlated 
outcomes is given in Section 4.1. A global test approach is applied to interval- 
censored survival data in Section 4.2. In Chapter 3, the efficient score and Fisher’s 
information were derived on the basis of the complementary log-log link and were 
then applied to binary data. An adaptation to interval-censored data is now provided in 
Section 4.3, with a procedure for the derivation of an estimator for the covariance 
between two score statistics, which consequently gives an estimator for the 
correlation. A description of common bivariate survival data then follows.
The estimation of an overall treatment effect is provided in Section 4.4. The 
proposed method is then applied in Section 4.5 to non-recurrent real data sets from 
various clinical trials. Recurrent events are next described based on some key model 
components, followed by an application of the proposed method to a recurrent real 
data set, in Section 4.6. An overall discussion is given in Section 4.7.
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4.1. Bivariate Survival Data
Clinical trials are often conducted to compare two or more treatment groups with 
regard to their efficacy. Efficacy, for the purpose of this comparison, is often 
measured by more than one patient response, thus leading to multivariate data. 
Existing univariate methods can be employed for assessing each variable 
characteristic, but often an overall objective measure to quantify the efficacy is still 
required. As described in Chapter 2, global tests are becoming the methods of choice 
in stroke studies, to detect differences between groups when multiple endpoints are 
concerned. Bivariate survival data involves two endpoints which cannot be assumed to 
be independent, and one of the main interests in the analysis of bivariate survival data 
is the measure of dependence or association of these two variables. The complexity of 
studies concerning such correlated times-to-event which may involve multiple 
endpoints on the same subject, requires methods to take into account the correlation 
between multiple endpoints. For such data, the correlation between two score statistics 
can be used to obtain an overall treatment efficacy, which is central to this study.
Outcomes are regarded as correlated if one occurrence is dependent on the 
others. An example of such correlated occurrences is provided by time to 
cytomegalovirus (CMV) shedding in blood and time to CMV shedding in urine 
observed in an AIDS clinical trial on HIV-infected individuals. Similarly, time to 
disease progression (a pathological condition characterized by identifiable symptoms) 
and time to death for a cancer patient are also correlated. Another situation is present 
when the event times of several individuals are somehow related; for example 
lifespans of twins, or married couples who are exposed to the same household 
conditions. Correlated outcomes also arise from similar organs of a person, such as 
blindness in left and right eyes or failure of both the left and right kidneys of a chronic
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diabetic patient, cartilage loss of left and right knees or failure of both the left and 
right hip joint replacements for an osteoarthritis patient. Another common type of 
correlated outcome is recurrence, for example, event times of the first and second 
asthma exacerbations, or of tumour recurrences of a bladder cancer patient.
In dealing with correlated survival outcomes in cross-over trials, fixed effects 
models can be applied by fitting Cox’s proportional hazards regression model 
stratified by subject. However, in parallel group trials where patients are randomized 
to experimental and control treatments, as considered in this study, these methods fail. 
To overcome this difficulty, recourse can be made to one of two methods, namely 
marginal and frailty modelling. Marginal modelling involves fitting data to Cox’s 
regression model without any assumption of correlation, and then adjusting the 
estimated variance of the coefficients. This type of model, which relates to our 
approach, is later described in Section 6.1.1. A frailty model is a random effects model 
for event time data where subject effects are modelled as random variables; a good 
description is given by Hougaard (2000).
4.2. Adaptation of the Global Test to Interval-censored Survival Data
In Chapter 2, global test methodology was demonstrated in the context of multiple 
binary endpoints involving stroke data. In this section, the methodology is applied to 
bivariate interval-censored survival data. An instance of univariate interval-censored 
survival data was illustrated in Section 3.1.2 earlier, with consideration of multiple 
intervals. Referring to the 2 x 2 tables given in that section (Table 3.1 and Table 3.2), 
similarly the measure of treatment advantage given by the log hazard ratio, 
6 = -\og{hE{t)lhc(t)} is assumed to be constant over all times t. This method of
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combining the 2 x 2  tables for univariate interval-censored survival data is now 
extended to the bivariate case, invoking the proportional hazards assumption.
This study considers three types of real bivariate survival data. The first type 
involves failure of similar physically related parts or paired organs: for example, 
right/left hip of an individual. The second concerns time to related events or 
indicators: for example, time to disease progression and time to death of a patient. The 
third involves recurrent events, where the same event can happen several times for an 
individual: for example, tumour recurrences. The first two types do not involve 
distinct ordering and hence are simpler than the third. These cases are termed paired, 
general and recurrent events respectively. Complete (uncensored) bivariate data are 
also examined for comparison purposes. Further descriptions of these data types and 
their classification are given in the subsequent sections, within the context of 
correlation between two score statistics.
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4.2.1. Bivariate Interval-censored Survival Data
Suppose now that there are two endpoints of interest, giving two failure times, say T\ 
and 72, with each patient’s two outcomes recorded for each of a series of prespecified 
time intervals. To describe this scenario fully, the following notation is necessary, 
where
r\i = no. of patients at risk of event 1 at the end of interval i, 
ou = no. of patients who had event 1 at the end of interval i, 
r2j = no. of patients at risk of event 2 at the end of interval /, and 
02j = no. of patients who had event 2 at the end of interval j.
The combined outcomes relating to any pair of intervals t,•) and (/}.], tj) can be
presented in Table 4.1. Note that this table is similar to Table 3.2, except that the 
counts of outcomes are now for combined variables. The abbreviations, FF and SF 
respectively refer to the number of patients who failed for both events and those 
succeeded for event 1 but failed for event 2. A similar convention applies for FS and 
SS. In reality, most survival data naturally involve censoring. Say the event times, T\ 
and 72 are subject to their own censoring with variables Ci and C2 accordingly. The 
consequences of such a censoring mechanism may result in patients missing T\, or T2 
or even both, and this can be summarized in Table 4.1, where M  denotes the censored 
or missing outcome.
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Table 4.1: A 2 x 2 contingency table of censored bivariate data for patients on control
for each time interval.
For control occurence in (t - b  U)
TotalFailure Success Missing
t 2 Failure FF SF MF ° 2 j C
occurence in Success FS SS MS r  2 j C - ° 2 jC
(tj.i, t j) Missing FM SM MM m  2/C
Total °  \ iC r  \ i C - °  1/C m  1 iC ?
The question mark at the bottom right comer of Table 4.1 is intentionally inserted to 
emphasize that the total number of patients at risk of event 1, event 2and of both, may 
no longer be the same when survival data are censored. Focussing only on the failures 
and successes in the paired (if) intervals, further notation follows:
0 (i2),(y) = no. of patients who had event 1 during interval i and also had
event 2 during interval j,
r0 2 )Uj) = no- Patents at risk of event 1 at the end of interval i and
also at risk of event 2 at the end of interval j,
°(i*) (y) = n0‘ Patients w^° had event 1 during interval i and also at
risk of event 2 (but did not have event 2) during interval j, and
° ( . 2 )  a j )  =  n o - Patients who had event 2 during interval j  and also at
risk of event 1 (but did not have event 1) during interval i.
From Table 4.1 (for control), the number of patients who had both events 
°(i2) me  is given by FF and the number at risk for both events, r{X2) iij)C is given by the
sum of FF, FS, SF and SS. Within the same risk set, o(l.Wj)C = FF + FS, and o(m2)(ij)C =
FF + SF. When the events are related, the marginal contribution of individual event 1 
during interval i, and event 2 during interval j, and the combined contribution of both
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events from the paired ij intervals are required to derive the correlation between two 
score statistics.
4.3. The Correlation between Two Score Statistics
Correlation is a measure of association estimated by the correlation coefficient, often 
itself abbreviated to ‘correlation’, and this terminology is used throughout this thesis. 
As with all types of data, techniques are required for analyses performed on correlated 
survival data. Such a technique is not as simple as those established over the past few 
decades for continuous and binary data. Our proposed method offers a straightforward 
account of such correlation. This section describes the theories and procedures 
involved in deriving various estimators of the parameters of interest; namely the 
covariance and the correlation between two score statistics, Z\ and Z2.
The proposed method is a marginal modelling, an approach where the effect of 
explanatory variables is estimated on the basis of the marginal distributions. In 
survival applications, the related events are usually assumed to be independent or to 
have some other imposed structure and existing models are often fitted to Cox’s 
model described in Section 3.1.1. The subsequent section demonstrates our direct 
approach to the estimation of the covariance and correlation between two score 
statistics.
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4.3.1. Derivation of Estimators for Covariance and Correlation
Assuming independent events for bivariate interval-censored survival data, the values 
of Z and V  can be obtained for each event by using Method 5 (Table 3.5). As 
described in Section 2.2, the covariance between two score statistics is denoted by 
cov(ZM, Zv), where u, v = 1, 2 now denote two survival endpoints. The covariance 
between the score statistic with respect to event 1 during interval i and the score 
statistic with respect to event 2 during interval j, is given by cov(Zi,-, Zij) = E{Zu Z2;) -  
E (Z u)E(Z2j). Upon substituting the expressions for Z as per equation (3.22), we get
where the covariances between the numbers of failures for event 1, and those for event 
2, on experimental and control, are each conditioned on the total numbers of events, 
ou and 02j respectively. Such conditioning on the margins for bivariate data is based 
on the familiar construction of a 2 x 2 table depicted in Table 4.1 earlier. For bivariate 
survival data, the covariance between the total numbers of failures for event 1, and 
event 2, respectively for the subjects on control is given by the covariance between 
individual failures summed over their risk sets:
(4.1)
•tic




where XligC -  ] if event 1 occurred in ith interval to gth patient on C,
0 otherwise,
SUgC = 1 if gth patient on C is at risk of event 1 in z'th interval,
0 otherwise,
and ruc = no. of patients on C who are at risk of event 1 in ith interval.
A similar convention is applicable for patients in the experimental group and 
also for event 2, as denoted by the subscripts E  and 2 respectively. The individual 
outcome is a random variable Xngc, which follows a Bernoulli distribution with 
parameter pwc, that is the probability of a patient in the control group for whom event
1 had occurred in the Ith interval. XUgC ~ Bem(puc) , and therefore, E(XUgc) = puc,
while E{XljhC) = p2jC accordingly. Note that cov(XUgC,X2JhC) =0 if g ^  h, for different
individuals. Otherwise, for the same patient for whom both event 1 and event 2 had 
occurred,
co v(XlisC,X 2jlC) = E(XUgCX 2ilC) - E ( X Utcm X 2ilC), (4.3)
where
(XUgCX 2JgC)= 1 if the gth patient on Chas experienced both event 1 and event 2,
0 otherwise.
Similar to the case where the gth patient on C only experienced either event 1 
or event 2, the random variable XugcXygc also follows a Bernoulli distribution with 
parameter pnaj)c, which is the probability that for the gth patient on C both event 1 and
event 2 had occurred. (XligCX2jgC) ~ Bem{pm)C), and thus the expected value is 
E(X X ) = p The covariance of the outcomes for both events for the same
^  l igC  2 j g C '  * 12C ’
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individual on control can be approximated by cov(Xugc,X2jgc) = pamc - p ucpljc and
similarly on experimental, c o = PI2W£ ~ pIi£p2/, . From equations (4.2) and 
(4.3), the covariance is given by
COV( ° \ i C ’ °2 jC  I °1 i ’ ° 2 j )  =  r\2Jij)c(P\2Aij)C ~ P \ i c P 2 j c ) ’ (4-4)
for sample sizes of rue, , rye, and, rnypc for control and similarly for experimental, as 
already defined. Under the null hypothesis, the probabilities of occurrences of both
events on C and E  are equal: Pmij)C -  PnmE ~ Pn,(U) > where pXUij) is the estimated 
average probability of occurrence of both events during ith and / h intervals. Similarly 
for the probabilities of occurrence of individual events, puc = pUE ~ pu, and
Pijc ~ Pije ~ Pij where pu and p 2J are the estimated average probabilities of occurrence
of event 1 during the iih interval and event 2 during / h interval respectively. 
Substituting these estimates into equations (4.4) and (4.1) consecutively, the 
covariance between the two score statistics is estimated by
CO V(Z,.,Z2y) = ~  { ( r U E r 2 j E r (l2 ) ,U j)C  +  r \ iC r 2 j C r ( \ 2 ) X i j ) E ^ P { \ 2 U i j )  ~  A< •),«/) A*2),((/) 1
° U ° 2 j  (45)
Further, the probability of occurrence of both events can be approximated by 
the proportion of the number of occurrences from the number at risk:
h n m =% m lrmuD' and similarly for individual events, P0.)i(U) = riUUj) and
pw m - o w m !r(mij). Plugging these estimates into equation (4.5), the covariance
estimator, denoted by Cn(ij) is written as
The covariance between two score statistics can be directly calculated from the 
observed events and the numbers at risk for individual i and j  intervals as well as the 
paired ij intervals. Equation (4.6) is of the utmost importance in this research. 
Conditioning on the successive risk sets, the covariance estimator between two score 
statistics, Cn  is obtained by the summation of the covariances from each pair of 
intervals, denoted by Cnaj) as in equation (4.6). In the case of interval-censored data, 
the covariance of each pair of intervals is summed to give the total covariance:
^ 1 2  = 'Yj'YjCmij) •
/ = i  j - \
It can be shown that for very large samples n —> 00, Vi —> var(Zi), V2 —► 
var(Z2), and the estimate C12 —*• cov(Zi, Z2). In this study, our prime interest is in the 
estimator for cov(Zi, Z2), which subsequently gives us the estimator for the correlation 
between the two score statistics. Fundamentally, the correlation between the two score 
statistics is given by the division of their covariance by the square root of the product 
of their variances. As in Section 1.4, the variance of Z can be approximated by 
Fisher’s information V; hence the correlation is expressed as
/? = cov(Zj,Z2) / (4-7)
Therefore, the correlation p  between these two score statistics, can be estimated by
p = cl2/Jvy2. (4.8)
In equation (4.6), the covariance formulation comprises two distinct parts. The
first concerns marginal variables of qu Oi and r,, while the second involves the
combined or paired intervals with subscripts 12. As the number of marginal failures,
Ob approaches very small values relative to the number at risk, ru the quantity q f= -log
(1 -Oi/ri) « Oi/ri. Consequently, the marginal failures cancel out, leaving only the
combined failures and the various risk sets. This implies that with heavy censoring,
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the contribution of the marginal failures diminishes and the estimator relies largely on 
the risk sets and the combined failures.
To illustrate the techniques developed, three real bivariate survival data sets 
are showcased in Sections 4.5.1, 4.5.2 and 4.6.2. First, a description of unordered 
(non-recurrent) events is presented in the context of randomized clinical trials.
4.3.2. Paired Organs
The human anatomy includes many paired parts or organs and such pairs are 
inevitably associated to some extent. The case of paired organs concerns two event 
times for the same individual, and thus only one censoring variable applies, if 
censoring is by death. Consider a study of times to failure of non-simultaneous joint 
replacement of the left and right hips of an osteoarthritis patient. Suppose T\ is the 
time to failure of the left hip, and T2 is the time to failure of the right hip. Figure 4.1 
shows the possible scenarios for the paired case on a total time scale, where Cl to C3 
represent possible censoring scenarios.
Figure 4.1: Various censorings for the paired case, an example for T\ and T2 of left










For scenario Cl, the patient is censored for both events and t\ = t2 = c 1, while 
for C2, where t\ < c2 < t2, the left hip failure occurred at t\ but the right hip was 
censored at t2 = c2. Meanwhile, in scenario C3, both events occurred when censoring 
time exceeds both Tx and T2: t\ < h < c3 as shown above. An example of a study
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involving the survival of paired organs is provided by a case of non-simultaneous 
bilateral hip fractures, which reportedly occur, on average, five years apart from each 
other (Gaumetou, Zilber and Hemigou, 2011). For a hip fracture, an artificial hip joint 
replacement is the common treatment, and the time from hip replacement to its failure 
in each case, is also of interest. An example of such a study is illustrated in Section
4.5.1. In general, five of the major paired organs often studied are the breasts, lungs, 
kidneys, testes and ovaries (Roychoudhuri, Putcha and Moller, 2006). The importance 
of paired organ analysis justifies its inclusion as a case to be examined in this thesis.
4.3.3. Generally Related Events or Indicators
In clinical trials, often there are different measurements or indicators used to assess 
the effect of treatment on patients. For example, a cancer patient may be assessed on 
time to disease progression, T\, or time to death itself, 7?. In this thesis, such a case is 
termed generally as having related events or indicators. Another common case 
involves time to a certain event (for example death) for subjects who are related, such 
as twins or married couples or co-workers, who have been exposed to a similar 
environment. Say T\ is the lifetime of person 1 and T2 is the lifetime of person 2. In a 
study of the lifetimes of married couples, a clear choice for the assignment of 7j and 
T2 is often determined by gender. However, in the case of twins, T\ may be artificially 
assigned to the elder sibling and T2 to the younger; the choice can also be based on 
other factors deemed more appropriate. The basis for selection has its importance in 
the comparison of analyses and thus should be explicitly described by researchers.
Such cases therefore involve independent censoring variables; say C\ and C2 
which give different numbers for the subjects at risk of individual failures, as well as 
for those at risk of both failures: rxc + ric + m e,  for control treatment. Similar
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expressions are applicable to the experimental group. An example of this general 
censoring for the first failure for interval-censored data is depicted in Figure 4.2 where 
X  and C indicate the occurrence of an event and a censoring respectively.







thFor each subject at each i interval, there are four possible outcomes as 
indicated by the numbers on the left. As shown above, for outcome 1, the patient 
failed during interval 1, outcome 2: survived interval 1 and failed during interval 2, 
outcome 3: censored during interval 1, and outcome 4: survived interval 1 and was 
censored during interval 2. Note that only subjects with outcomes 1, 2, and 4 are 
considered to be at risk during interval 1 since subjects with outcome 3 have been 
censored before completing the 1st interval. The above diagram only shows outcomes 
for event 1 relating to T\, and for each of these outcomes, its corresponding outcome 
for event 2 relating to T2 can also take any of the four possibilities. Note that for the 1st 
interval, outcomes 2 and 4 are considered as successes. There are, in all, nine possible 
outcomes which contain both outcomes relating to 7j and T2 at any i interval of 7j, 






T i (ith interval)
98
4.3.4. Progression-Free Survival
In recent years, progression-free survival (PFS) has been increasingly accepted as the 
surrogate endpoint for overall survival (OS) in oncology trials. OS is defined as the 
time from randomization until death from any cause, while PFS refers to the time 
from randomization until tumour progression (TTP) or death from any cause, 
whichever occurs first. TTP considers the time from initial therapy to first evidence of 
tumour progression (either objective radiographic documentation or clinical 
deterioration). For more precise definitions of PFS and TTP, the reader is referred to 
the guidelines for criteria such as RECIST (Therasse et al., 2000, and Eisenhauer et 
al., 2009) for solid tumours.
An example of a PFS study is available in Lim et al. (2011) where the primary 
objective was the assessment of the PFS rate after 12 weeks of treatment with 
Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients. 
Secondary objectives included further evaluation of PFS, time to treatment failure 
(TTF) and overall survival time. PFS was defined as the time from the first study 
medication to the first observation of radiologically confirmed disease progression, 
symptomatic deterioration leading to discontinuation of the study treatment (unless 
imaging confirmed absence of progressive disease), or death due to any cause.
Increasing interest in PFS analysis is evident from the number of papers 
published within the past decade. A search in the Web o f Science for “progression- 
free survival” in the title shows that between years 1990 and 2000 only 13 of 20 
articles published were in the subject area of Oncology. As of late March 2011, a 
similar search between years 2001-2011 reveals a dramatic ten-fold increase with 128 
of 188 articles published in Oncology. The prominence of PFS analysis justifies its 
consideration in this research study.
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4.4. Estimation of an Overall Treatment Effect
As mentioned in Chapter 2, a key question in a clinical trial involving multiple 
endpoints concerns the magnitude of the overall treatment advantage. Suppose the 
parameter of interest corresponding to treatment is the log hazard ratio denoted by 6. 
Under the null hypothesis that the two treatment groups have identical survival 
experience, the experimental has zero treatment effect and the proportional hazards 
assumption is true. There exists a common treatment advantage, 6X=00 = 6 and under 
Hq. 6 — 0\  hence p-values are always valid. However, under the alternative, H\\ 
0l =02 = 0 , but 0 * 0 .  The logrank test is efficient in detecting such a proportional 
hazards alternative. When the assumption of equal treatment effect is met, the 
complex multivariate problem of analyzing the multiple endpoints is simplified to the 
univariate problem of comparing the common effect across the treatments. Even if the 
equality assumption is not met, the power should be good if the spread of 6 is 
reasonably small.
The estimated common treatment advantage is given by 6 -  wx0x + w202
where w is some weighting with subscripts 1 and 2 for the 1st and 2nd events 
respectively, and wj + W2 = 1. Two ways can be employed to estimate a common 
treatment advantage; the simplest being to take the ratio of the global score statistic to
its variance: 6* = Z * IV * . As for its marginal counterparts, the variance of 6 * is 
simply given by 1/V*. From the expressions for Z* and V* in Section 2.1.1, Z* = 
Z+V+/var(Z+) and V* = V+2/var(Z+). The effect of var(Z+) which contains the 
covariance cancels out, leaving only the ratio of a sum of Zs to a sum of Vis, and hence 





Notice that the weighting in equation (4.9) is a direct form of the proportion of the 
variances and is ideal for independent endpoints.
Alternatively, when endpoints are not independent, it is possible to derive an 
optimal weighting (Wei and Johnson, 1985), which yields the smallest variance out of
all weighted averages of 0, and 02. From the common formulation: 0  — wx0x + w202,
the variance is given by
w i2 , w i  , 2W|W2C|var(<9) = — + -J -  + 12v, v2 vyt
where Vx = var(Z,), V2 = var(Z2)and C12 =cov(Zp Z2) as described in Section 4.3.1. Let
the variance of 0  be a function of w\:
« w.2 (1-w.)2 Iw ^l-w ^C y
f(w l) = v ar0 = - ^  + ------ 1— + 1 1 '■vv* 1  2
Upon simple differentiation with respect to wi, and setting its derivative to zero, the 
optimal weighting is given by
( w „ w 2) y,-c,12 V2 - C I2V , + V 2 - 2 C12 V, + V 2 — 2C,12 J
A
Using the weighting in equation (4.10), the variance of 0  is given by
(4.10)
VV2 - C l2
var(0)  =  — ------------------------------------------------------
V1V2(Vl +V2 - 2 C 12) (4.11)
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This variance is the ratio of unity minus the square covariance to the sum of 
variance-covariance. It is to be noticed that equation (4.9) is identical to equation 
(4.10) when the covariance is zero. For comparison purposes, both standard and
optimal estimates of the overall treatment advantage, 6 * and 0 respectively, are 
reported in the data analyses performed in the subsequent sections. It is to be recalled 
from equation (1.16) that 0 = -log{-logS'£(O} + log{-Tog1S'c(f)} and a positive value 
indicates superiority of treatment E over treatment C. In this thesis, 9 - - f i  where /? 
is the coefficient of the regression, given by the S AS PROC PHREG procedure, when 
E  is given a bigger coding integer than C. For example, treatment E is coded as 1, 
while C is coded as 0, as is commonly practiced. An example is shown later in 
Chapter 6.
4.5. Application to Real Data: Non-recurrent Events
The proposed method is illustrated by application to two data sets from previous 
clinical trials: hip revision and cancer. Prior to any processing, each raw data set is 
examined using the existing standard survival analysis tools which are described in the 
next section. Upon gaining more knowledge about the data set itself, the actual 
procedure of the proposed method is carried out. The bivariate survival endpoints are 
first categorized into multiple intervals; as if they were interval-censored data and the 
marginal estimates of the treatment effect can be obtained from the expression 6 ~ 
Z/V. The covariance is then obtained directly from the two survival endpoints, say T\ 
and T2, using equation (4.6) as derived in Section 4.3.1. The following analyses have 
been conducted using specially written SAS programs. The programs were written 
primarily to enable calculation of Z, V, C]2 and consequently the correlation estimate
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p  . For application to the real data, the significance test level is arbitrarily set at 2.5% 
(one-sided) for convenience.
The selection of specific cut-off points to define the time intervals is aspect 
important in ensuring minimal loss of information while achieving a reasonable 
covariance estimate, Cn. Coarse intervals may result in loss of information, and 
overestimation of the treatment effect, as <9 = Z IV  . Finer intervals may contain more 
information, but may lead to less reliable parameter estimation if the number of 
failures in each interval is too small. How do we strike the right balance? In this study, 
the interval setting is based on equal distribution of failures for each event type. To 
determine an appropriate number of intervals for analysing survival data using our 
method, an exploration is undertaken in the subsequent sections. In the meantime, for 
the purpose of illustration, a convenient choice of intervals is made for each data set. 
A step-by-step explanation is given for the first data set, while others are described 
more concisely. A complete set of SAS codes for the analysis of real data, using the 
proposed method, is given in Appendix A.
4.5.1. Paired Organs: Hip Replacement Revision
A hip replacement data set from Young Patient study, which is currently on-going at 
the Centre for Hip Surgery, Wrightington Hospital, is used to illustrate the method for 
paired organs. The data have been collected over 40 years from patients who have had 
revision of artificial hip joints, known as Charnley low-friction arthroplasty, LFA 
(Wroblewski and Siney, 1992). As with a natural hip, the artificial joint is subject to 
wear and tear; hence requires a revision. Revision is defined as exchange or removal 
of one or both components consisting of a plastic cup and a metal stem.
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In this analysis, only 342 bilateral patients who had revisions on both hips are 
considered. Since the data were not taken from a randomized trial, the factor of 
interest will be taken to be the positioning of the cup in relation to the acetabulum: a 
“socket” formed by the cavity in the pelvic bone. We consider treatment 1 for when it 
is located in the acetabulum (Medial) and treatment 2 for when the cup is located 
either on the rim of the acetabulum (Rim) or when a part of the cup is not supported 
by the bone (Uncovered). There should be no treatment difference in this setting as the 
two “treatments” are generally considered to be equivalent. A schematic diagram 
showing the basic components of Chamley’s LFA, namely the stem, ball and cup, is 
given in Figure 4.3.
Figure 4.3: A schematic diagram o f the basic components o f Chamley’s LFA.
Cup
BaH
^  : 
Stem
The hip data contain the following variables: ID = patient's identification, Hip 
= hip number (1 = 1st hip, 2 = 2nd hip), Opdate = time of the hip replacement surgery 
for Hip 1 or 2, Revdate = time of the hip revision, or last follow-up time if the hip 
revision does not occur, Status = event status (1 = revision, 0 = censored) and Cup 
positions (1 = Medial, 2= Rim/Uncovered) are taken as treatments. It is noted that the
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hips were not revised simultaneously and the ordering is by time of hip revision: the 
time to revision of the first hip is considered as T \ ,  while that of the other hip is T 2 .
Prior to further preparation, the raw data were first examined for survival 
functions, median survival times, hazard functions and censoring proportion by using 
the PROC LIFETEST procedure and fitting to Cox’s model, via the PROC PHREG 
procedure. The Kaplan-Meier plots of survival distributions for T \  and T 2 are given in 
Figure 4. 4, and Figure 4.5 respectively.
Figure 4.4: Survival distribution for time to left hip revision, T \  in years, stratified by
the cup position (cup_pos).
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Both Figures 4.4 and 4.5 show that the survival distribution functions for T \  
and T 2 respectively, do not differ between the cup positions, as anticipated. It is to be 
noted that there seems to be a slight separation for T 2 during the interval 15 to 25 
years, and a few patients with cup position 1 had longer censoring times compared to 
those with cup position 2. Further examination is undertaken to quantify the actual 
effect of cup positioning on the survival of the bilateral hips replacement, taking cup 
positions 1 and 2 respectively as treatment groups C and E ,  hereafter.
Stratifying by the treatment group for individual event, the median survival 
times, mGm and estimated mean survival times, iuGm are obtained from the former 
procedure, G  =  E ,  C  and m =  1, 2. By definition, half of the patients have event times 
longer than the median. Assuming an exponential distribution, the hazard function of 
patients on C for event 1, X C \ = ( l o g  2)/mCi and similarly for those on E .  In this case, 
the median survival for patients on C  is 35 years, and hence the hazard function is 
0.00005/day. Alternatively, or when a median does not exist (due to heavy censoring),
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such as for the case of hip patients on E  in Figure 4.4, the estimate of the mean can be 
used to find the hazard function where Xex = 1//u e \-
In SAS, the mean is a summation of the product of the Kaplan-Meier estimate 
of the survivor function at the event time u and the time gap since the previous event. 
However, the mean is underestimated when the largest observed time is censored and 
the estimation is restricted to the largest event time. For event 1 of the hip data, the 
estimate of the mean survival on E is 24 years with a standard error of 0.6 and hence 
the hazard function is 0.00011/day. Meanwhile, for event 2, /ua = 29 (0.8) and fiEi -  
25 (0.5) years, and their corresponding hazard functions are 0.00009/day and 
0.00011/day respectively. These hazards are indeed very small, which is common for 
such a low risk event as that of hip replacement failure. A summary of the censoring 
proportions stratified by event type (hip) is presented in Table 4.2.
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Table 4.2: Summary for hip replacement revision data of 342 bilateral patients,
stratified by hip (left and right).
Stratum Observations Events Censored (Percent)
1 342 80 262 (77%)
2 342 64 278 (81%)
Total 684 144 540 (79%)
As shown in Table 4.2, a large proportion of the observations are censored 
(about 80%). A detailed description is now provided for the proposed method. First, 
an equal distribution of failures for each event is obtained by ranking each failure time 
and dividing equally into k intervals. For simplicity, k = 2 is chosen in this detailed 
illustration. This is achieved by using the PROC UNIVARIATE procedure specifying 
the percentile points (50 and 100 for k = 2) for each T\ and T2. For the hip data, 
coincidentally the cut-off points are at 15 and 35 years for both T\ and T2. Therefore, 
the two intervals of equal failures are fixed at (0, 15] and (15, 35] for each T\ and T2 
accordingly. Next, the failures and successes are counted for each pair of intervals, 
which can be presented by multiple 2 x 2  tables, similar to Table 4.1. The summary of 
failures and number at risk for individual events and paired intervals is given in Table 
4.3.
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Table 4.3: Count of failures and numbers at risk for both patients on E and C for each 
pair of intervals ij relating to both T\ and 7?, and those relating to individual i and j  
intervals, for the hip replacement revision data.
Double failure (No. at risk):
° ( \ 2 ) ,  (ij ) ( r  (12),( i j ) )
T i
(0, 15] (15, 35]










T  i (0, 15] (15, 35] t 2 (0, 15] (15, 35]
0  ME 20 16 ° 2 j E 13 12
°  1 iC 21 23 ° 2 j C 20 19
o u 41 39 ° 2 j 33 31
r  ME 122 16 r 2jE 120 12
r  1 iC 141 26 r 2jC 138 22
? M 263 42 r 2j 258 34
Q m 0.169 2.639 q  2j 0.137 2.428
The top part of Table 4.3 contains the components of combined events, with 
double failure and number at risk for that specific pair of intervals. For example, in the 
control group, 2 patients had event 1 failure within the first 15 years, and had event 2 
failure within the following 20 years. The other 20 patients in the control group, who 
were also at risk of failure for the same pair of intervals, did not fail. The lower part of 
the table lists the marginal failures and numbers at risk for the individual events. For 
the control group, during the 1st interval (0, 15], only 21 patients failed out of 141 
patients who were at risk of event 1 during this interval. At the rightmost column, 19 
of 22 patients at risk of event 2 during the 2nd interval (15, 35], had failed. The values 
of q- given by - log(l -ojri) for each event and interval are also computed accordingly.
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Putting the required values from Table 4.3 above into equation (4.6), the 
estimate of covariance between Zu  and Z2j  is directly computed for each pair of 
intervals, while Z and V  are calculated for each event. The results are summarized in 
Table 4.4.
Table 4.4: Calculated values for covariance, score statistic, and Fisher’s information 
for the hip replacement revision data, using k = 2 intervals.
c  12(ij)
T  i
Z v V y
(0, 15] (15, 35]
T 2
(0, 15] 3.624 -0.398 2.513 8.229
(15, 35] -0.369 2.977 -2.819 4.563
Z u -1.066 -3.248 Z i = 2 7 i i  -4.315
V u 10.211 5.436 V x = Y y u 15.647
Z  2 =  £ Z  2j  
-0.306
v2 = i v 2j
12.792
C  \2 = Y £  12(ij)
5.834
The covariances for each pair of ij intervals are listed in Table 4.4: for 
example, the covariance for incidence of event 1 within the first 15 months and that of 
event 2 within the next 20 months is -0.369. Summing up the covariances for each of 
the four pairs of intervals, gives us the estimated covariance, Cn  at the bottom right 
comer, 5.834. The score statistics, Z\  and Z2 as well as the Fisher’s information V\ and 
V2 are also determined from the sum for each interval as shown above. Using equation 
(4.8), the correlation can be estimated accordingly. For the hip revision data analyzed 
using two intervals, the estimated correlation, p  = 0.412. This example demonstrates 
the capability of the proposed method to provide an estimator for the correlation 
between two score statistics, arising from interval-censored survival data. The
estimates of treatment advantages, 6 * and 6 are also obtained via the methods 
described in Section 4.4, but only the p-values relating to the optimal 6 are reported
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in this thesis. The same procedure is repeated using five and ten intervals by 
specifying the percentile points accordingly. The results for analyses using Ti and Ti 
intervals of two, five and ten are summarized in Table 4.5.
Table 4.5: Results for the hip replacement revision data, using different number of
intervals (k = 2, 5 and 10).
Parameter (s.e.) @ 2 intervals @ 5 intervals @10 intervals
Zi -4.31 -3.12 -2.70
Z 2 -0.31 0.91 2.23
z * -3.28 -1.63 -0.35
Vi 15.65 18.77 18.94
v 2 12.79 14.75 15.52
y* 20.17 24.74 25.30
-0.2758 (0.2528) -0.1662(0.2308) -0.0969 (0.2298)
4 -0.0239 (0.2796) 0.0617 (0.2603) 0.2625 (0.2538)
O * -0.1625 (0.2227) -0.0659 (0.2010) 0.0618(0.1988)
e -0.1713 (0.2225) -0.0734 (0.2008) 0.0492(0.1987)
p-value 0.779 0.448 0.544
C n 5.834 5.948 6.235
P 0.412 0.357 0.364
All the estimates of treatment effect are small relative to their standard errors, 
indicating zero treatment effect. As anticipated, the result clearly shows a lack of 
overall treatment effect and the p-values are in agreement for all three different 
numbers of intervals used. The sums of the score statistics derived from this interval- 
censored data set of 10 intervals are closest to the logrank statistics and their 
corresponding Fisher’s information, as shown in parentheses; Zj = -2.70 (-0.31), Z2 = 
2.23 (3.25), V\ = 18.94 (19.08) and V2 = 15.52 (15.16). The logrank test statistics, 
given by z H v ,  from the standard analysis for the 1st and 2nd events, are 0.94 and 0.32 
respectively, while their corresponding values using our method for 10 intervals are
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0.38 and 0.40. The values for the standard analysis are obtained via PROC LIFETEST 
in SAS for illustration purposes. The information V and covariance are quite 
consistent for all of the three different intervals used, giving the correlation p  = 0.4. 
At this juncture, the choice of k = 10 intervals seems to be favourable since it gives the 
smallest standard error of estimates, the largest information and the closest values of Z 
and V when compared to the logrank. Nevertheless, the subsequent investigations 
continue with 2, 5 and 10 intervals until sufficient evidence is obtained to determine 
the best choice of k.
It is to be noted that the hip data are not 'parallel' in that the patients were 
recruited sequentially, over a period of 27 years (1963 - 1990) and moreover, primary 
bilateral prostheses may not be implanted on the same day. For example, a patient had 
the first hip replaced in 1978 and the second hip replaced in 1988, yielding a time-gap 
of 10 years. Such an effect of non-parallel data may reduce the correlation between 
two endpoints. However, such an extreme situation (time-gap equal to or greater than 
10 years) accounts only for less than 10% of the hip patients and hence the effect may 
be minimal.
Another feature of the data which may impact in terms of the treatment 
comparison is that the patients may undergo different procedures with regard to the 
cup position (treatment group). For the hip data, 78 of 342 patients (23%) had both 
treatment types, the majority of which were from those with wider time-gap between 
replacements. The presence of these patients with both treatment types implies that the 
data are not ideal for the implementation of the method. Nevertheless, for illustration 
purposes, the treatment type for the first hip was considered for both hips of the same
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patient. Alternatively and more appropriately, these 78 patients should either be 
omitted or a more elaborate analysis should be performed on them.
4.5.2. Related Indicators and PFS: Cancer Data
To illustrate the proposed method for the cases of related indicators and PFS, a data 
set from a cancer study in a pharmaceutical company is used. Unfortunately, no 
further detail is available for disclosure. The trial consists of 330 patients each with 
two endpoints recorded, T \  and T 2 , relating to disease progression and death 
respectively. Plots of survival distribution functions for these endpoints are given in 
Figure 4.6 and Figure 4.7.
Figure 4.6: Survival distribution function for time to disease progression, T \  in days, 
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Figure 4.7: Survival distribution function for time to death, T 2 in days, for the cancer
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Figure 4.6 shows a steep slope for T \ ,  and the median survival times for 
patients on C  and E  respectively are 169 and 170 days. These translate into similar 
hazard functions, Xc\ = Xe\ = 0.0041/day, which are rather common for an aggressive 
type of cancer. Meanwhile, Figure 4.7 depicts a gradual decline in the survival 
function for the second endpoint, the median survival times being rnci = 653 and mE2= 
751 days, and their corresponding hazard functions 0.0011/day and 0.0009/day 
respectively. Neither figure suggests that the survival distribution functions differ 
between the treatment groups, there being a few crossings at certain time points.
There exist two possible ways of analyzing data consisting of time to tumour 
progression (TTP) and time to death (overall survival, OS). One is to consider a death 
occurring before progression as censoring the progression time: a case of related 
indicators. Another adopts the approach of PFS whereby a death occurring before 
progression will be taken to be a progression event. This implies that PFS = minimum 
(TTP, OS) which requires some data preparation as illustrated in Table 4.6.
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Table 4.6: Example of data sets for related indicators and PFS. (* indicates censoring)




1 110 200 110 200
2 630* 630 630 630
3 50* 145 145 145
4 210* 150* 210* 210*
With reference to Table 4.6, Patient 1 had a progression (TTP) at day 110, and 
subsequently died at day 200, both indicators and PFS analyses using the same event 
times as shown above. When Patient 2 died at day 630 before progression, an analysis 
for related indicators considers censoring for TTP at the same time. However, PFS 
analysis will consider an event for both PFS and OS at day 630. In the case of Patient 
3, censoring for TTP occurred at day 50, before death at day 145. The data remain the 
same for indicators analysis, but PFS considers an event for both PFS and OS at day 
145. For Patient 4, when both TTP and OS are censored, a PFS analysis takes the later 
censoring to be applicable for both PFS and OS, in this case at day 210. In both 
analyses of indicators and PFS, event 2 is taken as death (OS), while the former and 
the latter consider TTP and PFS respectively as event 1. The impact of such event 
dependence imposed by PFS analysis on the cancer data is reflected Table 4.7.







1 330 261 69 (21%) 312 18 (5%)
2 330 271 59 (18%) 271 59 (18%)
Total 660 532 128 (19%) 583 77 (12%)
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Table 4.7 shows that for event 1, the censoring percentage is reduced from 
21% to 5% as an event of death (OS) before progression is taken to be an event of 
progression or death (PFS), too, when considering a PFS analysis. Technically these 
two types of analysis are expected to yield different results as presented in Table 4.8.
Table 4.8: Results for the cancer data using 2, 5 and 10 intervals based on the analysis
of related indicators.
Parameter (s.e.) @ 2 intervals 
(Indicators)




Z i -0.30 -0.91 1.51
Z 2 8.11 11.80 10.96
z * 5.70 7.60 8.84
Vi 55.95 63.69 65.09
^2 47.66 62.42 66.21
y  * 75.52 88.02 93.13
0* -0.0053 (0.1337) -0.0143 (0.1253) 0.0232 (0.1239)
4 0.1702(0.1448) 0.1890(0.1266) 0.1655 (0.1229)
6  * 0.0755 (0.1151) 0.0863 (0.1066) 0.0949 (0.1036)
e 0.0713(0.1150) 0.0855 (0.1066) 0.0954 (0.1036)
p-value 0.268 0.211 0.179
C 12 19.267 27.294 26.905
P 0.373 0.433 0.410
From the analysis of the indicators data it is seen that all the estimates of 
treatment effect for progression, 0, are smaller than those for death, §2. The estimates
of treatment effect are small relative to their standard errors, with p-values indicating 
no significance for all choices of intervals. The estimates of covariance between the 
score statistics are very close (except for 2 intervals), and the correlation estimates are 
0.4 (moderate) for all interval settings. The values of Z and V for the cases of 5 and 10 
intervals are consistently larger than those for the 2 intervals case. The Z and V for 10 
intervals case are the closest to those obtained from the standard logrank test shown in
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parentheses: Zj = 1.51 (1.45), Z2 = 10.96 (9.02), Vi = 65.09 (64.16) and V2 = 66.21 
(67.56). This finding, that values from the proposed method matched closely those 
from the logrank test, is consistent with that for the hip data in Section 4.5.1.
Table 4.9: Results for the cancer data using 2, 5 and 10 intervals based on PFS.
Parameter (s.e.) @ 2 intervals 
(PFS)
@ 5 intervals 
(PFS)
@ 10 intervals 
(PFS)
Z i 4.28 15.14 13.24
Z 2 8.11 11.80 10.96
z * 8.13 17.61 15.92
Vi 50.19 69.04 74.54
V 2 47.66 62.42 66.21
y* 64.19 85.95 92.62
0.0853 (0.1412) 0.2193 (0.1204) 0.1776 (0.1158)
4 0.1702 (0.1448) 0.1890(0.1266) 0.1655 (0.1229)
e  * 0.1267(0.1248) 0.2049(0.1079) 0.1719(0.1039)
3 0.1255 (0.1248) 0.2058 (0.1078) 0.1723 (0.1038)
p-value 0.157 0.028 0.049
C 12 25.650 34.802 36.574
P 0.524 0.530 0.521
For PFS, a small estimate of 6X is obtained when using 2 intervals with a p-
value larger than when using 5 and 10 intervals. Nevertheless, analyses using all the 
interval setttings yield p-values indicating no significant evidence (at the 2.5% level) 
to reject the null hypothesis. Moderate correlations of 0.5 are obtained in all three 
scenarios (k = 2, 5, 10). A bigger V\ compared to V2 across all settings of intervals 
suggests that there is more information relating to event 1, due to the imposed event 2, 
as described earlier. The value of V\ when using 10 intervals is closest to that given by 
the standard logrank analysis as shown in parentheses: Vi = 74.54 (76.71). However, 
Zi from the 2 intervals case, 4.28 is closest to the logrank statistic, 6.99.
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4.6. Recurrent Events
Recurrent events data arise in many diverse fields: numerous examples from 
medicine, manufacturing and the social sciences are given by Nelson (2003). The 
methodology for survival analysis of recurrent events has been applied in biostatistics 
(Genser & Wemecke, 2005), marketing (Bijwaard et al., 2006), sports (Gutierrez et 
al., 2011) and even in political science (Box-Steffensmeier & Zorn, 2002). 
Consequently, interest in recurrent events has grown over the recent decades. A quick 
scan on the Web of Science (search by recurrent in the title) shows more than 13,000 
articles from 2001 until March 2011, which is equivalent to the number of articles for 
the prior two decades. More interesting is the rapid growth in the subject area of 
Oncology, where in the past decade, over 2,000 articles have been published, double 
the number in the 90s. Oncology has also overtaken Surgery as the subject area with 
the most publications on recurrent events in the past decade. This could be driven by 
the overwhelming public health concerns regarding the widespread increase of cancer 
around the globe.
There are a few special features distinguishing recurrent events data from the 
rest. Firstly, the events are ordered within each individual: the second event can only 
occur after the first event. Censoring applies only to the last observed time for each 
individual and if the first observation is censored, then the second observation is 
completely missing. An individual is at risk for one event at any particular time, since 
these events occur in sequence. Naturally, event times for the same individual are 
correlated; hence the study of within-subject correlation is of interest. Methods depend 
on the choice of risk intervals, baseline hazards and techniques used to allow for the 
subject effect, as described in the next section.
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Among the methods for recurrent events are those by Cook & Lawless (1997) 
and Wei, Lin & Weissfeld (1989). Counting process models provide a powerful 
framework for the analysis of such event history data when subjects are under 
continuous observation (Anderson et al., 1993). Random effects models (Abulibdeh, 
Turnbull and Clark, 1990) and marginal models (Ng and Cook, 1999) are also 
convenient for adoption in such a setting. Numerous examples exist in other settings 
when the events of interest are detected only by periodic intensive examination: 
interval-censored recurrent events. For example, in urology, different types of 
recurrent superficial bladder cancer tumours may be detected via periodic 
examination, and in studies of osteoporosis, different types of skeletal changes may be 
of interest and detectable only by periodic radiographic examination. Prior to 
describing such data structure in detail, it is important to review the key components 
that make up the models for recurrent events.
4.6.1. Key Model Components
In a study, the choice of model is highly dependent upon the questions to be answered. 
Some of the common questions for recurrent data are as follows. How can the 
influence of a factor such as treatment be measured? What is the treatment effect for 
each event? What is the average effect over all events? How can all of the data be 
used to test for the effect of a factor? How to allow for subject effect? Systematic 
identification as to how the models differ might assist in understanding and hence, 
assist in achieving an appropriate model selection. Kelly & Lim (2000) developed key 
components for a Cox-based recurrent events model. The components concerning the 
risk intervals, baseline hazards and allowance for within-subject correlation are first 
described here and are referred to again in later sections.
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Risk intervals define when a subject is at risk of the mth event for a given time 
T = tm. There are three types of risk intervals namely total time, gap time, and 
counting process. Total time is measured from a specified time, for example the time 
from the subject’s entry into the study or the time from randomization. Gap time 
concerns the time to an event since the prior event. The term ‘total time’ is applicable 
to any form of survival data, while gap time and counting process are specific to 
recurrent events. However, the counting process is not covered in this thesis. The 
reader can be referred to texts such as Themeau & Grambsch (2000). To describe the 
total time and gap time risk intervals, consider a hypothetical example of patients A, B 
and C, each with recorded recurrences or last follow-up times at the months as shown 
below. Figure 4.8 to Figure 4.10 are taken from Kelly & Lim (2000) for the purpose 
of illustration.
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Patient A has two recurrences at months 2 and 5, before being censored at 
month 13, while patient B has three recurrences at months 7, 11 and 17. However, 










depict the two different risk intervals for this scenario, where the numbers on the left 
hand side indicate the recurrences.







A total time model considers each recurrence from the beginning of the study 
or randomization, therefore an mth event time is always greater than or equal to the 
( m - l ) th event time, as shown above. By definition, it involves cumulative time to 
event, which is completely different from gap time. It is to be noted that the total time 
approach is also applicable to non-recurrent events such as those for paired organs and 
related indicator data, since the ordering of events is not actually used. The recurrence 
time can also be measured as gap time, as is described next.
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Figure 4.10: Gap time risk intervals for the scenario depicted in Figure 4.8.
r  t  ■
0 5 10 15 20
Time
Gap time is defined as the time since the previous event; for example, patient 
A has a gap time of 3 months for the 2nd recurrence. In terms of the total time 
convention used earlier, patient A has a total time of 5 months for the 2nd recurrence 
as measured from the time of randomization. For gap time, the time scale is no longer 
time-since-randomization because the clock restarts after each occurrence, as depicted 
in Figure 4.10. Therefore, for gap time, it is possible for T2 to be smaller than 7j, 
whereas T2>T\ for total time.
For interval-censored recurrent events, there are only six ways of combining 
outcomes of which the subjects are considered at risk of the 1st event during the z'th 
interval: FF, FS, FM, SS, SF, and SM (as shown in Table 4.1). When a subject is 
censored for the 1st recurrence, then the 2nd recurrence is no longer possible. 
Therefore, there are in that case, only four combined outcomes possible for T2: FF, 
FS, SS, and SF. This means a substantial loss of information about T2 especially if 
there is a large proportion of censored T1.
Depending on data preparation, both total time and gap time can be fitted by
the same algorithm; the choice of model should answer the question of interest. For
example, total time is the logical choice if the interest is in modelling the full time
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course of the recurrent events, such as evaluating whether treatment is effective for the 
m event since the start of treatment. Meanwhile, the gap time model is appropriate 
when the goal of the analysis is to determine whether treatment is effective for the mth 
event since the time of the prior event. An example is to be found in assessing whether 
treatment is effective in delaying the first infection (say, after a surgery) but not for 
subsequent recurrences.
Another key component of a recurrent events model is baseline hazards which 
relate to stratification of data. As briefly decribed in Section 1.6 earlier, stratification 
implies that patients in each stratum have a different baseline hazard function, but all 
other explanatory variables satisfy the proportional hazards assumption within each 
stratum. A common baseline hazard is assumed if no stratification is applied to the 
data modelling. In the case of recurrent events, when data are stratified by event type, 
for example when the 1st recurrence is in stratum 1 and the 2nd recurrence is in stratum 
2, the baseline hazards are event-specific. In other words, each stratum is fitted by a 
model separately, thus giving a marginal estimate of the parameter of interest. Further 
description and examples of such models are given in Section 6.1.1.
The last key component concerns the subject effect which is an intrinsic factor. 
Apart from the observed explanatory variables and factors that influence the outcomes 
for a subject with regard to treatment given, naturally there also exist random chances 
as well as unobserved characteristics of a subject. When there are repeated 
observations from a subject, such as recurrent events, the unobserved characteristics 
of the subject may be taken into account. Allowance for subject effect which 
represents such characteristics can be achieved by using a marginal model (as with the 
approach taken here), frailty model or copula. The first is described in Section 6.1.1 
while the other two are out of scope.
123
4.6.2. Application to Bladder Cancer Data
To illustrate the analysis of a recurrent events case, a bladder cancer data set based on 
a study conducted by the Veterans Administration Cooperative Urological Research 
Group, is used. The full data set is listed in Wei, Lin, and Weissfeld (1989). The study 
comprises 86 patients with superficial bladder tumours, which were removed 
transurethrally when the patients entered the study; 48 were randomized into the 
placebo group (control), and 38 were randomized into the thiotepa group 
(experimental). The majority of patients experienced multiple recurrences of tumours 
during the study, and new tumours were removed at each visit.
The original data set contains the first four recurrences of the tumour for each 
patient, and each recurrence time was measured from the patient's entry time into the 
study. However, our analysis setting is limited to the first and second recurrences, 
with only one covariate, that is the treatment group. The bladder cancer data consist of 
the following variables: ID = patient ID; Trt = treatment group (1 = placebo and 2 = 
thiotepa); T\ = time to first recurrence; T2 = time to second recurrence (total time); T2G 
= time to second recurrence (gap time); censl is the censoring indicator for T\ (1 = 
event and 0 = censored) and similarly, cens2 for that of T2. The bladder data as used in 
this study are presented in Table 4.10.
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Table 4.10: Tumour recurrence data extracted from Wei, Lin & Weissfeld (1989), 
presented in total time (T\, T2) and gap time (Tig).
ID Tit T, censl T2 T2g cens2 ID Trt T, censl T2 T2g cens2
1 1 0 0 0 0 0 44 1 3 1 15 12 1
2 1 1 0 1 0 0 45 1 59 0 59 0 0
3 1 4 0 4 0 0 46 1 2 1 15 13 1
4 1 7 0 7 0 0 47 1 5 1 14 9 1
5 1 10 0 10 0 0 48 1 2 1 8 6 1
6 1 6 1 10 4 0 49 2 1 0 1 0 0
7 1 14 0 14 0 0 50 2 1 0 1 0 0
8 1 18 0 18 0 0 51 2 5 1 5 0 0
9 1 5 1 18 13 0 52 2 9 0 9 0 0
10 1 12 1 16 4 1 53 2 10 0 10 0 0
11 1 23 23 0 0 54 2 13 0 13 0 0
12 1 10 1 15 5 1 55 2 3 1 14 11 0
13 1 3 1 16 13 1 56 2 1 1 3 2 1
14 1 3 1 9 6 1 57 2 18 0 18 0 0
15 1 7 1 10 3 1 58 2 17 1 18 1 0
16 1 3 1 15 12 1 59 2 2 1 19 17 0
17 1 26 26 0 0 60 2 17 1 19 2 1
18 1 1 1 26 25 0 61 2 22 0 22 0 0
19 1 2 1 26 24 1 62 2 25 0 25 0 0
20 1 25 1 28 3 0 63 2 25 0 25 0 0
21 1 29 0 29 0 0 64 2 25 0 25 0 0
22 1 29 0 29 0 0 65 2 6 1 12 6 1
23 1 29 0 29 0 0 66 2 6 1 27 21 0
24 1 28 1 30 2 1 67 2 2 1 29 27 0
25 1 2 1 17 15 1 68 2 26 1 35 9 1
26 1 3 1 6 3 1 69 2 38 0 38 0 0
27 1 12 1 15 3 1 70 2 22 1 23 1 1
28 1 32 0 32 0 0 71 2 4 1 16 12 1
29 1 34 0 34 0 0 72 2 24 1 26 2 1
30 1 36 0 36 0 0 73 2 41 0 41 0 0
31 1 29 1 36 7 0 74 2 41 0 41 0 0
32 1 37 0 37 0 0 75 2 1 1 27 26 1
33 1 9 1 17 8 1 76 2 44 0 44 0 0
34 1 16 1 19 3 1 77 2 2 1 20 18 1
35 1 41 41 0 0 78 2 45 0 45 0 0
36 1 3 1 43 40 0 79 2 2 1 46 44 0
37 1 6 1 43 37 0 80 2 46 0 46 0 0
38 1 3 1 6 3 1 81 2 49 0 49 0 0
39 1 9 1 11 2 1 82 2 50 0 50 0 0
40 1 18 1 48 30 0 83 2 4 1 24 20 1
41 1 49 49 0 0 84 2 54 0 54 0 0
42 1 35 1 51 16 0 85 2 38 1 54 16 0
43 1 17 1 53 36 0 86 2 59 0 59 0 0
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It is to be noted that, for recurrent events, a patient with only one recurrence is 
censored for the 2nd recurrence relating to T 2 . For example, in Table 4.10, patient ID 6 
had the 1st recurrence six months after tumour removal and was followed up for the 
next four months, therefore censl =1, T \  = 6, T 2 =  10, T 2g =  4 and cens2 = 0. The plots 
of survival distribution function against survival time in months, for the bladder 
cancer data, are depicted in Figures 4.11 to 4.13.
Figure 4.11: Survival distribution for time to first recurrence, T \  in months, for the 
bladder cancer data, stratified by treatment group.
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Figure 4.12: Survival distribution for time to second recurrence, T2 (total time) in
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Figure 4.13: Survival distribution for time to second recurrence, T 2 G (gap time) in 
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Figures 4.11 and 4.12 for the survival distribution functions using total time, 
show similar trends indicating some treatment effect on the experimental group (trt = 
2). For the 1st recurrence, the median survival times are 16 and 26 months for patients 
on control and experimental respectively; hence the hazard function for patients on E  
is 0.0010/day, slightly lower than 0.0014/day for patients on C. For the 2nd recurrence,
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no median exists, and the means are nci = 23 (1.4) and /ie i— 30 (1.6) years; their 
corresponding hazard functions are 0.0014/day and 0.0011/day respectively. Figure 
4.13 does not indicate a consistent treatment advantage for the experimental group 
when the gap time to second recurrence is considered. Out of the 86 patients, 47 
patients had the first tumour recurrence, and 29 of them experienced the second 
recurrence, as summarized in Table 4.11.
Table 4.11: Summary of outcomes for the bladder cancer data.
Stratum Observations Events Censored (Percent)
1 86 47 39 (45%)
2 86 29 57 (66%)
Total 172 76 96 (56)%
Table 4.11 shows heavy censoring for the bladder cancer data for each event. 
The results for time intervals of two, five and ten are summarized for TT and GT in 
the subsequent tables.
Table 4.12: Results for bladder cancer data analyzed @ 2, 5 and 10 intervals (TT).
Parameter (s.e.) @ 2 intervals (TT) @ 5 intervals (TT) @10 intervals (TT)
Zi 5.96 5.40 4.47
z 2 4.33 4.26 3.95
z * 6.45 6.06 5.25
Vi 11.32 11.69 11.82
v 2 7.22 7.34 7.35
y * 11.63 11.93 11.96
0.5262 (0.2972) 0.4618 (0.2925) 0.3782 (0.2909)
4 0.5999 (0.3721) 0.5806 (0.3691) 0.5369 (0.3689)
6  * 0.5549 (0.2932) 0.5076 (0.2895) 0.4391 (0.2891)
0 0.5430 (0.2891) 0.4877 (0.2851) 0.4110(0.2844)






The estimates of treatment effect seem to decrease with the number of 
intervals used, while the p-values consistently indicate non-significance at the 2.5% 
level. The estimator of covariance yields consistent values, regardless of how many 
intervals are used, and the correlation is accurate at 0.6 (highly correlated). It can be 
concluded that a patient with a long time to the 1st recurrence is likely to experience a 
long time to the 2nd recurrence from the start of study. This is anticipated as T2 
contains T\ in TT risk interval.
The analysis using 10 intervals yields the values of Z and V closest to those 
from the logrank test, as shown in parentheses; Z\ -  4.47 (4.09), Z2 = 3.95 (3.83), V\ = 
11.82 (10.99) and V2 = 7.35 (7.06). Unlike the earlier data sets, the bladder cancer data 
set concerns recurrences, whereby a censored 1st recurrence results in a 2nd recurrence 
being missed. The impact of such dependence is evident from the values of V2 which 
are smaller than V\ in all settings: the information contained in T2 being less due to the 
censoring imposed by T\. Meanwhile, the resulting outputs when applying GT risk 
interval to the bladder cancer data, are summarized in Table 4.13.
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Table 4.13: Results for bladder cancer data analyzed @ 2, 5 and 10 intervals (GT).
Parameter (s.e.) @ 2 intervals (GT) @ 5 intervals (GT) @ 10 intervals (GT)
Z i 5.96 5.40 4.47
Z 2 0.84 1.14 1.14
z * 7.26 5.84 5.92
Vi 11.32 11.69 11.82
V 2 7.26 7.11 7.11
y* 19.16 19.69 19.96
0.5262 (0.2972) 0.4618 (0.2925) 0.3782 (0.2909)
4 0.1265 (0.3886) 0.1930 (0.3758) 0.1608(0.3751)
6  * 0.3787 (0.2284) 0.3604 (0.2192) 0.2966 (0.2239)
G 0.3756 (0.2284) 0.3575 (0.2192) 0.2952 (0.2238)
p-value 0.050 0.051 0.093
C 12 -0.572 -0.919 -0.488
P -0.066 -0.101 -0.053
The estimates of treatment effect 62 for GT are appreciably smaller than those
for TT since there is no carry-over effect from 7); hence a similar trend for 6  . There 
is no evidence to suggest any advantage from the experimental treatment, as is evident 
from the p-values at all interval settings. It is to be noted that the values of Z2 and V2 
when using 10 intervals are close to those given by the standard logrank analysis as 
shown in parentheses: Z2 =1.14 (1.15) and V2 = 7.11 (6.39). This shows that the 
interval-censored approach works well for the marginal analysis.
The main difference between TT and GT in this case is that GT yields negative 
covariance between the two score statistics. Mathematically, this is owing to the 
situation whereby the summation of covariance for each pair of intervals is close to 
zero. Upon checking for each of the 100 pairs of intervals (k = 10), 17 have positive 
covariance, 19 negative, 31 zeroes while 33 do not contribute (zero failures within the 
pair of intervals). This small total value leads to zero correlation, which suggests that
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the cumulative treatment effects for the 1st recurrence and time to the next recurrence 
are not correlated. It can be inferred that a patient with a long time to the 1st recurrence 
of a tumour is not unlikely to experience a short time to the 2nd recurrence. In short, 
the time to the 1st recurrence does not predict the time to the next one. This finding is 
consistent with that reported by Yan et al. (2002) whereby time to bladder tumour 
recurrence becomes shorter as the number of recurrences increases. Therefore, it is 
logical that recurrent GT analysis tends to yield negative or close to zero correlation 
between the score statistics as shown above. It is also uncommon for recurrence 
events analysis to be limited to a certain m number of events: for example, m -  4 in 
Wei et al. (1989), since events tend to be fewer for surviving subjects.
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4.7. Discussion
The most important part of this thesis, consists in deriving the estimated correlation 
coefficient for the complementary log-log model, incorporating interval-censored data 
structure, has been covered. Straightforward computation to yield the covariance 
between two score statistics for each pair of intervals was demonstrated with real data 
sets. Although the scope is only for bivariate survival data, the method can be easily 
extended for other multivariate data.
The results show that the proposed method works well for the real data sets 
comprising paired organs, related indicators, progression-free survival and recurrent 
events. Regardless of the number of intervals, our proposed method provides 
consistent estimates of the correlation, but treatment effects seem to vary: using fewer 
intervals tending to overestimate the treatment effects. It is evident that the number of 
intervals selected has an impact on the standard error of the parameter estimate: finer 
intervals give smaller standard errors.
As anticipated, the coarsening of the data through reduction in the number of 
intervals used in the analysis, does impact on the resulting output. Thall & Lachin
(1988), too, have also commented that test result could depend on the selection of the 
number of intervals and the intervals themselves. Basing results from the real data 
sets, using only two intervals is ruled out since it gives the biggest standard error and 
seems to overestimate the overall treatment effect, as is to be expected from the use of 
such coarse intervals. The true measure of the accuracy and suitability of this method 
as a survival analysis tool is demonstrated in an extensive simulation study in the next 
chapter.
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Chapter 5. Simulation Study
In Chapter 4, the proposed method for combining bivariate survival endpoints was 
successfully applied to real data. For convenience, it is now called ZW (Zain & 
Whitehead) throughout this thesis. The estimator of covariance and the global score 
test approach derived in Section 4.3.1 worked well for the interval-censored survival 
data. This chapter now investigates the properties of the estimator and evaluates the 
accuracy of bivariate tests using simulation.
Design details for the simulation study are developed in Section 5.1, followed 
by descriptions of key performance measures and combined hypothesis tests. 
Investigation of the properties of the estimator and evaluation of its accuracy are 
reported in Section 5.2, on the basis of the simulations performed. Results for each of 
the six cases investigated in Sections 5.2.1 to 5.2.6, are first given in turn, and 
followed by a summary of correlation ratios and overall results. A discussion 
concludes this chapter.
5.1. Design of Simulation Study
A full account of the method used to generate simulated data sets, is now given. As 
earlier described in Section 1.7, the amount of information, V=  {(ua + up)/0R}2 for a 
one-sided test. The relationship between V and n can be quantified by a constant value 
b: V = bn, which will then lead to the sample size needed for the trial. Tang et al.
(1989) showed the advantage in setting the sample size based on multiple endpoints, 
which requires a smaller sample size when compared to a design using only one 
endpoint. Using the same principle, for a fixed sample size, the treatment advantage, 
0R, at which a given power is achieved based on multiple endpoints, is smaller 
compared to that using a single endpoint.
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In this simulation study, the target type I error rate is 2.5% level (one-sided) 
and the target power is 90%; (ua + up)2 = 10.51. Subscripts 1 and 2 respectively 
indicate that a marginal parameter relates to the individual event based on T\ and To, 
while an asterisk or a subscript 12 indicates a global parameter based on both events. 
Note that the subscript m is used also to denote event, m = 1, 2 and G to denote 
treatment group, G = C, E. The six cases of bivariate survival data, which have been 
described in the previous chapter, are considered: complete (or uncensored), paired 
organs, related indicators, progression-free survival (PFS), recurrent events total time 
(TT) and recurrent events gap time (GT).
To determine sensible values for the hazard function for simulation purposes, 
the three real data sets from the previous chapter: hip revision, cancer and bladder 
cancer, are considered. The case of cancer with the highest hazard of disease 
progression of 0.004 (Section 4.5.2), is chosen. For simplicity in generating a big data 
set to estimate the cut-off points and b, Ae(0) is chosen to be 0.004, while 2c(o) is fixed 
at 0.006 and <9(0) = 0.4. This simulation model could represent an aggressive cancer 
study with time unit in days, whereby the median survival times for patients on C and 
E respectively are 115 days (3.8 months) and 173 days (5.8 months). Alternatively, it 
could be a longer term condition with time unit in months and the median survival 
times for patients on C and E respectively, are 115 months (9.5 years) and 173 months 
(14.4 years).
With the exception of the complete case, all the other five cases (listed above) 
are subjected to their specific censoring rules and censoring variables for simulation. 
The censoring proportions are set based on the three real data sets used in Sections 
4.5.1, 4.5.2 and 4.6.2. However, for the paired data, an alternative censoring 
proportion of 50% is used since the analysis with 80% censoring ( as observed in the
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real data set), was found to be less reliable (inflated type I error). Let the censoring 
proportion be x, so that x = 0.50 for the paired case. The percentage values of the 
censoring proportion (7i, T2) for each simulated case are: paired (50, 50), indicators 
(20, 20), PFS (8*, 20) and recurrent TT/GT (40, 60*). The censoring proportion 
without an asterisk is entered directly as x  in the simulation program for each T\ and 
72. Meanwhile, those with asterisks are further subjected to specific censoring rules, 
as discussed in their respective sections. The resulting censoring proportions are then 
verified to match those from the real data sets. For example, in the case of PFS, 7) is 
amended according to the censoring rule illustrated in Table 4.6. For the recurrent 
events, the censoring rules applied to the simulated data are described in Section 4.6.2. 
In other words, each simulation model is designed to simulate each case the closest 
possible to its corresponding real data set. It is to be noted that a wide range of 
censoring proportion (20% to 60%) is examined, for thoroughness.
In Chapter 4, the settings of five and ten intervals gave comparable results, 
hence k = 5, 10 are selected for the simulation study. From the simulation results, the 
most suitable number of intervals will be selected for subsequent analysis and 
comparison in later chapters. It is to be recalled from Chapter 4 that the procedure for 
ZW involves splitting the data set into k intervals of equal failures for each event and 
calculating the quantities of interest for each set of intervals. The procedure for 
analysis of real data is presented in a flow chart for comparison with the simulation 
procedure in this section. It is to be noted that the complete simulation procedure is 
repeated for specific case, hypothesis, and values of d and Jc, as will be decribed next.
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Figure 5.1: Process flow charts for analysis of real data and simulation run
(A) Analysis of real data (B) Set-up for simulations
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The hexagonal box in Figure 5.1 (B) represents the initial preparation, Step 0, 
which has been described earlier. Steps 1 to 3 are necessary to determine the set-up 
values for the actual simulation run as shown in Steps 4 and 5. Inputting the 
hypothetical values of Xe(o) = 0.004 and Xqo) = 0.006, the survival times, T\ and T2 
(days) are generated from an exponential distribution, Tim ~ EXP(XGexp(sl)), where st 
is a subject effect for patient i, following a normal distribution N(0, <r2). The standard 
deviation o of the subject effect is set to be d(log Xc -  log Xe), where d is a constant 
multiplier chosen to impose varying degrees of correlation: setting d = 1 ,5  and 10, 
creates low, medium and high correlations, respectively.
The Cox’s PH requires non-informative censoring such that the censoring is 
independent of the survival times. Therefore, assuming equal hazards, Xc = Xe = X, an 
overall censoring variable, C. ~ EXP(2Ay) is applied to the whole data set (both 
patients on C and E), where y = x /  {2(1 -  x)} and x is the censoring proportion. It is
to be recalled that, in general, patient i is censored for an event when Q < T{ for that 
event. Further censoring rules, specific to the simulated case will then be applied to 
the data sets accordingly.
To find the interval cut-off points, a very big sample size, ranging from 10,000 
to 10 million, is generated and simulated as the bivariate interval-censored case of 
interest. A big sample size is necessary to ensure large V, which is the amount of 
information on 6 contained in Z and consequently give the constant b, as will be 
shown next. As described in Section 4.5.1, these cut-off points are obtained by 
specifying the percentile points. The values of the cut-off points converge 
satisfactorily when n = 1 million, hence only this value of n is shown in Step 1 of the 
simulation flow chart in Figure 5.1.
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Step 2 involves finding specific values for the parameters required for the two 
hypotheses, including 0R under the alternative, while Xc is fixed at 0.006. Based on the 
useful expression, V = bn, and also V — {(ua+ up)l Or }2, we can find the Or at which a 
given power is achieved by fixing the sample size n, provided we know the constant b. 
Using the output for the interval cut-off points from Step 1, the same data sets, of
10,000 to 10 million patients are then split into the specified k intervals. This 
procedure is considered to yield the “truth” about the information, V, when the value 
of b converges satisfactorily. The fixed sample size is chosen to be 1,000 to calculate 
the value of the constant b to mimic a real study. The output of this procedure, when 
using k = 5 intervals, for the complete data is given as an example in Table 5.1.
Table 5.1: Average values for V* and b computed at various sample sizes for the
complete data (d =10, k = 5,).
Parameter 10,000 100,000 1,000,000 10,000,000
y  *














As displayed above, the value of b seems to converge at 0.2153 for n = 1 
million with acceptable computing time (6 minutes). The corresponding values of b 
for d -  1, and 5 are 0.3460 and 0.2399 respectively. Once the estimate of b (for n 
=1,000) is obtained, the 0R and XE can be calculated accordingly, where XE = 2c(exp(- 
0)). It is to be noted that now 0R= V( 10.51/1000Z?) as defined earlier. Plugging in these 
values for the settings under the null and alternative, the interval cut-off points are 
determined from a sample size of 1 million as shown in Step 3 of the simulation flow 
chart. The cut-off points for T\ when d = 10 in this scenario are 4, 40, 343 and 4134 
days. These cut-off points translate to intervals such as (0, 4], which means that
patients with 0 < Tx < 4 are grouped in the first interval and those with Tj >4134 in the
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last interval. It is to be noticed that Steps 1 to 3 in Figure 5.1 only show n = 1 million, 
as it is shown to be the most practical choice of sample size, to give reliable estimates.
It is to be clarified that these process steps involving big data set, is needed 
only for simulation runs, whereas in the actual analysis of real data set, the process 
steps are simply as demonstrated in Chapter 4 and shown in the flow chart (Figure
5.1). In Step 4, a sample size of 1,000 patients is simulated under both hypotheses to 
yield the estimates of Z, V, Cn and p. Finally, Step 5 involves 10,000 times replication
of Step 4 under each hypothesis to obtain the estimates for 6 , p (est), p^mpie), type I 
error a, and power 1-/?. The best estimates are taken to be the average values from the 
replications: each of these quantities will be further described in the next section.
The whole process from Step 1 to Step 5 is repeated for each scenario as 
specific cut-off points are applied to specific values of d, k, 6r and Xe for each case. 
This translates into 72 different scenarios for the whole simulation study (6 cases, 2 
hypotheses, k = 5, 10 and d = 1, 5, 10). It is to be noted that a mandatory censoring of 
patients in the last interval is imposed to emulate the end of study in a real clinical 
trial. An example of the input values for all cases is depicted in Table 5.2.
Table 5.2: Example of simulation setting for each case at d = 10 and k = 5 intervals.
Case
% censored for 
T h T 2
b (d = 10,
@ 5 intervals) Or XE
Uncensored N/A 0.2153 0.221 0.00481
Paired 50, 50 0.1127 0.305 0.00442
Indicators 20, 20 0.1394 0.275 0.00456
PFS 8*, 20 0.1387 0.275 0.00456
Recurrent (TT) 40,60* 0.1043 0.317 0.00437
Recurrent (GT) 40,60* 0.1259 0.289 0.00449
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The complete or uncensored case has the biggest b, resulting in the smallest Or  
when n is fixed: as anticipated since no censoring is involved. With a heavy censoring 
for the paired case, it is to be noticed that b is almost half that for the complete case 
and hence Or  is bigger. This implies that for the same sample size, a bigger treatment 
effect is needed for highly censored data to give the test a power similar to that of the 
uncensored. As already noted, the values for b, Or and Xe when d = 10 and k = 5 vary 
for each case. Therefore, a similar set of values is also needed to simulate data for d = 
1, 5 and k = 10 accordingly.
Under the null, the hazards are indeed proportional with a ratio equal to 1 (zero 
treatment advantage); hence it is easy to verify the type I error rate. However, under 
the alternative, the assumption of proportional hazards may no longer hold, as the 
common 0  assumed may actually vary. Under H\ \ 0  =  O r when O r  corresponds to n = 
1000. When n is fixed, 0  is adjusted to account for the within-subject correlation, to 
give the desired power. Therefore, the 0  input to the program is actually the log hazard 
ratio within subject, say 0 W■ This is a notional quantity as each subject receives only 
one treatment. Initially, 0  was set with a view to fixing power ( l - f i u  = 0.90), but in 
fact the power is determined by 0 B , the log hazard ratio between subjects. This means
A
that, the simulation output 6  indeed gives the estimated treatment effect associated 
with the log hazard ratio between subjects on E and C.
Suppose pE and pc are the probabilities of failure of an event for patients on E 
and C respectively. It is to be recalled from Section 3.1.4, that the log hazard ratio is 
expressed in terms of survivor functions: 0 = -log{-logSe(0} +log{-logSc(?)}.
However, when there is a random subject effect, a problem arises. Substituting the 
survivor functions with these probabilities into the equation, we get
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0 l°g{ log(l P£)} + log{-log(l-pc)}. Conditional on the subject effect Sj, a 
random effect model is expressed as log {—log(l — /?)} =  a  + 8z + si and 
( l _ /?) = E[exp{-exp(a' + 6>z + .si.)}]. For simplicity, setting a = 0, and z = 1 if the
patient is on E, 0 otherwise, the treatment effect based on the log hazard ratio between 
subjects is given by
^fl=-log{-log(E[exp{-exp(0+ii)}])}+log{-log(E[exp{-exp(ii)}])}.
Comparing the expressions for 9 and dB above, it is evident that 0B < 9, and as 
the standard deviation of s( approaches zero: a —> 0, 9b —> 9. This means that the 
power is achieved only at low correlations. Therefore, it is anticipated that the
program output will give 9 which is the estimate of 9B, itself smaller than the input 9: 
low power at high correlation. A similar relationship between 9 and 0B for a 
proportional odds model of binary data has been reported by Bolland (2003), which 
also relates to methodology presented by Neuhaus et al. (1991).
In the simulation results (Section 5.2), the directly estimated power is hence 
compared with its corresponding theoretical power, computed at the estimated 9B,
which is 9 . In reality, the assumption of a common treatment effect under H\ may be 
violated. The best we can do is to identify the proportional hazards model that is 
closest to the actual case we have. We generate a big data set (for example in Table
5.1), and choose the sample size when the required parameter converges to a constant 
value, as decribed earlier.
141
5.1.1. Key Performance Measures
To quantify the accuracy of the proposed method, as well as to justify the choice of 
intervals {k = 5 or 10?), there are five specific key measures which can be employed. 
The two most prominent performance measures are the type I error rate and the power 
of the test respectively, under the null and alternative hypotheses. Additionally, the 
correlation ratio, the coverage probability and the bias of 9 can also be taken into 
account. However, the coverage probability and the bias can only be determined if 
indeed the actual 9 is known. As already explained in the Section 5.1, in the computer 
code generating the simulated data we are able to fix 9W {within subject), while from 
the resulting survival times we estimate 9B {between subjects). Therefore, only the 
three aspects of accuracy assessment (type I, power and correlation ratio) are 
investigated and reported in Section 5.2.
The first two measures have been described in Section 1.7, and therefore are 
discussed only briefly here. As described in the previous section, some power loss is 
anticipated with increased correlation. The power will instead be compared to a
theoretical power denoted by TP, which appropriately compares the estimated 6  to 
the input 9 adjusted based on the same log hazard ratio between subjects. As already 
explained in Section 2.3, the advantage of a global test lies in between the two 
extreme cases of completely independent endpoints and totally dependent endpoints 
(as if there was only a single endpoint).
As to the correlation ratio, an ideal situation arises when the estimated
correlation using the proposed method, denoted by p(est)? is exactly the same as the
“true” correlation. It is to be recalled that each simulation is replicated 10,000 times
{N = 10,000) under each hypothesis. The estimate of the covariance between two
score statistics, Cn, is calculated from each replicate simulation and similarly for the
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correlation estimate/3. The average value of p  from the 10,000 replicates, gives the 
best estimate, P(est)- Since the “true” correlation is unknown, it is assumed that the 
correlation observed from its own samples of N, denoted by /)(sample) gives the true 
correlation asymptotically. With N  replicate simulations of the same study, the sample 
covariance, cov(Zi,Z2) can be obtained from the expression
cov(Zp Z2) = (X Z jZ 2 — ( ( ^ Z 1^ Z 2) / N) / (N  — 1)). The correlation derived from the
sample covariance is given by p {sample) = cov(Z,, Z2) /  ^ /var(Zj)varZ2 . Therefore, the
correlation ratio of both estimates, yO(est)/p(sampie), will be compared in investigating the 
properties of the correlation estimator and in evaluating the accuracy of this method.
Although the coverage probability and the bias are not considered in the 
assessment of accuracy in this study, they are briefly described here and are later 
commented in Section 5.2.8. The coverage probability of a confidence interval is 
estimated by the proportion of replicates for which the interval contains the true value 
of interest (Dodge, 2003), in this case the treatment effect. Meanwhile, the bias of the
estimate of 6 is given by 9 -0  and unbiasedness is indeed a desired property of a good 
estimator. In order to evaluate the bias and the coverage probability, it is necessary to 
know the true value of <9, and as explained earlier, the simulation method used does 
not allow this, except for simulations under the null hypothesis where 0= 0. The three 
key performance measures (type I error, power and correlation ratio) are reported in 
the results for individual case (Sections 5.2.1 to 5.2.7) and later summarized in the 
overall results (Section 5.2.8).
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5.1.2. Combined Hypothesis Tests
In Section 2.1.1, global tests have been described in the context of binary data. Here, 
they are extended to interval-censored survival data with 6m representing log hazard 
ratio for m event. Based on the normality assumption of Z, already described in 
Sections 1.4 and 2.1.1, the following hypothesis tests can be employed. In this section, 
only the score test and Wald test are considered, whilst a good description on test 
statistics which includes the likelihood ratio test is available from Azzalini (1996). It 
is to be recalled from Section 4.4 that there are two ways to estimate the overall 
treatment effect. Consequently, two options of hypothesis tests are available and are 
described here.
For the standard estimate of overall treatment effect, 0 * , under the null, 0 = 0; 
hence Z*2/F* can be tested against the chi-squared distribution with one degree of 
freedom, %\. Equivalently, Z*Nv* can be compared with the critical value for a 
standard normal distribution, N(0, 1). This is an extension of the logrank test for 
univariate case as described in Section 1.6, now adapted for bivariate case. From
Section 4.4, the standard error of 0 * is given by iHv, and hence an approximate 95%
confidence interval for 6 * is expressed as (ZW * ± 1.96/Vv*).
Alternatively, and more appropriately, using the optimal weighting in equation 
(4.10), the standard error of the optimal estimate of the treatment advantage, s.e.(0) , 
is given by the square root of equation (4.11). Similar to its standard counterpart 
described earlier, O !s .e0 )  c a n  be tested against A(0, 1) or {62 / var(0) against / j 2. 
Therefore, the p-value is given by 1 - 0 {6 / s.e.{0)) and this expression is used to 
compute all the p-values for the remainder of this thesis, unless noted otherwise.
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5.2. Simulation and Results
With reference to Step 4 in Figure 5.1, the fixed number of patients, n = 1,000 are 
generated and randomized equally to control and experimental. In this investigation, 
only 6 corresponding to V* is used since the main interest is the overall treatment 
effect. The effect of increasing the standard deviation of the subject effect, a is also 
investigated by varying d. Each data set is generated based on the variables set for 
each value of d and k, on each hypothesis: an example was earlier displayed in Table
5.2.
The score statistics, Fisher’s information and covariance for each interval are 
computed to yield the global score statistics, variances and covariance estimator, Cn 
and hence the correlation estimator, p . It is to be recalled that this part of the 
procedure was illustrated in Section 4.5.1 earlier. All simulation runs are replicated
10,000 times under each hypothesis, the average values from which are taken to be the 
best estimates. The results for each of the six cases are summarized in tables and 
figures.
5.2.1. Complete or Uncensored Data
Complete data sets with no censoring are simulated as the first check point since the 
simple setting does not involve any censoring rules. In Section 2.1.1, the theory states 
that Z ~ N(6V, V) for large V and small 6: the variance of Z is approximately V. In this 
study involving 10,000 replicate simulations of a sample size of 1,000 each, the 
average values of V and variance of Z, obtained under each hypothesis, are 
summarized in Table 5.3.
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Table 5.3: Average values of V and var Z for the complete case under the null and
alternative hypotheses.
Complete d Vi Var Zj v 2 Var Tjj v* VarZ*
1 196.8 196.2 196.8 190.6 385.3 379.2
Ho 5 196.9 195.2 196.9 195.3 285.0 288.8
V 10 196.8 197.4 196.8 195.0 236.6 240.3Jv — D
1 196.5 193.7 196.6 189.3 382.7 368.8
H! 5 196.5 192.2 196.6 193.7 284.2 284.0
10 196.6 195.3 196.7 194.7 236.4 238.7
1 223.2 225.3 223.2 217.9 436.8 434.4
Ho 5 223.2 224.7 223.1 222.0 326.0 337.3
k =  10
10 223.2 224.8 223.2 223.6 271.4 284.4
1 222.3 220.1 222.2 214.9 432.6 417.5
Hi 5 222.5 221.9 222.5 218.1 324.8 331.4
10 222.9 224.1 222.9 222.3 271.0 282.9
It is clearly apparent in the table above that the variance of Z is very close to 
information V in each setting under both hypotheses. For example, the first row shows 
that V\ (196.8) and var Z\ (196.2). It is worth noting that a similar observation is found 
in all the cases simulated, where var Z « V holds. Also, as expected, an increase in the 
number of intervals gives a bigger V, as more information about 0 is contained in Z. 
These values are listed in this section only for illustration purposes, as they are not of 
prime interest in this study.
A standard table of results summarizing the three key measures is presented 
for each case studied under the null (H0) and alternative (Hi), with varying degrees of 
correlation: d = 1 (low), 5 (medium), 10 (high) and number of intervals (k = 5, 10). In 
such a table as that below (Table 5.4), it is to be noted that the first two columns 
contain the values set for d and 6, while others relate to the estimates obtained. To
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assess the validity of the assumption of a common treatment advantage, 0X =02 = 6,
the estimates are tabulated alongside their corresponding type I errors and powers. 
The type I error rates, corresponding to the marginal tests based on Th T2 and the 
global test based on both, are a\, a2 and a\2 respectively. Similarly, their alternative
counterparts are denoted by l-/?i, \-f}2 and l-f}n . The theoretical power for 0 (Section
5.1) denoted by TP, serves as a baseline for comparison with the global power l-/?i2- 
Meanwhile, p(est) and P(sampie) respectively are the correlation estimated using the 
proposed method, and the correlation derived from the samples. It is to be noted that 
in the tables of results for the remainder of this thesis, texts in bold highlight particular 
values which are worthy of remark.
Table 5.4: Summary of results for the complete case under the null and alternative,
using 5 and 10 intervals.
H0@ 5 intervals
d e 4 4 6 a ] a 2 a  12 N/A P (e s t) P (sa m p le )
1 0 . 0 0 0 0 . 0 0 0 0 . 0 0 0 0 . 0 0 0 0.023 0.021 0.023 N/A 0.023 0.026
5 0 . 0 0 0 -0.001 -0.001 -0.001 0.024 0.025 0.026 N/A 0.382 0.412
10 0 . 0 0 0 -0.001 -0.001 -0.001 0.024 0.027 0.025 N/A 0.664 0.693
Hi @ 5 intervals
d e k 4 0 1-41 \ - P 2 1-4 12 TP P (e s t) P (sa m p le )
1 0.174 0.171 0.171 0.171 0.67 0.67 0.92 0.89 0.028 0.027
5 0.209 0.139 0.139 0.139 0.50 0.49 0.65 0.58 0.384 0.412
10 0.221 0.089 0.088 0.088 0.24 0.23 0.28 0.25 0.664 0.694
Ho @ 10 intervals
d 6 k 4 6 a ! a 2 a  12 N/A P (e s t) P ( sa m p le )
1 0 . 0 0 0 0 . 0 0 0 0 . 0 0 0 0 . 0 0 0 0.024 0.022 0.024 N/A 0.023 0.026
5 0 . 0 0 0 -0.001 -0.001 -0.001 0.024 0.026 0.028 N/A 0.370 0.415
10 0 . 0 0 0 -0.001 -0.001 -0.001 0.025 0.026 0.027 N/A 0.645 0.715
Hx@ 10 intervals
d 6 k 4 0 1-41 l-4 2 1-412 TP P (e s t) P ( sa m p le )
1 0.165 0.162 0.162 0.162 0.68 0.68 0.92 0.89 0.028 0.025
5 0.197 0.130 0.130 0.130 0.50 0.49 0.65 0.57 0.371 0.416
10 0.208 0.083 0.083 0.083 0.24 0.23 0.28 0.25 0.645 0.713
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In each setting for the complete data, the type I error is well within the 95% 
probability interval (0.022, 0.028), the global power exceeds its theoretical power and 
the estimated correlation /?(est) seems close to its sampled correlation P(SamPie)- However, 
a slightly inflated type I error is observed at 10 intervals {an = 0.028). The estimates 
of the marginal and global 6s are exactly of the same value in each setting under both
hypotheses: a valid assumption of 0l =02 = 6. The marginal powers 1- and 1- /?2,
based on individual T\ and r 2 respectively, are obviously smaller than the global 
power: similar findings which demonstrate the advantage of global test as seen in 
Chapter 2 earlier.
In Table 5.4 above, it is evident that upon increasing the correlation multiplier 
d, the required 6 gets larger, but as anticipated the power is gradually lost with 
increasing d. As explained in Section 5.1, the estimate, 0B is expected to be smaller 
than the value set 6 = 6w, as correlation increases. For example, when d = 10 (5
intervals), 6 is only 0.088 compared to the setting of 6 = 0.221, which seems to be 
about 60% underestimation. Consequently, the power of the test for the combined 
score, 1 - flu  is only “accurate” compared to the 95% probability interval (0.89, 0.91) 
at low correlation (d = 1) at both interval settings. Upon comparing the results for 5 
and 10 intervals, the former seems to give better results in terms of type I error and 
correlation ratio ( d  = 10), while the power is exactly the same as that for the latter.
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5.2.2. Paired Organs
To simulate the case of paired organs, T\ and T2 are generated in a similar way as to 
the complete case, except that a 50% censoring proportion is now applied to the data, 
as shown in Table 5.2 earlier. Only one censoring variable exists as T\ and T2 concern 
the same patient. The data are then subjected to the specific censoring rules, as already 
described in Section 4.3.2. The results are summarized in Table 5.5.
Table 5.5: Summary of results for the paired case under the null and alternative.
H 0 @ 5 intervals
d e 4 4 0 a ! a 2 «12 N/A P  (est) P  (sample)
1 0 . 0 0 0 0.000 0.000 0.000 0.025 0.023 0.026 N/A 0.035 0.027
5 0 . 0 0 0 0.001 0.000 0.000 0.028 0.025 0.028 N/A 0.421 0.437
10 0 . 0 0 0 0.001 0.002 0.001 0.027 0.025 0.026 N/A 0.674 0.685
H i @ 5 intervals
d e k 4 0 1-41 i -42 1-412 TP P  (est) P  (sample)
1 0.241 0.235 0.236 0.235 0.65 0.65 0.90 0.89 0.041 0.022
5 0.287 0.190 0.190 0.190 0.47 0.48 0.61 0.57 0.422 0.437
10 0.305 0.120 0.120 0.120 0.23 0.22 0.25 0.25 0.692 0.704
Ho @10 intervals
d e k 4 6 a j a 2 a 12 N/A P  (est) P  (sample)
1 0.000 0.000 0 .0 0 1 0.001 0.025 0.025 0.028 N/A 0.031 0.026
5 0.000 0.000 0 .0 0 1 0.001 0.028 0.024 0.025 N/A 0.412 0.428
10 0.000 0.001 0 . 0 0 2 0.002 0.026 0.025 0.026 N/A 0.679 0.706
H i @10 intervals
d e k 4 e 1-41 1 - 4 2 l"4l2 TP P (est) P  (sample)
1 0.228 0.222 0.224 0.223 0.65 0.66 0.91 0.89 0.037 0.023
5 0.271 0.180 0.181 0.180 0.48 0.48 0.62 0.58 0.413 0.429
10 0.288 0.115 0.116 0.115 0.22 0.23 0.26 0.25 0.679 0.707
For the paired data, slightly inflated type I error rates are observed, but they 
are still within the 95% PI (0.022, 0.028). The global power achieved is higher than 
the theoretical power and the correlation estimates p(est) and pimple) are consistent for 
each scenario above. The global test advantage is clearly evident whereby the global 
power is much larger than that of the marginals. This is anticipated since the
assumption of equal treatment effect is satisfactorily met, as shown in the above table. 
Additionally, it seems that the 10 intervals setting yields a slightly higher power, by 
1 %, but a similar type I error compared to the 5 intervals.
5.2.3. Related Indicators
As mentioned in Section 5.1, the generally related indicators are simulated with mild 
censoring (20%). Unlike the paired case earlier, each T\ and T2 can be censored 
independently as described in Section 4.3.3 and the censoring rules illustrated in 
Section 4.5.2 are applied. The results for both interval settings are given in Table 5.6.
Table 5.6: Results for the indicators case under the null and alternative.
Ho @ 5 intervals
d e k k 6 a i a 2 a 12 N/A P (est) P (sample)
1 0.000 0.000 -0.001 -0.001 0.022 0.023 0.023 N/A 0.023 0.032
5 0.000 -0.001 -0.001 -0.001 0.022 0.026 0.027 N/A 0.387 0.404
10 0.000 -0.001 -0.001 -0.001 0.025 0.025 0.026 N/A 0.670 0.688
Hr @ 5 intervals
d e k k 6 i-/?i 1 2 17? 12 TP P (est) P (sample)
1 0.194 0.189 0.189 0.189 0.66 0.66 0.91 0.89 0.028 0.034
5 0.245 0.161 0.161 0.161 0.50 0.49 0.65 0.57 0.389 0.406
10 0.275 0.107 0.107 0.107 0.24 0.23 0.26 0.24 0.671 0.685
Ho @10 intervals
d e k k 6 a i a 2 a 12 N/A P (est) P (sample)
1 0.000 0.000 -0.001 -0.001 0.021 0.023 0.022 N/A 0.023 0.033
5 0.000 -0.001 -0.001 -0.001 0.024 0.027 0.028 N/A 0.374 0.404
10 0.000 -0.001 -0.001 -0.001 0.025 0.025 0.027 N/A 0.649 0.686
Hr @ 10 intervals
d k k 0 1-/11 l"/?2 1-/? 12 TP P (est) P (sample)
0.180 0.179 0.179 0.67 0.66 0.92 0.89 0.028 0.032
0.151 0.151 0.151 0.49 0.50 0.66 0.57 0.375 0.402
10 0.101 0.101 0.101 0.23 0.23 0.28 0.25 0.649 0.686
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For the related indicators, the type I error rates are within the 95% PI (0.022, 
0.028) for all settings with 5 intervals showing a slight advantage over 10 intervals, 
with regard to the global an- As with the earlier cases, the global power exceeds its 
theoretical power in each scenario. The setting of 10 intervals yields higher power 
(1% to 2%) compared to that of 5 intervals. However, the coarser intervals perform 
better than the finer in terms of the correlation estimates under both hypotheses.
5.2.4. Progression-Free Survival
A progression-free survival analysis dictates more events on T\ (Section 4.3.4) 
compared to the earlier case of related indicators. Using the same initial data as 
generated in the latter case, adjustment is then made according to the censoring rules 
described in Section 4.5.2 earlier. The simulation study for PFS yields the following 
output as shown in Table 5.7.
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Table 5.7: Summary of results for the PFS case under the null and alternative.
H @ 5 intervals
d e
4 4 0 a i a 2 a  12 N/A P (e s t) P ( sa m p le )
1 0.000 0.000 -0.001 0.000 0.025 0.023 0.024 N/A 0.589 0.601
5 0.000 0.000 0.000 0.000 0.026 0.025 0.026 N/A 0.755 0.779
10 0.000 -0.001 -0.001 -0.001 0.024 0.023 0.025 N/A 0.869 0.882
H , @ 5 intervals
d e 4 4 0 l-/?i 1-42 1 - 4 1 2 TP P ( e s t) P ( sa m p le )
1 0.223 0.214 0.225 0.218 0.83 0.81 0.90 0.89 0.592 0.601
5 0.252 0.156 0.167 0.159 0.55 0.52 0.59 0.53 0.755 0.779
10 0.275 0.102 0.108 0.103 0.24 0.23 0.25 0.23 0.869 0.882
Ho @10 intervals
d e 4 4 0 a i a  2 a  12 N/A P (e s t) P ( sa m p le )
1 0 . 0 0 0 0 . 0 0 0 -0.001 0 . 0 0 0 0.026 0.021 0.024 N/A 0.608 0.629
5 0 . 0 0 0 0 . 0 0 0 0 . 0 0 0 0 . 0 0 0 0.026 0.025 0.026 N/A 0.734 0.774
10 0 . 0 0 0 -0.001 0 . 0 0 0 -0.001 0.024 0.026 0.025 N/A 0.848 0.876
H  i @10 intervals
d 6 4 4 0 1 - 4 1 1 ~ 4  2 1 “4  12 TP P ( e s t) P ( sa m p le )
1 0.212 0.201 0.214 0.206 0.84 0.81 0.90 0.88 0.610 0.628
5 0.238 0.146 0.157 0.149 0.55 0.53 0.59 0.53 0.757 0.798
10 0.259 0.096 0.102 0.097 0.25 0.24 0.26 0.23 0.861 0.891
As in the earlier cases, the type I error rate is within the 95% PI, and the global
power exceeds its theoretical power (TP) in each setting. The correlation estimates are 
consistent, although slightly higher values are observed under the alternative, at 10 
intervals (d = 5, 10), compared to those under the null. It is notable that the estimates 
of marginal and global treatment effects are no longer equal, unlike the earlier cases. 
The impact of the invalid assumption of 6 equality is reflected in the power of test: the 
marginal power is now closer to the global, compared to all the earlier cases. Upon 
comparing the performances of the 5 and 10 intervals, the former gives better results 
for the type I error and correlation estimate, while the latter is slightly more 
advantageous in terms of power.
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5.2.5. Recurrent Events (Total Time)
For the recurrent events total time model, time to the second recurrence, T2 contains 
time to the first recurrence, T\ and therefore the data generation differs from the other 
cases. Two time variables, say T\ and Tig, are generated as described in Section 5.1, 
and their sum makes up T2 . An alternative method is also explored, whereby the 
smaller value of the two time variables is taken as T\ and the larger as T2 '. their results 
are displayed under the label “2nd option”. The simulated data are then similarly 
subjected to the censoring rules relating to the features described in Section 4.6.1. For 
example, when T\ is censored at t\ = c\, T2 is also censored at the same time c\. As 
already acknowledged, the recurrent TT case is expected to be highly correlated since 
the magnitude of T2 includes T\ as well. The simulation results are displayed in Table 
5.8 and the results for the 2nd option are commented last.
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Table 5.8: Results for the recurrent events TT case under the null and alternative.
H 0 @ 5 intervals
d 6 4 4 0 a ! a 2 « 12 N/A P (est) P (sample)
1 0.000 0.000 0.001 0.000 0.026 0.025 0.027 N/A 0.539 0.557
5 0.000 0.001 0.001 0.001 0.028 0.025 0.028 N/A 0.730 0.751
10 0.000 0.001 0.001 0.001 0.026 0.025 0.026 N/A 0.848 0.855
H x @ 5 intervals
d 6
4 4 0 M i M 2 M 12 TP P (est) P (sample)
1 0.293 0.282 0.430 0.317 0.86 0.96 0.95 0.94 0.543 0.555
5 0.311 0.192 0.238 0.200 0.53 0.57 0.58 0.55 0.730 0.749
10 0.317 0.118 0.131 0.120 0.24 0.24 0.24 0.23 0.848 0.856
Ho @10 intervals
d 9 k 4 e a  i a  2 a 12 N/A P (est) P (sample)
1 0.000 -0.001 0.001 0.000 0.026 0.025 0.028 N/A 0.551 0.588
5 0.000 0.000 0.000 0.000 0.028 0.025 0.027 N/A 0.723 0.751
10 0.000 0.001 0.001 0.001 0.026 0.023 0.026 N/A 0.839 0.855
H x @10 intervals
d 9 k 4 6 M i M  2 M 12 TP P (est) P (sample)
1 0.278 0.261 0.404 0.299 0.86 0.95 0.95 0.94 0.553 0.576
5 0.293 0.181 0.226 0.189 0.53 0.57 0.58 0.55 0.723 0.750
10 0.299 0.113 0.127 0.115 0.24 0.24 0.25 0.24 0.839 0.855
2nd option @ H  j (5 intervals)
d k 4 0 M i M 2 M l 2 TP P (est) P (sample)
\A 0.247 0.360 0.280 0.85 0.93 0.96 0.95 0.414 0.418
0.177 0.223 0.187 0.54 0.57 0.60 0.57 0.655 0.669
10 0.113 0.128 0.115 0.24 0.23 0.25 0.23 0.803 0.812
The intended type I error rates are achieved, but they are close to the high limit
for both interval settings. The global power exceeds the theoretical power and the 
values of estimated correlation, p(est) are close to their corresponding pimple), in all 
settings. While the marginal powers for individual T\ and T2 were similar in the earlier 
cases, the recurrent case reveals a slight increase in power for the latter. In fact, for 
d = 1 (5 intervals), a marginal power l-/?2 of 0.96 exceeds the global power (0.95). It 
is to be noticed that the assumption of 9 equality is violated, with the marginal
estimate 92 much larger than the global estimate, 0 . This accounts for the lack of
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global power in this case. However, for the 2nd option the estimates of treatment effect 
are now closer to each other and consequently, the global power is always higher than 
the marginal power. This implies that the 2nd option yields recurrent TT data that is 
closer to the assumption of 6 equality and hence resulting in an advantage of the 
global test methodology. Overall, for the recurrent TT case, the use of 10 intervals 
seems to yield improved performance in terms of type I error and power, but slightly 
lower correlation ratio compared to those for 5 intervals.
5.2.6. Recurrent Events (Gap Time)
To generate data for the recurrent events gap time model, T\ and Tig are subjected to a 
common censoring variable, similar to the recurrent TT. However, in gap time 
convention, T2 = T2G, and when 7j is censored, T2 = 0 (gap time). In other words, 
when T\ is censored, T2 is completely missing. Since the magnitude of T\ is no longer 
contained within T2G for GT, the outcomes for each of the paired intervals are quite 
different from those when using TT. Thus, it is only logical that the correlation 
between the events is much lower in GT compared to that for TT, as already observed 
with the bladder cancer data in Section 4.6.2. The simulation results for recurrent GT 
are summarized in Table 5.9.
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Table 5.9: Results for the recurrent events GT case under the null and alternative.
# 0 @ 5 intervals
d 6 4 4 e a ] «2 a 12 N/A P (est) P (sample)
1 0.000 -0.001 0.000 0.000 0.025 0.025 0.026 N/A 0.040 0.030
5 0.000 0.001 0.000 0.000 0.026 0.022 0.022 N/A 0.305 0.235
10 0.000 0.001 0.000 0.001 0.026 0.027 0.020 N/A 0.512 0.352
H i @ 5 intervals
d e k k 0 1 - /4 1 - / 4 1"A 12 TP P (est) P (sample)
1 0.235 0.229 0.228 0.228 0.70 0.58 0.90 0.88 0.045 0.030
5 0.271 0.180 0.137 0.162 0.49 0.25 0.53 0.49 0.306 0.238
10 0.289 0.116 0.069 0.096 0.23 0.10 0.19 0.19 0.511 0.355
H 0 @10 intervals
d 6 k 4 0 a i (X 2 a 12 N/A P (est) P (sample)
1 0.000 -0.001 0.000 0.000 0.025 0.025 0.023 N/A 0.034 0.031
5 0.000 0.000 0.000 0.000 0.026 0.023 0.021 N/A 0.298 0.194
10 0.000 0.001 0.001 0.001 0.026 0.027 0.017 N/A 0.504 0.287
H } @ 10 intervals
d v*V k 4 0 1 - /4 1 - / 4 12 TP P (est) P (sample)
1 0.216 0.215 0.215 0.70 0.58 0.90 0.88 0.039 0.031
( 0.170 0.131 0.154 0.49 0.26 0.54 0.49 0.298 0.191
10 "1X272 0.110 0.066 0.092 0.23 0.10 0.18 0.19 0.504 0.291
At high correlations (d = 10), the global type I error rates are rather
conservative and the global power is just equal to, or slightly lower than its theoretical 
power. The marginal type I error rates are within the 95% PI, and unlike the other 
cases, the marginal power 1-/6 is appreciably higher than 1 -fii and even exceeded the 
global power at d = 10. Such trend is unsurprising for a recurrent events GT model. It 
is apparent that the estimated correlation, /?(est), is substantially larger than /?(SamPie) at 
higher correlations (<d = 5, 10). This overestimation suggests that the proposed method 
may not be suitable for the recurrent GT case when the correlation is high.
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5.2.7. Summary of Correlation Ratios
A simple linear regression method is adopted in assessing the accuracy of the 
correlation estimate. The comparison between p (est) and /?(sampie) is given in a scatter 
plot with a trend line passing through the origin (0, 0) and the gradient from the linear 
equation gives the correlation ratio of /?(est)/p(samPie): y = x  being the perfect estimation. 
The plot for each case under both hypotheses is given individually where (5) and (10) 
in front of the equation indicates the number of intervals.
As shown in Figure 5.2 (a), the linear fit equations for the complete case show 
gradients of 0.95 (5 intervals) and 0.90 (10 intervals): a 5% advantage for the coarser 
intervals. Similar trends are evident for all the other four cases shown in Figures 5.2
(b) to (e), with the advantage of 5 intervals ranging from 1% to 3% for correlation 
ratios of about 0.97 and 0.98. The first five charts show that the proposed method 
yields better correlation estimate using 5 intervals compared to 10 intervals. However, 
the recurrent GT shows some discrepancies in Figure 5.2 (f). There is a huge 
overestimation and the use of 10 intervals gives a higher correlation ratio (1.68) than 
does the 5 intervals option (1.40).
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Figure 5.2: The correlation ratio for each case at 5 and 10 intervals.
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5.2.8. Overall Results: Five vs Ten Intervals
The overall results intend to answer two main questions: the accuracy of the proposed 
method and the appropriate number of intervals for bivariate survival data. The 
following figures display the results for the three key measures, on the x-axis for 5 
intervals and on the y-axis for 10 intervals, under the null and alternative. To ensure 
clarity of choice, a visual presentation is constructed from the set of tables displayed 
in earlier sections. A diagonal line of y = x serves as a reference when both interval 
settings perform equally well; the points below or above it indicating a certain 
superiority, are described accordingly.
Figure 5.3 (a) displays the type I error rate for each case under the null, with 
points above the diagonal line indicating that the method using 5 intervals performs 
better than that using 10 intervals. It can be seen that only the paired and recurrent TT 
give better type I error rates at 10 intervals. The same data points are used to plot 
Figure 5.3 (b) but are now categorized by the degree of correlation: low for d = 1, 
medium for d = 5 and high for d = 10. No particular trend is observed for these two 
plots, and some outliers belong to the recurrent GT, consistent with the earlier 
findings in Section 5.2.6.
Figure 5.3 (c) shows that 10 intervals gives slightly higher power than 5 
intervals. As observed in the earlier sections, a power of 0.90 is achieved at low 
correlation (d = 1). When higher correlations are imposed, there is a noticeable 
clustering of points around 0.6 (d = 5) and 0.3 (d = 10), consistent with the calculated 
theoretical powers. Meanwhile, no appreciable change is observed with regards to the 
accuracy of the correlation estimate as the value of d is increased under the null and 
alternative, therefore an overall plot of both hypotheses is given in Figure 5.3 (d). It is 
clearly visible that a better estimation of correlation is achieved using 5 intervals
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compared to 10 intervals, with correlation ratios of 0.99 and 0.97 respectively. It is to 
be noted that the outliers above the lines are due to the recurrent GT, as already 
commented in the previous section. Excluding these points, the corresponding ratios 
for 5 and 10 intervals respectively are 0.98 and 0.95. On the basis of the overall results 
presented above, it can be concluded that the setting of 5 intervals yields higher 
accuracy than 10 intervals.
Figure 5.3: Type I error rates, power and correlation ratio using 5 and 10 intervals.
0.030 - (a) Type I Error
0.028 -
0 030 1 (b) Type I Error
0.028 -
• complete
0.026 - 0.026 -° indicators
> 0.024 - > 0.024 - • low corr- paired
° medium corr• =  0.022  -•S 0.022 - x recurrent 
TT 
- PFS
highcorr0.020  -0.020  -




(d) Correlation Ratio(c) Power o f Test @ H] (n=1000)
A 5 intervals 
x 10 intervals
• low corr 
0 medium corr 
° highcorr (10): y = 0.9693x
0.0 0.0
0.0 0.2 0.4 0.6
5 intervals
Meanwhile, it is worth commenting that under the null Ho: 0 = 0, bias 0 was 
essentially zero, as 0B —> 0 = 0. Under the alternative, bias 0 was also zero at low 
correlation (d = 1) as 0B -> 0 = 0W. Consequently, the coverage probabilities were 
essentially 0.95 under Ho and when d = 1 under H\. This topic has been discussed in 
Section 5.1. A general comparison is now given based on the individual case 
presented earlier. Unlike the other cases, the recurrent TT data is structured such that
160
T\ is directly contained within T2, hence embedding the treatment advantage from the 
1st recurrent into the 2nd, resulting in larger treatment advantage and power. Whereas 
in a combined test, these effects are diluted as governed by the weighting scheme used 
(Section 4.4), leading to a smaller power compared to that for the marginal test on T2. 
Also, notice that the values of 9 for the paired, recurrent TT and recurrent GT cases 
(in the previous sections) are appreciably larger than those for other cases, to 
compensate for the heavy censoring imposed.
For the cases of complete, paired and indicators, the assumption of a common 
treatment effect is valid and hence reflected in the superiority of the global power 
compared to those of the marginal. PFS shows a slight variation between the estimates 
of treatment effect, and the marginal power is close to the global. The recurrent TT 
shows wider spread of the estimates, resulting in marginal power of bigger than the 
global. The superiority of global power is recovered when the 2nd option of data 
generation is used. Meanwhile, for the recurrent GT, the estimates are equal when d = 
1, hence the global superiority is observed. However, as the correlation increases, the 
estimates of marginal treatment effects start to vary and at d =10, the marginal power 
based on the 1st event exceeds the global power.
The results in this section imply that the method of data generation described 
in earlier sections gave data sets with proportional hazards for most of the cases, 
except for the recurrent events, although the 2nd option was close. The relationship 
between adherence to this key assumption and the performance of the global test 
shown here is similar to that of the proportional odds assumption displayed in Table 
2.12 on Page 50. Overall, this evidence further strengthens the theoretical advantage 
of the relationship between the Fisher’s information and sample size, as well as the 
superiority of the global test methodology when the assumption is valid.
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5.3. Discussion
The proposed method has achieved the intended type I error rate under the null 
hypothesis of zero treatment effect, and yielded accurate power relative to its 
theoretical power under the alternative hypothesis. The fundamental equations in 
Section 5.1, referencing to Section 1.7, simplify the procedure for deriving sample 
size and power for a clinical trial. This illustrates the benefit of the global test 
approach for the correlated bivariate survival data analysis. Meanwhile, the overall 
correlation ratio is good with a slight underestimation of 1%.
The comparison of the powers of marginal tests to that of the combined test in 
the previous section reveals an interesting finding with regard to the recurrent TT 
case. The higher power of the marginal test on T2 indicates that combined analysis 
may not be beneficial for the case of recurrent TT. This may be one of the scenarios in 
which previous authors have cautioned about regarding the appropriateness of use of 
the global test approach (Section 2.1). Additionally, when the data were generated 
differently, so as to give better adherence to the assumption of proportional hazards, 
the global power won back. It is to be learned from this particular simulation that 
perhaps when the correlation between the endpoints is high (e.g. the 2nd contains the 
1st), combining their analyses into one may not be beneficial: one may as well use the 
simpler marginal analysis for each endpoint.
Since the assumption of a proportional hazards ratio is deployed in this study 
design, any deviation from it may degrade the power of the test. In reality, this 
assumption is not always true and perhaps using the global test is still the best choice 
in general. For example, in the case of recurrent TT (Section 5.2.5), we may lose a bit 
on the power of the global test over the marginal, but in most cases the former is 
clearly superior to the latter. The global test methodology is intended for use where
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the correlation is positive, and it may be inappropriate in the case of negative 
correlation as might arise in situations such as duration of stay in ICU and time to 
kidney failure. As explained in Section 5.1, the diminishing power at high correlation 
is anticipated owing to the data generation method which yields Or  associated with the 
log hazard ratio within subject, Ow. The remaining challenge is to devise a method that 
gives the appropriate Or  which is based on the log hazard ratio between subjects, Ob -
In all of the analyses, the continuous data sets (real and simulated) were 
transformed into interval-censored data to enable the application of the proposed 
method. A problem inherent in our approach is that taking the intervals leads to a 
slight loss of power, as shown in the simulation results. Furthermore, appropriate 
choice of the number of intervals, as well as of the size of the interval, is important. 
Based on the exploration undertaken, setting up five intervals seemed to perform 
better than setting up ten in terms of the key performance measures defined. It is 
worth noting that the intervals used for the 10,000 simulation runs were fixed and thus 
may not have accurately divided the events from each run equally across each 
interval; although the impact should be minimal since the intervals were obtained 
using a very large sample size of 1 million.
As described in earlier sections, many real clinical studies deal with interval- 
censored survival data. An example of a naturally interval-censored survival data set 
is seen in a clinical trial comparing treatment advantage by analysing X-ray gradation 
which measures the loss of cartilage in the knee of arthritis patients (Whitehead & 
Thomas, 1997). As observed in the simulation study, application of interval censoring 
to continuous survival data should be carried out with caution as the number of 
intervals may affect the results appreciably.
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To conclude, the encouraging results, evident for both real and simulated data, 
show that our method works for the bivariate interval-censored survival data: 
complete, paired, related indicators, progression-free survival and recurrent TT. 
However, its suitability as a correlation estimator for the recurrent gap time model is 
questionable and is further investigated in Chapter 6, upon comparing it with the 
existing method of Wei, Lin Weissfeld (1989).
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Chapter 6. Comparison with the Wei, Lin and Weissfeld Method
In this chapter, a well-known approach to the estimation of the correlation between 
two estimates of treatment advantage for multivariate survival data, namely the Wei, 
Lin and Weissfeld method (WLW), is compared with our present method (ZW), 
which was described and investigated respectively in Chapters 4 and 5.
To begin with, a number of existing methods for multivariate survival analysis 
are introduced to paint the background in Section 6.1. This introduction is followed in 
Section 6.1.1 by an overview of marginal models. A description of the influence of an 
individual observation on a parameter estimate, including the jackknife technique and 
the delta-beta approximation is given in the subsequent sections; these are related to 
WLW, as will be shown in later sections. The concepts of the WLW approach will be 
described at length in Section 6.2, and its use in estimating overall treatment effect in 
Section 6.3. The subsequent Section 6.4 focuses on a theoretical comparison of ZW 
and WLW.
Practical applications to real data sets are demonstrated in Section 6.5, 
followed by a short discussion to preview Section 6.6 which centres on a simulation 
study to evaluate and compare the accuracy of these contending methods. Simulation 
results for each of the seven scenarios are presented and the overall results are then 
summarized in Section 6.7. A discussion of the findings concludes this chapter.
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6.1. Background
As clarified in earlier chapters, the scope of this thesis covers bivariate survival data, 
which provide the simplest case of multivariate data; an extension to other 
multivariate cases is also feasible. By definition, multivariate survival data arise when
(i) each subject may experience several events or (ii) there exists some clustering of 
subjects, which induces dependence among event times within the same cluster. 
Extensions of methods of univariate survival analysis to the multivariate setting have 
proved to be rather difficult, resulting in many different approaches: three of these are 
known as marginal, frailty and copula.
In marginal models, the association structure is left unspecified. It is to be 
recalled that our proposed method (ZW) decribed in Chapter 4, was developed from a 
marginal model. In this chapter, other marginal methods are now reviewed: namely 
AG (Andersen and Gill, 1982), PWP (Prentice, Williams and Peterson, 1981), and 
LWA (Lee, Wei and Amato, 1992) as well as WLW (Wei, Lin and Weissfeld, 1989). 
The methods of AG, PWP and LWA will be covered briefly in the next section, while 
WLW is described in more detail throughout this chapter.
Another approach is a frailty model, whereby the distribution of a random 
effect is specified. Meanwhile, a copula model offers an alternative by combining 
marginal distributions via a copula function, which specifies the dependence structure. 
Both the frailty model and the copula model are not within the scope of this work, but 
good descriptions are made available by Hougaard (2000) and Sun (2006) 
respectively.
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Oyer the past two decades, WLW has become a popular method for dealing 
with recurrent events. To date, the paper by Wei et al. (1989) has been cited over 600 
times. It has attracted criticism from many quarters, and a complete summary and 
appraisal are given by Metcalfe & Thompson (2007). They also claimed that as of 
August 2003, application of WLW in the analysis of recurrent events was reported in 
31 articles, while the use of the PWP method was reported in 24 publications. Several 
other authors have also studied WLW and assessed its suitability in many aspects; 
application to recurring and terminating events (Li and Lagakos, 1997), adaptation to 
the competing risks (Wei and Glidden, 1997), analysis of composite endpoints of 
longitudinal and survival data (Seville, Herring and Koch, 2010), and systematic 
characterization of methods for recurrent events using risk intervals, baseline hazard, 
risk set and correlation adjustment (Kelly and Lim, 2000). To describe the WLW 
method, we shall start with an overview of the existing marginal models, following 
this by a review of the jackknife technique as well as of both the exact delta beta 
technique and its approximation DFBETA, which are important in deriving the robust 
variance estimation in WLW.
6.1.1. M arginal Models
Marginal models are methods where the effects of explanatory variables are estimated 
on the basis of the marginal distributions. In the case of bivariate survival data 
involving two endpoints, this simply means that the set of data, say T\ and T%, for each 
endpoint is fitted to a standard Cox’s proportional hazards (PH) regression model 
separately without assuming any correlation. The marginal hazard function for the mth 
type of event on the iih subject is given by hm (t\ x im) = h0m (t) exp(^' x im) for a set of p
fixed covariates x t with a vector of regression coefficients, /?, m = 1, 2. It is to be
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noticed that the baseline hazard is specific to the mth event, but can be considered as 
common across all m events by omitting the subscript m accordingly. The choice of 
stratification has been described in Sections 1.6 and 4.6.1.
As mentioned earlier, the ‘working model’ assumes that the observations are 
independent. A model-based variance estimate is obtained from the inverse of the 
information matrix. However, due to the correlation between event times, it may not 
be a consistent estimate of the asymptotic variance. Thus, the estimates of the 
regression coefficients are used with empirical adjustment of their estimated variance 
using a sandwich estimator (further described later). This is the means to account for 
within-subject correlation. In this section, the well-known marginal models due to 
Andersen & Gill (1982), Prentice, Williams & Peterson (1981), Lee, Wei & Amato 
(1992) and Wei, Lin & Weissfeld (1989) are reviewed. Only the general principles are 
considered here, while more technical details are provided in those references.
The intensity model, AG (Andersen and Gill, 1982) assumes that all events are 
independent and are of the same type, and hence provides estimates of the treatment 
effect on the rate of events as a whole. Meanwhile, the PWP model (Prentice et al., 
1981) considers an extension of the stratified PH model with the m events as strata: 
the hazard function is event-specific. AG and PWP methods originally used a model- 
based covariance estimate which is the default in the SAS PROC PHREG procedure, 
but the robust variance sandwich estimator has been applied to these models by other 
researchers (Finkelstein, Schoenfeld and Stamenovic, 1997), to adjust for correlation.
The LWA model (Lee et al., 1992) is unstratified and hence assumes a 
common baseline hazard. It allows a subject to be at risk of multiple events 
simultaneously and accounts for the within-subject correlation by using the sandwich 
estimator. The WLW model (Wei et al., 1989) is rather similar to LWA except that the
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former is stratified by event type, giving event-specific hazard functions. For each 
model, the specific partial likelihood can be constructed accordingly in order to derive 
the parameter estimates and their variances. A good comparison of the hazard 
functions and partial likelihoods for these methods is given by Kelly & Lim (2000).
In normal distribution models, residuals are often evaluated for the purposes of 
checking the model assumptions and evaluating the variance estimates. Residuals for 
survival data can be similarly evaluated, although the precision depends on the nature 
of the data: observed event time or censored observation. The variance estimates 
derived in this manner are different from those usually obtained from the second 
derivative of the log likelihood function, which are the usual model-based estimators.
The variance matrix of the regression coefficients is given by Y =1 RI 1, where I  is 
the matrix of second derivative of the log likelihood function and R  is the variance 
matrix of a score vector. This sandwich-like form renders the name sandwich 
estimator, also often known as the robust covariance matrix estimator or the empirical 
covariance matrix estimator. A more detailed account of the derivation of residuals 
and influence diagnostics specifically for Wei, Lin & Weissfeld is given in the 
subsequent sections.
The sandwich estimator has achieved increasing use with the growing 
popularity of generalized estimating equations (GEE) in linear models; a similar 
version in survival analysis is provided by Wei et al. (1989). Traceable to Huber 
(1967) and White (1982), the method yields asymptotically consistent estimates of the 
covariance matrix for parameter estimates when a parametric model assumption is 
invalid, or is not even specified. Standard statistical softwares incorporate the various 
types of variance estimates into analyses such as SAS PROC PHREG, which can give 
both the model-based and sandwich-based statistics: illustrated in Section 6.2.
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6.1.2. Jackknife Method
Jackknifing is a well-known computational technique for estimating the bias and 
standard error of an estimate; which is very similar to its famous successor, the 
bootstrap. The general idea was proposed by Quenouille (1949) for estimation of bias, 
and Tukey (1958) explored its potential for estimating standard errors: further 
development has been provided by others since then. As with any resampling 
technique, the jackknife does not make any specific distributional assumption. The 
procedure consists in taking repeated subsamples of the original sample of n 
independent observations by omitting a single observation at a time: useful in 
evaluating subject or case influence. Its relationship to WLW is quite interesting and 
shall be demonstrated in the subsequent sections.
Suppose we are interested in a parameter P on a basis of random sample x  -  
(xj, X2,...,xn) of an unknown population G. Taking this random sample of n 
observations would give an estimate p  which may be biased, and for which 
estimation of standard error is needed. The jackknife uses the sample by removing the 
first observation xj, leaving a “jackknife data set” of resampled values, say x (]). The 
statistical analysis is performed on the reduced sample size of n - 1, giving another
value of the parameter estimate, say . Then another resampling is done, this time
throwing out the second observation x2, and p {2) is obtained from the subsample x (2).
The process is repeated for each observation in the sample resulting in a set of values
/?(1),/?(2), . . . , T h u s ,  each subsample x (i) comprises n -  1 observations formed by
deleting a different observation from the sample of size n. A schematic illustrating the 
jackknife algorithm for estimating parameter is provided in Figure 6.1.
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Figure 6.1: Schematic of the jackknife algorithm for estimating parameter, inspired by 
the bootstrap algorithm (Efron & Tibshirani, 1993 p48).
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The jackknife estimate and its standard error are then calculated from these 
reduced subsamples: n  subsamples each of size n  - 1. The former is the mean of the 
jackknife estimates P {i), given by
a . ) = E A o / ni=i
while the latter is defined as (Efron and Tibshirani, 1993)
(6 .1)




Notice that the jackknife estimate of the standard error for P (, } , involves an inflation
factor of n - 1  compared to the standard deviation for f i ( i ) .
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To illustrate the need for this inflation factor, Efiron & Tibshirani (1993) 
consider a special case where P = n and f i  = x . Then it can be shown that
K ) =x(i)= ( n x - x i) I ( n - l )  (6-3)
and subsequently the average of the jackknife estimate of parameter ft is
R - I V -  - -  (6'4)A*) *(•)
n  i=i
Substituting equations (6.3) and (6.4) into equation (6.2), we get
f n -  A ''seJK -  j ~ x ) 2/ n \
(6.5)
which resembles the usual definition of a standard deviation for the population. This 
explains the need for the inflation factor of n  -1 in equation (6.2), to make the 
jackknife estimate of the standard error unbiased. The reason for the difference is that
A A
the jackknife sample means J3{i) are distributed n  -1 times closer to the mean /?(#) than 
the original values, A . Consequently, the jackknife estimate of variance for J3 is
„ n - \ ^  ~ 2 (6-6)
var(/?) = ----- £  (J)m -  # . ) )  .
n ,_i
Although the inflation factor is justified by considering a special case in which f t  = x  
, it appears to be workable in general. Note that ft is a  scalar parameter in the above 
expression for univariate data. For ease of referencing, the term jackknife influence 
represents the quantity fi{i) -  J3{m) hereafter in this thesis.
Suppose n subjects are randomized between treatments E  and C. Equations 
(6.1) and (6.6) can be used to obtain the jackknife estimates of treatment advantage
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and its variance respectively. In the case of bivariate survival data with two event 
times, is now a vector parameter of treatment effects, and the corresponding
estimate,/?' = (PX,P2) . Their variances, var(^) and var(/?2) can be obtained using 
equation (6.6). The jackknife influence can be generalized by p{i)m - P{.)m where m =
1, 2 for such bivariate case. To further simplify, put Jmi = f3{l)m -  P(.)m and equation
2
(6.6) is rewritten as varp m = {(n - 1) / n) ^  Jmi .
i=1
As described in Section 4.1, to estimate an overall treatment advantage, p , we 
need to find the covariance between the two estimates of the marginal treatment 
advantages, cov{/3x,J32) . According to Efron (1982), the jackknife variance-covariance
matrix between two parameter estimates, fix and P2 is given by
COV(Pv P2) = — P(,)\)(P(i)2 ~ P{»)2)
n i=1
The covariance is given by the summation of the product of the jackknife estimates for 
the 1st and 2nd events, with an inflation factor similar to that for the variance above. 
This can be rewritten as
~ ~ n - l ^ ,  T _ (6-8)
CO V ( P X , P 2) = --------- ^ J UJ 2i-
n /=i
Consequently, the jackknife estimate of correlation can be expressed as
corrJf, (/?,,/?,)= , a • (6.9)Jn n 21 21/=1 i= l
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In matrix notation, this can be further simplified by taking being a
column vector of the n jackknife estimates for mth event, m = 1, 2, and giving the
covariance as
( R  R \  n ~ l T ' r  ( 6 , 1 ° )CO v(j31,fi2) = — j ;j 2, 
n
and the correlation
corrjk0 v Pi ) = , T, T lT tT ,1/2-
j ;j 2 (6.11)
(j ;j j 2j 2)1
The correlation between the jackknife estimates of parameters P{ and p 2 is used for 
comparison with alternative methods in the next section.
Efron & Tibshirani (1993) cover a good deal on the jackknife technique 
although specifically in its relation with the bootstrap method. Meanwhile, an account 
of the use of the jackknife in the derivation of a robust estimate of variance for the 
Cox’s model is given by Themeau & Grambsch (2000). They claimed that such
natural approximation cov{pv P2) by ignoring the inflation factor (n - 1 /n), as
mentioned earlier may be preferable. A study by Lipsitz et al. (1990) concluded that 
this approximation is indeed preferred even for a small sample size. It resembles a 
sandwich estimator which is common from robust variance estimation in parametric 
models and in GEE-like methods such as that of Liang & Zeger (1986). A sandwich 
estimator appropriate to the Cox’s model has been derived by Lin and Wei (1989) and 
is algebraically equivalent to J[J2 but was not described within the jackknife context: 
a point explored in the subsequent sections of this chapter.
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6.1.3. Exact Delta Beta and its Approximation (DFBETA)
A logical way of evaluating the influence of any observation is by observing the 
difference in parameter estimates, one made when that particular observation is 
omitted, and the other made when the full data set is used. This procedure is related to 
the jackknife method with the exception that the effect of removing ith observation is
quantified by the difference between the parameter estimates p  and p {i). Instead of
A A
taking the difference between the average of the jackknife estimates, j3(%) and J3(i), the
parameter estimate f t , which is obtained from the complete sample size of n is used. 
In this thesis, the actual influence of the observation termed “delta-beta” is expressed 
as A.y# = fl{0 - P ; adopting the notation used for the plots in Section 4.3.1 of Collett 
(2003).
Both the jackknife influence (J3(n -  p {,}) and the delta-beta ( p (0 -  P ) require
computation of P(i) for their evaluation. The exact computation of Pin involves
refitting the model each time a subject is omitted, which is computationally expensive 
when the sample size is large. The effect of removing one observation from a survival 
data set is more complicated than for other types of data. Mathematically, the log 
likelihood function for the Cox’s model cannot be expressed as the sum of terms in 
which each term is the contribution by each observation. This implies that any 
exclusion of an observation cannot be simply modelled by omitting a single 
corresponding term. In fact, the exclusion of one observation affects the risk sets over 
which quantities of the form exp(/?'x) are summed (Collett, 2003). A practical option 
is given by Cain and Lange (1984) who derived the following approximation of delta- 
beta as weighted score residuals.
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Suppose each individual has a set of data comprising a vector (t, 3, x ) where t 
is the time from the start of the study until death or censoring, 3 is the censoring 
indicator, 0 for censored, 1 for death, and x  is a row vector of covariates. When there 
are no ties, the partial likelihood is given by the product of the partial likelihood 
corresponding to the risk set R{tj),
where D is the set of subjects who died at time U and U > tj. Its similar form to that of 
the earlier equation (3.8) is to be noticed.
Cain & Lange (1984) derived an approximation to f3{i) based on the first-order 
Taylor series. Suppose that observation j  is given weight vv, leading to a likelihood of
Now, we focus on subject i, and its parameter estimate, fi(i). For 
approximating fi(i), Cain & Lange choose the weighting wj = w if j  = i, wj = 1 
otherwise. Further denote the estimated vector of coefficients P  when this weighting 
is used, by # ( w) . If w = 1, then all observations are weighted equally and the standard 
estimation is obtained: #(1) =P- If w = 0, then the ith observation is simply excluded,
u p ) = r i A w = n j  exp ( ^ ) 7 x  exp<x/?)
the form
z wi tx v(x iP)
Then, the log likelihood is given by




so that f l ( Q ) = f t { f r  The approximation to delta-beta based on the first-order Taylor
series expansion about w = 1 is thus approximately equal to the derivative of j|(w ) 
where
dB-d) (6.14)
A (w )= f l( i)  + ( w - l ) S f i W .
aw
Now substituting w  = 0 and re-arranging, we have
0 - f i m =dfi,(l)ldw,  »-15)
as stated by Cain & Lange. The derivative term in equation (6.15) is the 
approximation used in the infinitesimal jackknife (Miller, 1974; Efron, 1981). It is to 
be recalled that previously, the score statistic was denoted by Z  when evaluated under 
the null. In this section, U  is used instead, as the the score vector is now a function o f
both J 3 ( w )  and w .  To evaluate 3 $ (l)/5 w , their relationship is defined at
u (f l(w ),w j = 0 . The derivative of the score vector is thus given by
(dU /  c ji)(c p  /  dw) + (8U  /  Sh-)(5vi' /  dw) = 0, (6-16>
and therefore the delta-beta approximation is
d p i d w  = ( -8U/djST'dU/dw.  (6 J 7 )
It is to be noted that the term in parentheses is the observed information matrix and is 
denoted by I  in this chapter. From equation (6.13), the log likelihood can be re- 
expressed as
m = p ’L * /jx i - ' L wi logj 2 ]  wi expC-^y?) [•
j e . D  j e D  J (6.18)
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Following the relationship described in Section 1.4, and from equation (6.18), the 
derivative of the log likelihood with respect to fi  is the score vector U :
To distinguish explicitly between the contributions when subject i is in the risk 
set and that when subject i is excluded from the risk set, further notation is necessary. 
Suppose Di is the set of all subjects, other than subject i who have died, while <5, = 1 if 
subject i died and Sj = 1 if subject i is at risk when subject j  died, 0 otherwise. 
Equation (6.19) can be rewritten as
where R(tj,t) is the risk set at time tj, excluding subject i. Its derivative with respect to 
w can be obtained via the product rule and subsequently the quotient rule,
Z w ix i exp(*/>ff)
Z  Wzexv ix tP)
(6.19)
I z R ( t j )
^  x l exp(jc;/?) + wSjx i exp(jc(./?)
Z  exP(x,P)X  i > + w8j exp(jc./?)
(6.20)leR(tjj)
^  x t exp(xz/?) + wxt Qxp(xt fl)
JeD, z exp(xz/?) + wexp(*z/?)
dU „ v - s i{«?(*,•£)}(Ajx i - Bj)
- t -  = 3 * i - L  ------------- 7 1 ---------------6W jeDi j
Z  x l exp(*z/0) + wxt exp ix fi)
2  exp(xzyff) + WQxp{xtP)
l eR(t j )





Aj ~ j X  exP(*//0 + wSj exp(*(./?) I , B. =J Y  xt expixfl)  + wSix i exp(x,.y#) L
[ W j j )  J [/e*(Ov> J
4  =  I  ex p ^ y ^ ) +  wexp(x.y^) L ^ . = 1  JC( exp (x /yff) +  WX; exp(jt(/?) i.
J [/e/?(r(V) J
It is to be noted that R(tij) is the risk set at time % excluding subject i. Putting w = 1 in




^  *, expfx,/?)
^  exp(x,/?)
IsR(t j )






Z  x , eM x iP)
leR(tj)
£  e x p ( ^ )
l sR( t j )
(6.22)
The change in the score vector t7 with respect to changes in w, is given by the 
sum of two parts, as shown in equation (6.22). It is to be noted that the first part is 
included only when individual i died (St =1) ,  which is the difference between the 
covariates for i and the weighted average of covariates for all individuals who are at 
risk at time u. This part is indeed the Schoenfeld residual (Schoenfeld, 1984). 
Meanwhile, the second part is a summation of the effects that changes in w have upon 
all the risk sets that include individual i at time tj. Graphical representation of 
individual parts as well as the resulting approximation per equation (6.22) are 
illustrated and examined by Cain & Lange (1984). Combining equations (6.15), (6.17)
and (6.22) provides an expression for ft - f i (i), the delta-beta approximation.
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An alternative expression is given by Collett (2003, p H 9) in the form of score 
residuals,
which is indeed the same as the quantity Wifi) formulated by Wei et al. (1989) as part 
of equation A.2 in their Appendix. This means that all these three quantities appearing 
in Wei et al. (1989), Collett (2003) and Cain & Lange (1984) are indeed different 
ways of expressing the same approximation.
Consequently, putting equation (6.23) into equation (6.15), the approximation
A
to delta-beta can now be expressed as R I  where R  is the vector of score residuals as
given above, and I  is the inverse of the information matrix. The quantity R I  is an 
output known as the matrix of DFBETA residuals, readily given in statistical software 
packages such as SAS. As shown earlier, these DFBETA statistics are a 
transformation of the score residuals, and are utilized in computing the robust 
sandwich variance estimators of Lin and Wei (1989) and Wei, Lin, and Weissfeld 
(1989). Further description follows in later sections.
eXp(/?W) (6.23)
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6.1.4. Comparison of Influences: Jackknife, Delta-beta and DFBETA
The jackknife influence, exact delta-beta and DFBETA have been described in the 
previous sections. Considering bivariate data (m = 1, 2), a comparison between the
jackknife influence (J3m(i) -jfl„l(#)), the exact delta-beta -  f$m) and the DFBETA
(RJm), is shown below. The construction of these plots is quite similar to that given
in Cain & Lange (1984) and Section 4.3.1 of Collett (2003), except for the inclusion 
of the jackknife influence. In Figures 6.2 (a) to (c) below, the vertical axis is the 
quantity we can generally call influence which are evaluated using the jackknife 
influence, exact delta beta, and DFBETA.
In this section, the bladder cancer data (Section 4.6.2) is used for illustration. 
Due to the nature of the data set, whereby the times are recorded to the nearest month 
resulting in many ties, plotting against the rank order of event times as per Cain & 
Lange (1984) and Collett (2003) is not favoured. Alternatively, we shall examine the 
influence for treatment against the patient’s ID via these three methods. T\ and T2 are 
the times from start of study to the 1st and 2nd recurrence of tumour respectively based 
on 86 patients in the bladder cancer study described in Chapter 4 earlier. Influences 
based on T2g are also plotted for the gap time between the 1st and 2nd recurrences.
181
Figure 6.2: Plot of the influence using the jackknife, exact and DFBETA methods for 
treatment against patient id for the bladder cancer data
(a) failed and censored for 7j
x Jackknife (censored) a Exact (censored) 
x Jackknife (failed) A Exact (failed)
O DFBETA (censored) 










The points in red are influences for the patients who failed and blue indicates 
those who were censored. Notice a clear separation (above and below 0) between 
patient ID 1 to 48 on control from those on experimental. It is observed that DFBETA 
gives slightly lower values than the exact method, and the jackknife. There are two 
large influences of about 0.06 for treatment observed for patients 56 and 75 on 
experimental who both failed at month 1. This suggests that the exclusion of either 
patient changes the hazard of tumour recurrence relative to the baseline hazard, thus 
making the effect of treatment either slightly more or slightly less significant, but may 
or may not necessarily be of clinical importance. Meanwhile, patients 49 and 50 on 
experimental who were censored at month 1, and patients 24 and 31 on control who 
failed at month 5, show almost zero influence for treatment. Figures 6.2 (b) and (c) 
show similar plots for T2 and T^ g-
182







x Jackknife (censored) a Exact (censored) 0  DFBETA (censored)
•DFBETA (failed)x  Jackknife (failed) A Exact (failed)
(c) failed and censored for (gap time)
x  Jackknife (censored) * Exact (censored) o DFBETA (censored)

























w  « 30 S 40 .  50 60 m 10
Q
-------------- 8 ------





---- &—------ 8  » s
8
Patient's ID
It is evident from these plots that all three methods give very close values of 
the influence. The jackknife technique gives values closest to the exact method, while 
the approximate DFBETA approach tends to underestimate slightly for some patients. 
No incident of overestimation by DFBETA is observed in any of the plots above. This
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illustration supports (although it is not a comprehensive justification) the use of 
DFBETA as an economical approximation to the delta-beta. Two points to note are:
(i) clear separation between control and experimental except for Tic (gap time), and
(ii) the values for Ti failures (beyond id 48) are about twice of those for T\ failures as 
T2 includes 7j in total time convention. When using the gap time, there were forty 
observations (26 censored, 14 failed) with zero influence, most of which T2G were 
censored due to censored T\ at month 1, while no particular pattern is observed. Figure 
6.2 (c) reveals some interesting findings. For example, it did not matter much whether 
or not those subjects who were censored for T\ were included when computing the 
parameter estimates with respect to Tig- However, their inclusion would reduce the 
variance of such estimates for Tzg- N ow that the relationship between the jackknife 
and DFBETA is clearly established, the WLW method is described in the next section.
6.2. The Wei, Lin and Weissfeld (WLW) Method
Consider a study to compare the treatment effects of experimental and control using 
bivariate survival data comprising two correlated event times for each patient with 
fixed covariates. As mentioned earlier, a marginal model uses a standard Cox’s 
regression model to fit data at each event time separately (say T\ and T2), assuming no 
correlation within or between subjects. The parameters p x and p 2 represent the 
effects on the whole population and hence their estimates represent the effects of 
covariates (e.g. treatment) on the population average. The estimates of regression
coefficients Px and P2 are then used, but their estimated variance is empirically
adjusted using a sandwich estimator. This is analogous to the GEE approach of Liang 
and Zeger (1986), applied to Cox’s models by Lin and Wei (1989); Wei, Lin and 
Weissfeld (1989); Lin (1991); and Lee, Wei and Amato (1992).
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WLW offers a solution for analyzing bivariate survival by providing robust 
variance estimates that allow for multiple event times. To date, none of the mentioned 
methods, with the exception of WLW, give the estimation of the correlation 
coefficient and hence the covariance which is our key objective in this research. This 
justifies the comparison of our method with that of WLW. As already noted, WLW 
uses the standard Cox’s PH model, stratified by type of event, in computing the 
estimates. Suppose we have the mth type of event, m = 1, 2, let tmi be the event time of 
the zth subject, i = 1,2,..., n and tmi = min(tmi, cmi), where cmi is the censoring time. For 
each observed event time, let S ■ = 0 if tmi = cmi (censored), and 1 otherwise. Now
consider a p  x 1 vector of covariates x mi = (xlmi,...,x  for the ith subject at time
t > 0 with regard to the mth type of event. By analogy to equation (3.8), the partial 






where Pm' = is the event specific regression parameter and
< tmi |  is the risk set just before event time tmi with regard to the m 
event. In situations of common P , the subscript m in equation (6.24) is to be omitted. 
As usual, the maximum partial likelihood estimator f im is defined as the solution to
the first derivative of the log likelihood: d£ / dp , = 0, and these P ,  s are generally 
correlated. These maximum likelihood estimates are therefore the values that 
maximize the likelihood function. Details of a complicated derivation using 
martingale and counting process theories are not reproduced here and can be found in
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Wei et al. (1989). Alternatively, we describe WLW in a simpler way, based on the 
fundamental influence diagnostic described in the previous section.
As introduced earlier, WLW uses Cox’s model directly to obtain the estimates 
for each event separately, and p 2, while the adjusted standard error is given by 
using the robust sandwich variance estimation method. Wei et al. (1989) showed that 
asymptotically, f i  ~  N(J8,Y), where J0 = (/?,,$>)' and the estimated covariance
matrix Y is composed of the submatrices Ynm = {Rmi m) \R mi m) , given by the product
of the matrix of DFBETAs with its own transpose (Section 6.1.3). Notice that upon re­
arranging the expression, the inverse matrices of information on both sides of the 
residual scores resemble the bread of a sandwich.
In computing the robust sandwich variance estimators of Wei, Lin, and 
Weissfeld (1989) and also described in Lin and Wei, (1989), it is more convenient to 
use the DFBETA statistics than the score residuals, since the latter would require 
further coding. As described in the previous section, DFBETA is an approximation to 
the exact delta-beta, which is also close to the jackknife. Hence, alternatively, 
DFBETA could be replaced by these two influences in WLW, which are explored 
later in this section. In this study, treatment is considered to be the only covariate; 
hence the parameter of interest /? is the treatment effect. It is to be recalled from 
Section 4.4, that the SAS PROC PHREG procedure is computed such that /? is 
negative, when experimental is better than control. Therefore, relating this quantity to 
the notation used for ZW, the treatment effect 9 = -p. To illustrate WLW, the 
following SAS codes and their corresponding outputs for the bladder cancer data are 
given in Figures 6.3 to 6.5.
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Figure 6.3: Part 1: SAS codes and output for analysis of the bladder cancer data using
WLW.
PROC PHREG data = sint_wlw outest = estl COVS (AGGREGATE) ; 
MODEL tstop*status(0) = trtl-trt2;
TREATMENT: TEST trt1,trt2/AVERAGE e;





T es t in g  Global Null H ypo thes is :  BETA®0
Test Ch i-Square DF Pr > Ch i Sq
L ik e ! ih o o d  R a t io 3.5494 2 0.1695
Score  (Model-Based) 3.4887 2 0.1748
Score (Sandwich) 2.3520 2 0.3085
Wald (Model-Based) 3.4228 2 0.1806
Wald (Sandwich) 2.3163 2 0.3141
t r t  I 
t r t 2
A n a ly s is  o f  Maximum L ik e lih o o d  E s t im a te s
Param eter S tandard S tdE rr Hazard
DF E s tim a te E rro r R a t io  Chi -Square Pr > ChiSq Rat io
1 -0 .36266 0.29721 0.982 1.4889 0.2224 0.696
1 -0 .55178 0.37247 0.952 2.1946 0.1385 0.576
L i n e a r  C o e f f i c i e n t s f o r  T e s t TREATMENT
A v erag e
P a r a m e te r Row 1 Row 2 E f f e c t
t r t l 1 0 0 .7 9 7 8 3
t r t 2 0 1 0 .2 0 2 1 7
CONSTANT 0 0 0 .0 0 0 0 0
T e s t  TREATMENT R e s u l t s
Maid 
Ch i - S q u a r e DF
2
P r  > Ch i Sq 
0 .31412 .3 1 6 3
A v erag e  E f f e c t  f o r  T e s t  TREATMENT
E s t  im ate  
-0 .4 0 0 9
S ta n d a r d
E r r o r
0 .2 9 1 3
z - S c o r e  
-1 .3 7 6 1
P r  > i z i  
0 .1 6 8 8
187
The first line in Figure 6.3 is a standard SAS statement for Cox’s PH 
regression model, with CO VS specifying a sandwich-based covariance instead of the 
usual default, a model-based covariance. Consequently, the first part of the output 
shows a typical PHREG output, with inclusion of the sandwich Wald and Score tests. 
It is to be noticed that these sandwich quantities give smaller chi-squares compared to 
their corresponding model-based quantities. For example, the sandwich-based score 
test gives chi-square value of 2.3520, which is smaller than 3.4887 of the model- 
based. Consequently, a global null hypothesis test for the former gives a larger p-value 
(0.3085) compared to the latter (0.1748). The model-based covariance matrix is 
simply the inverse of the observed information matrix, while the sandwich counterpart
is further described later. The parameter estimates for trt 1 and trt2 refer to /?, and p 2
respectively; their hazards ratios are given by exp( Px) and exp( p 2), for example, the
hazard ratio for trt 1 is exp(-0.3627) = 0.696. Notice that the analysis of MLE gives a 
Std Error Ratio, which is the ratio of the sandwich-based standard error estimate to the 
model-based standard error estimate.
The robust sandwich estimate is used in the Wald tests for testing the global 
null hypothesis, and null hypotheses of individual parameters. These tests are so
constructed that the former is given by p 2 / var($) + p 2 / var(/?2) ~ j 2 and the latter
p 2 / var(P) ~ Zi • The AGGREGATE option requests a summing up of the score 
residuals for each distinct ID pattern in the computation of the robust sandwich 
covariance estimate. Note that the ID statement on the second last line is necessary for 
this AGGREGATE option to work: taking into account the fact that the recurrent 
event times are from the same individual. The MODEL statement specifies the 
variables of survival times and censoring indicators.
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The TREATMENT: TEST statement is used to perform the global test of no 
treatment effect for each tumour recurrence, while the AVERAGE option is specified
to estimate the parameter for the common treatment effect ( p  -  -0.4009), and the E 
option displays the optimal weights for the common treatment effect. These weights 
are displayed as the average effect for trtl (0.79783) and trt2 (0.20217) above, and are 
described further in Section 6.3. The last three lines of the above codes are standard 
commands for SAS to stratify by visit, identify output of DFBETA by ID and RUN 
the codes. The resulting p-value for the bladder cancer data above is 0.1688 (two- 
sided), thus there is no significant evidence to reject the null hypothesis of zero 
common treatment effect. Next, the DFBETAs computed for each individual in the 
standard PROC PHREG as shown in Part 1 earlier, are now subjected to further 
processing using the codes displayed in Figure 6.4.
Figure 6.4: Part 2: SAS codes for summing DFBETA from the output of WLW
earlier.
PROC HEANS data = outl noprint;
BY id;
VAR dtl-dt2;
OUTPUT out = out2 sum = dtl-dt2; 
RUN;
To compute the correlation of our interest in this thesis, these DFBETAs 
termed as dtl and d tl in SAS, are then summed by ID via PROC MEANS procedure, 
as displayed in Figure 6.4 above. The sums of DFBETAs per individual are then 
called out for a standard matrix manipulation using PROC IML, to arrive at the 
variance-covariance matrix and ultimately the correlation. The codes used for this 
purpose are listed in Figure 6.5.
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Figure 6,5; Pan 3: SAS codes and output for WLW to compute the estimated 
covariance and correlation (Courtesy o f Thomas Hamhorg).
PROC IHL;
USE out.2;
READ all var{dt 1 at.2> into x; 
v  = x ' * x;
RESET noname;
vnarae = < " t r t l" ,  "trt.2 "} ;
corr = v[l,2]/SQRT(v[l,l]#v[2,2] ) ;
v[l,l] = l/v[l,l];
v [2,2] = l/v[2,2];
v [ l j r  2] = v[l,2] # v[l,l] # v[2, 2] ;
v[2,l] = v [ l , 2];
CALL SYMPUT(1vlwCorr*,LEFT(CHAR(corr,6,4))};
PRINT, "estimated covariance matrix (¥L¥)", ,
v[colname = vname rownaitte = vname format = 1 0 . 5 ] ;  
PRINT, "estimated correlation", corr[colname="corr"]; 
CREATE rcov from v[colname = vname roiname - vname] ; 












It is to be noticed that the variable coded as x  above is the DFBETA, labelled 
as dtl and d tl  for the 1st and 2nd events respectively. The computation o f “v = x ' * x ” 
yields the matrix product




Kdt2^ ' * 2 n  J A ^ 2 n  y
YK.* 21 Y 22 J (6.25)
where Y}} and Y22 are the variances of the estimated treatment advantages and fi2
respectively, and F12 = Y2] = covariance between the two estimates, as shown in
Figure 6.5. Taking an inverse square root of Fn (11.32) gives exactly the standard
error for trt 1 (0.2972) in Figure 6.3 and similarly for Y22 which concerns the 2nd 
event, trt2. The written SAS program gives exactly the same output as the PHREG 
codes, but includes the covariance and the correlation, which is estimated by
corT(M) = ^ * ^  = - f e = .
4 YuY22 yYnY22 (6.26)
Part 3 coding shows how this parameter is computed in various steps described above. 
A complete set of SAS codes to run this program for analysis of real data is attached 
in Appendix B.
As mentioned earlier, the DFBETA was shown to slightly underestimate the 
influences given by the exact delta-beta and the jackknife. How would such 
differences affect the estimated correlation? To answer the question, an investigation 
is carried out using the bladder cancer data. As already described in Sections 6.1.2 and
6.1.3, computation of both the jackknife and exact delta-beta requires that each of the
86 observations be omitted one at a time and the (n - 1) estimates, jd{i) be found.
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Specific codes are needed to exclude each observation in turn and each of the 86 
estimates can be achieved by using SAS codes in Figure 6.3, but removing the “COVS 
(AGGREGATE)” option and the “ID id” accordingly. The only difference is that the
jackknife compares p (i) with the average of the (n - 1) estimates, 0 {m), whereas the
exact delta-beta compares j3{i) with the estimate from the complete data set p . Using
these different values for the influence, the estimates of the two treatment advantages 
and the covariance between them can be computed using similar codes in Figure 6.5, 
but replacing the quantity DFBETA by that of the exact delta-beta and jackknife 
influences accordingly. A complete set of SAS codes to perform this comparison is 
attached in Appendix C. The results for the bladder cancer data using these three 
influences are presented for total time and gap time in Table 6.1.
Table 6.1: Various estimated quantities for the bladder cancer data using the methods 
of jackknife, exact delta-beta and WLW for total time (TT).
(N.B. Multi-place decimals are intentional to show the minute difference)
Parameter
(s.e.)
Jackknife Exact Delta-Beta WLW (DFBETA)
4





















From Table 6.1, the jackknife method gives slightly higher estimates of 
individual treatment advantage when compared to those for the exact and WLW. As 
anticipated, the estimates of variance using the exact and jackknife methods are very 
close to each other, but much higher than those of WLW which uses DFBETA; note
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similar observation for the covariance* The correlation mines for al! methods are 
comparable to each other and exact to one decimal point (0.6) for TT.
Table 6 2 Various estimated quantities for the Madder cancer data using the methods 
of jackknife. exact delta-beta and WLW for gap tune (GT).
Parameter





















Meanwhile, Table 6.2 shows that the estimates from all three methods have 
similar values, the jackknife giving the highest estimate of covariance. However, all 
the covariances and the correlations are essentially zero for the bladder cancer data 
using the GT model. This small evidence may support the justification for using the 
DFBETA in practical applications.
6.3. Estimation of an Overall Treatm ent Advantage: WLW
As described in Section 4.4 earlier, a key objective of a clinical trial is to compare the 
overall treatment advantage, say p  between experimental and control treatments. The
assumption of equal treatment advantage $  = /?, = p  is always valid under the null
hypothesis since the common value is zero. However, under the alternative where
Pi = p 2 = p  9 but p  * 0 , it is natural to estimate p  by a linear combination of f t , with
the relationship p  = wxp{ + w2P2. The choice of weighting which yields the smallest 
asymptotic variance among all of the linear estimators (Wei & Johnson, 1985) is
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adopted in WLW. Solving for the derivative of vajfjB) equals to zero, the optimal 
weighting for WLW is
(v 'i ' lt ; )\\TW ~ y~ ~ c, a - c ,
V )i + 3J2 -  ’ A + )?2 ~  2Cu- (6.27)
where yx = vai'(^), y2 = var(/?2), and cw = cov($ ,;#,). This equation is similar to the 
optimal weighting used for ZW in equation (4.10), except that the variances and 
covariances relate to Z, in the latter. As shown in the previous section, this optimal 
weighting is specified by including CO VS (AGGREGATE) within the options of 
PROC PHREG statement. Without specifying the option “AGGREGATE”, SAS 
would treat the recurrent event times from the same individual as if they were from 
different individuals. Therefore, the covariance in equation (6.27) is taken as zero, and 
consequently giving a different overall treatment advantage. In fact, when cw = 0, the 
overall treatment advantage is found to be exactly the same value as our estimate,
#* = Z * / V *, but of opposite sign ( 6 = - f t )  as already defined in Chapter 4. The 
effects of both types of weighting on the estimated overall treatment advantage are 
illustrated using real data in Section 6.5.
The option COVS (AGGREGATE) gives the robust sandwich estimate of the 
covariance matrix, and the score residuals used in computing the middle part of the 
sandwich estimate are aggregated over identical ID values. This is a means of 
empirical adjustment for correlation within the data sets without specifying any 
dependence structure within the model itself. As shown by the standard error ratio in 
the previous section, the robust sandwich gives a smaller estimate of standard error 
compared to the model-based. This robust variance estimate was proposed by Lin and 
Wei (1989) and Reid and Crepeau(1985), and adopted by WLW (Wei et al., 1989).
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As described earlier, the optimal weighting serves to correct for the 
dependence structure between the multiple events, hence giving the smallest variance. 
However, the optimal weighting which weights the marginal estimates by the inverse 
of the covariance matrix has been criticized for its peculiarity of yielding undesirable 
negative weighting (Pocock, 1997; Tang et al., 1993). This situation is evident in the 
case of the bladder cancer data for the third recurrence (Wei et al., 1989): the optimal 
weight for estimating the parameter of the common treatment effect is -0.07547 as 
cited in SAS 9.2 example. This negative weighting scenario arises when the 
covariance is larger than the variance as permissible in equation (6.25). Saville et al. 
(2010) claimed that use of equal weighting for WLW provided better performance 
than the weighting used by Wei et al. (1989); the former is hence recommended. 
Nevertheless, our method adopts the latter as it yields the smallest variance estimate 
and consistent with our comparator, WLW.
Although WLW was not intended exclusively for recurrent events, following 
its first appearance in illustrating recurrent failures, it has been a popular choice for 
such cases. There is a mixed opinion among authors as some recommend it while 
others criticize. For example, Lipschutz & Snapinn (1997), Kelly & Lim (2000), and 
Metcalfe & Thompson (2006) contended that WLW overestimates the treatment 
advantage, largely owing to the carry-over effect when using total time model. 
However, Metcalfe & Thompson (2007) later reviewed and evaluated the semi- 
parametric model method in the analysis of recurrent event data and concluded that 
the application of this method to recurrent event data is justified. None of the above 
mentioned authors employed WLW using the gap time. Wei et al. (1989) have used 
gap time in their illustration, but no substantial discussion followed. Here, we 
compare and contrast WLW with ZW for both total time and gap time risk intervals.
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6.4. Theoretical Comparison: ZW vs. WLW
From earlier sections, the coefficient of covariates is denoted by . Since this study 
considers treatment as the only covariate, the focus is on treatment advantage. It is 
recalled from Section 4.4 that 0  equals minus (3 and the former notation is now 
adopted throughout the remainder of this thesis. Restating, WLW provides estimates 
which asymptotically follow the normal distribution, 0 ~  N {0,Y) where Y  is the 
robust variance-covariance matrix.
As described in Chapter 4, our method is a direct approach which conditions 
on the successive risk sets and reproduces the familiar form of logrank variance. It 
capitalizes on the efficient score, Z which is essentially the cumulative treatment 
advantage. Meanwhile, its null variance is given by the Fisher’s information V. 
Asymptotically, Z follows a normal distribution, Z ~ N(6V, V). Both quantities Z and V 
are calculated as interval-censored logrank statistics and their null variances 
respectively, with unadjusted standard errors. The null hypothesis of no treatment 
difference is tested using Z\ + Z2 and its null variance V\ + V2 + 2Ci2 where C12 is the 
estimated covariance as derived in Chapter 4.
The WLW procedure used to estimate the variance is applied to the whole data 
set hence termed population-average method. On the other hand, ZW computes the 
variance for each set of 2 x 2 tables in turn, and sums up the covariance. In WLW, the
Wald test statistic is given by 0/s.e.{6) with an adjusted standard error. 
Unconditionally (on the risk sets), the score residuals R defined in equation (6.23) are 
independent, identically distributed random variables, obtained by evaluating the 
changes in the score vector V  with respect to changes in weighting of the z'th
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individual, as shown in Section 6.1.3, resulting in equation (6.22). In WLW, the 
covariance is evaluated and the parameters are estimated under the alternative 
hypothesis (Wald test), while those for the combined score test approach of ZW are 
accomplished under the null.
Consider a simple case where we have subjects randomized to experimental 
and control groups, with two correlated event types, m = 1, 2, and we want to find the 
treatment advantage 0. As shown in Chapter 4, the treatment advantage can be
A A
estimated by 0 = Z ! V , and therefore var( <9 )= 1/V since var(Z)«  V. The covariance 
between treatment advantage for the 1st event and that for the 2nd event can be 
expressed as
co v(01,02) = E f z z  'I12 ( z i l (  Z2 1- E 1 E
VVV 12 J U J I y j
_ cov(Zj,Z2)
(6.28)VV12
The relationship between the two covariances in equation (6.28) enables the derivation 
of a corresponding relationship between the correlations:
c o r r « U ) =  , C° V^ ’4 ) . = ^ M l  = corr (Z„Z2).
y  var(4) var(#2) j ViV 2 (6.29)
As shown in equation (6.29), the correlation between the treatment advantages 
of two dependent events is theoretically equivalent to the correlation between two 
score statistics of those events. A similar relationship was also reported by Whitehead 
et al. (2010), in deriving a global score test for binary and ordinal endpoints. Despite 
the key difference in approach to estimating the covariance, both WLW and ZW 
should yield approximately the same correlation estimate: which is illustrated in the 
next section using real data. This transformation is made possible by the very 
definition of the score statistic being the cumulative treatment advantage (Section
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1.4). Nevertheless, adopting WLW in an analysis of interval-censored data may yield 
a lower power of test than that for continuous data. In the following sections, both ZW 
and WLW are employed for estimating the treatment advantages and constructing 
tests when dealing with real and simulated data sets respectively.
On the basis of special characteristics of recurrent events described in Section 
4.6, we shall compare the choice of risk intervals and stratification for both WLW and 
ZW. The former is applicable to both total and gap time, while the latter has proved to 
work well when using total time model. Overestimation of the correlation pertaining 
to gap time is further investigated in Section 6.6.6. Both methods imply that the 
baseline hazards are event-specific, while ZW can further model the baseline hazard 
to be interval-specific too, owing to its interval-censored nature.
Although both methods are developed based on the proportional hazards 
assumption, they differ slightly in detail. While WLW allows for a proportional 
hazards ratio specific to the m^ event, ZW offers more flexibility in permitting a 
proportional hazards ratio within each interval, as illustrated in Section 3.1.4. Despite 
suitability in the analysis of censored multiple endpoints, WLW offers no insight into 
the interrelationships among event times. It provides inference as to the population- 
average covariate effects on event times, but does not address the question as to how 
prior events affect the risk of having future recurrences. Wei and Glidden (1997) 
suggested that the AG, PWP and frailty models may be appropriate in affording some 
answers to that question
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6.5. Applications to Real Data: ZW vs. WLW
To illustrate the use of WLW, we employ the real data sets which have been used for 
ZW in Chapter 4. As demonstrated earlier, the correlation between two score statistics 
closely approximates the correlation between the two treatment advantages given by 
ZW and WLW respectively. Thus, these two correlations are interchangeable for the 
remainder of this thesis. The estimated correlation and common treatment advantage 
are compared for three real data sets earlier described in Chapter 4: (i) bladder cancer 
tumour recurrence, (ii) paired hips replacement revision and (iii) cancer data.
Note that all analyses using ZW were based on 5 and 10 intervals of event 
times T\ and T2, as commented upon in Chapter 5; the first data set is presented with 
more parameters for illustration purposes, while those for the other two are 
summarized using the key parameters only. Similar to Chapter 5, the null hypothesis 
test is conducted to detect significance at 2.5% (one-sided), so that the two sets of 
results given by ZW and WLW can be compared accordingly.
6.5.1. Recurrent Events: Bladder Cancer Data
For bivariate survival data, WLW computation dictates that two observations be 
created for each patient: one row of data for each of the two events. For two events of 
tumour recurrence (refer Section 4.6.2), analyses are carried out using total time (TT) 
and gap time (GT). WLW is applied to the raw data set as well as to its interval- 
censored version (as was used for ZW), for investigation purposes. The standard
overall treatment advantage, 0 *, is also given in this section, for comparison with the 
optimal overall treatment advantage, 6 . The results are summarized in Table 6.3 and 
Table 6.4 for TT and GT respectively.
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Table 6.3: Results for the bladder cancer data using total time (TT) for WLW and ZW.
(ZW results correspond to Table 4.12 and WLW to Table 6.1 earlier).
Parameter
WLW TT
WLW TT WLW TT ZW TT ZW TT
(s.e.) (5 intervals) (10 intervals) (5 intervals) (10 intervals)
A 0.363 0.325 0.318 0.462 0.378
(0.297) (0.278) (0.286) (0.293) (0.291)
A 0.552 0.567 0.550 0.581 0.537
(0.373) (0.360) (0.370) (0.370) (0.369)
0 * 0.436 0.415 0.405 0.508 0.439
(0.296) (0.277) (0.287) (0.290) (0.289)
§ 0.401 0.371 0.359 0.488 0.411
(0.232) (0.272) (0.281) (0.285) (0.284)
p-value 0.169 0.173 0.202 0.087 0.148
cov(Z1,Z 2) 5.812 6.101 5.995 5.659 5.771
con(Zl, Z 2) 0.643 0.610 0.632 0.611 0.619
Z i 4.1 4.2 3.9 5.4 4.5
z 2 4.0 4.4 4.0 4.3 4.0
z * 5.0 5.4 4.9 6.1 5.3
Vi 11.3 13.0 12.3 11.7 11.8
V2 7.2 7.7 7.3 7.3 7.4
y* 11.4 13.0 12.2 11.9 12.0
As shown in Table 6.3, the p-values are in agreement which suggest no 
significant evidence to reject the null hypothesis. It is observed that the finer intervals
give smaller estimates of treatment advantage and the optimal 0 is smaller than the
/V A
standard 6  * . WLW seems to yield a consistent 0 (0.4) even when intervals are used, 
whereas ZW varies by about 0.1. The standard error values are similar for the two
methods, except that for the optimal 0  (TT), where ZW yields higher values of about 
0.29 compared to 0.23 when using WLW (without intervals). The covariances are 
close to one another and the estimated correlations are consistent at 0.6. Upon
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comparing all the estimates from ZW with those from WLW, the use of 10 intervals 
for the former seems to give the values closest to the latter. This reaffirms the finding 
in the simulation study of recurrent TT events earlier (Section 5.2.5). It is also worth 
noting that the values of Z and V for both methods seem to be in good agreement in all 
cases, hence they are not presented for the subsequent data sets.
Table 6.4: Results for the bladder cancer data using gap time (GT) for WLW and ZW 












4 0.363 0.325 0.318 0.462 0.378
(0.297) (0.278) (0.286) (0.293) (0.291)
4 0.174 0.281 0.264 0.193 0.161
0*
(0.377) (0.349) (0.360) (0.376) (0.375)
0.290 0.308 0.297 0.360 0.297
(0.228) (0.221) (0.228) (0.219) (0.224)
6 0.289 0.308 0.297 0.358 0.295
(0.233) (0.221) (0.228) (0.219) (0.224)
p-value 0.204 0.163 0.193 0.103 0.186
cov(Zl5 Z 2) -0.443 0.358 0.417 -0.919 -0.488
corr(Z1; Z 2) -0.050 0.035 0.043 -0.101 -0.053
Zi 4.1 4.2 3.9 5.4 4.5
z 2 1.2 2.3 2.0 1.1 1.1
z* 5.6 6.2 5.7 5.8 5.9
Vi 11.3 13.0 12.3 11.7 11.8
^2 7.1 8.2 7.7 7.1 7.1
y* 19.3 20.5 19.2 19.7 20.0
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Meanwhile, for the gap time (Table 6.4), the p-values consistently indicate no 
significant evidence to reject the null hypothesis. It is to be noted that 6 here has a 
different meaning compared to that of the total time (Section 4.6.1). The score statistic 
when using GT is considerably smaller than TT as it is indeed measuring a cumulative 
treatment effect using a different time scale. For example, when using WLW, Z2 = 1.2 
for GT compared to Z2 = 4.0 for TT (Table 6.3). Consequently, the estimated 
treatment effect for T2 for GT is also smaller compared to those for TT earlier. This is 
expected owing to the carry-over effect of T\ unto T2 when using the latter time.
Both methods give very small correlations, which suggest that there is no 
evidence to show that the time from randomization to first recurrence (0, Ti) correlates 
with the time between the first and second recurrence (T\, T2). Earlier, the analysis 
using total time has shown some evidence that the time from randomization to the first 
event (0, T\) is highly correlated with the time from randomization to the second 
recurrence (0, T\ + T2g): corr (Zj, Z2) = 0.6. This high correlation when using total 
time is largely attributable to the dominating T\. As explained above, these two 
models have different interpretation as their times are measured differently. The 
model of choice hence depends on the questions of interest, as already discussed in 
Section 4.6.1.
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6.5.2. Paired Organs: Hip Replacement Revision
A detailed description of this data set can be seen in Section 4.5.1: it is to be 
remembered that we consider the different types of cup positioning with respect to the 
acetabulum as different “treatments”. Thus, it is anticipated that the treatment 
advantage is zero as both “treatments” are supposed to be ethically equivalent. The 
results for both ZW and WLW are summarized in Table 6.5.
Table 6.5: Results for the hip replacement revision data using WLW and ZW
(ZW results correspond to Table 4.5).
Parameter (s.e) WLW ZW (5 interval) ZW (10 interval)
4 -0.016 -0.166 -0.143
(0.223) (0.231) (0.230)
4 0.214 0.062 0.144
(0.257) (0.260) (0.254)
e 0.072 -0.073 -0.022
(0.199) (0.201) (0.199)
p-value 0.360 0.643 0.544
co v(Z1?Z 2) 7.187 5.947 6.235
corr(Z1,Z 2) 0.412 0.357 0.364
Table 6.5 shows that the p-values are qualitatively in agreement: there is no 
treatment advantage, as anticipated. The setting of 10 intervals gives the estimates 
closest to those for WLW. This is consistent with an earlier finding in the simulation 
study for paired organs where 10 intervals gave better accuracy based on the key 
performance measures (Section 5.2.2). The methods give similar correlations near 0.4 
(that for ZW is slightly lower), indicating that the treatment advantages for the two 
hips are moderately correlated.
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6.5.3. Generally Related Indicators and PFS: Cancer Data
The cancer data used here can be referred to in Section 4.5.2. The correlated events of 
disease progression and death are analyzed in two ways: (i) taking each as a separate 
event with its own censoring variable, labelled as an indicator (Section 4.3.4) and (ii) 
considering a progression-free survival whereby either a progression or death is 
considered as an event, labelled as a PFS. Output from WLW for each case is now 
compared to that earlier obtained using ZW, in Table 6.6.
Table 6.6: Results for the cancer data using WLW and ZW (5 intervals)











o, 0.022 -0.014 0.090 0.219
(0.122) (0.125) (0.112) (0.120)
4 0.133 0.189 0.133 0.189
(0.121) (0.127) (0.121) (0.127)
e 0.078 0.086 0.110 0.206
(0.086) (0.107) (0.082) (0.108)
p-value 0.363 0.422 0.182 0.056
co v (Z !,Z 2) 27.790 27.294 43.450 34.802
corr(Zb Z 2) 0.412 0.433 0.591 0.530
When considering the case of related indicators, all parameter estimates using 
both methods are in good agreement. The p-values conclude that there is no 
significant evidence to reject the H0, zero treatment advantage. The correlation 
estimates are accurately matched at 0.4 (ZW slightly higher). Meanwhile, the results 
from PFS analysis in the last two columns show that ZW gives higher estimates for 
the treatment effect when comparedwith WLW. Nevertheless, the p-values are leading 
towards the same conclusion not to reject Ho at the 2.5% (one-sided) level of
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significance. Both methods give higher correlation when evaluating either progression 
or death as an event than those in the indicators case, due to the imposed dependence 
on their censoring variables: for PFS, 0.59 (WLW) and 0.53 (ZW). It is worth noting 
that the covariance for WLW is higher than that for ZW whereas the variances of Zx 
(given by Vi) are about the same.
In summary, the above applications to real data seem to suggest that our 
method is comparable to WLW. Whether or not these two methods are equally 
accurate is answered in the subsequent sections.
6.6. Simulation and Results
Thus far, the analyses of ZW and WLW have been justified by theory and illustrated 
by practical application to real data sets. The accuracy of the former has been 
evaluated in Chapter 5. Now, the latter is also applied to the same simulated data sets 
as have earlier been analyzed using ZW. It is to be noted that WLW requires two sets 
of observations for each invididual, as explained in Section 6.5.1.The same key 
measures as in Section 5.2 are used: (i) type I error, conventionally labelled as a, (ii) 
power (1 - P), and (iii) ratio of p(est) to /^ sample). It is recalled that each setting covers 
both the null and alternative, with sample size n = 1000, and is based on the overall 
results in Section 5.2.8, the results for ZW when using 5 intervals being compared 
with the simulation results for WLW in this chapter.
In Chapter 5, the simulation was formulated to give a theoretical power which 
varies with d under the alternative of 6 = 0R where 0R corresponds to n=  1,000 for ZW 
specifically. The reader is reminded that the setting of 0R was based on the log hazard 
ratio within subject, 6W, whereas the simulation design yields an output of 0B, which is 
the log hazard ratio between subjects. Therefore, each power is comparable to its
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corresponding theoretical power, TP. For a detailed description of the theoretical 
power the reader is referred to Section 5.1. To compare the performance of ZW with 
that of WLW, the same data sets are now used for WLW, without recalculation of 0R. 
Also, as in the earlier setting for ZW, the type I error rate is set at 0.025 (one­
sided).and the level of accuracy sought is 0.025 ± 0.003 (.N  = 10,000 replicates). The 
outputs for the cases of complete (uncensored), paired, indicators, PFS, recurrent TT 
and recurrent GT, are tabulated and discussed in turn.
6.6.1. Complete or Uncensored
With reference to Section 5.1, the multiplier constant d is varied in such a way that 
d g {1,5,10} corresponds to low, medium and high correlation respectively. The target
treatment effect, 6 is determined for each correlation as governed by d. For each 
varying correlation, 10,000 simulations in total were run under each hypothesis and 
the mean value of each key performance measure for the uncensored case is presented 
in Table 6.7. It is to be noted that the correlation ratios are later summarized in Figure 
6.6 (a).
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Table 6.7: Simulation results for the complete case under the null and alternative using 
WLW and ZW (ZW results correspond to Table 5.4).
WLW: Ho
d e 4 4 0 a \ a 2 a 12 N/A P (est) P (sample)
1 0.000 0.000 0.000 0.000 0.025 0.021 0.023 N/A 0.023 0.027
5 0.000 -0.001 -0.001 -0.001 0.025 0.026 0.026 N/A 0.410 0.419
10 0.000 -0.001 -0.001 -0.001 0.025 0.025 0.025 N/A 0.708 0.710
WLW: H  i
d e 4 4 e 1 ~P 2 1“/? 12 TP P (est) P (sample)
1 0.174 0.171 0.171 0.171 0.68 0.68 0.92 0.89 0.023 0.027
5 0.209 0.139 0.139 0.139 0.51 0.50 0.65 0.58 0.410 0.420
10 0.221 0.089 0.088 0.088 0.24 0.23 0.27 0.25 0.708 0.709
ZW: H 0 @ 5 intervals
d 6 4 4 0 a i a 2 <*12 N/A P (est) P (sample)
1 0.000 0.000 0.000 0.000 0.023 0.021 0.023 N/A 0.023 0.026
5 0.000 -0.001 -0.001 -0.001 0.024 0.025 0.026 N/A 0.382 0.412
10 0.000 -0.001 -0.001 -0.001 0.024 0.027 0.025 N/A 0.664 0.693
ZW: H i @ 5 intervals
d 4 4 e l-/?i l-/?2 12 TP P (est) P (sample)
3 ^ 7 1 0.171 0.171 0.171 0.67 0.67 0.92 0.89 0.028 0.027
0.139 0.139 0.139 0.50 0.49 0.65 0.58 0.384 0.412
10 (U21 0.089 0.088 0.088 0.24 0.23 0.28 0.25 0.664 0.694
As shown in the above table, under the null, the estimates of treatment 
advantage are essentially zero and the type I error rates are well within the 95% 
probability interval (0.022, 0.028). The power exceeds its theoretical value (TP) and 
the estimated correlation is very close to its sample value for each setting. It is to be 
noticed that the assumption of equal 6 is satisfactorily met, hence a clear advantage 




The simulation results for the paired organs using WLW are summarized in Table 6.8, 
while the correlation ratios for comparison with ZW are presented in Figure 6.6 (b).
Table 6.8; Simulation results for the paired case under the null and alternative using 
WLW and ZW (ZW results correspond to Table 5.5).
WLW: Ho
d e 4 4 e a i a 2 a 12 N/A P  (est) P (sample)
1 0.000 0.000 0.000 0.000 0.024 0.023 0.027 N/A 0.027 0.018
5 0.000 0.000 0.000 0.000 0.028 0.024 0.026 N/A 0.431 0.434
10 0.000 0.001 0.001 0.001 0.027 0.026 0.025 N/A 0.688 0.681
WLW: H  i
d e 4 4 0 M i m 2 M l2 TP P (est) P (sample)
1 0.241 0.236 0.238 0.237 0.65 0.66 0.91 0.89 0.027 0.016
5 0.287 0.191 0.191 0.191 0.48 0.48 0.61 0.58 0.430 0.433
10 0.305 0.119 0.119 0.119 0.23 0.22 0.24 0.24 0.705 0.700
ZW: H 0 @ 5 intervals
d e 4 4 e a i a 2 0£ 12 N/A P (est) P (sample)
1 0.000 0.000 0.000 0.000 0.025 0.023 0.026 N/A 0.035 0.027
5 0.000 0.001 0.000 0.000 0.028 0.025 0.028 N/A 0.421 0.437
10 0.000 0.001 0.002 0.001 0.027 0.025 0.026 N/A 0.674 0.685
ZW: H i @ 5 intervals
d y O f V 4 4 6 M i m 2 to TP P (est) P (sample)
0.235 0.236 0.235 0.65 0.65 0.90 0.89 0.041 0.022
0.190 0.190 0.190 0.47 0.48 0.61 0.57 0.422 0.437
10 0.120 0.120 0.120 0.23 0.22 0.25 0.25 0.692 0.704
The results for the paired organs are very similar to those for the complete 
case, except that the power is slightly lower because, probably, of the censoring in the 
former, and that the type I error («i = 0.028 at cl = 5) is slightly inflated. Again, a 
similar trend to that for ZW is observed, including the slightly higher correlation (d = 
10) under the alternative compared to the null.
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6.6.3. Related Indicators
Resembling the analysis of cancer data comprising TTP and OS (Section 4.5.2), the 
simulation results for these related indicators are presented in Table 6.9 and Figure 6.6 
(c).
Table 6.9: Simulation results for the indicators under the null and alternative using 
WLW and ZW (ZW results correspond to Table 5.6).
WLW: H 0
d e 4 4 6 a l a  2 ® 12 N/A P (est) P (sample)
1 0.000 -0.001 -0.001 -0.001 0.020 0.023 0.023 N/A 0.023 0.034
5 0.000 -0.001 -0.001 -0.001 0.021 0.027 0.026 N/A 0.409 0.413
10 0.000 -0.001 -0.001 -0.001 0.025 0.024 0.025 N/A 0.695 0.696
WLW: H ,
d e 4 4 0 l-pl M 2 M  12 TP P (est) P (sample)
1 0.194 0.189 0.189 0.189 0.67 0.67 0.92 0.89 0.023 0.035
5 0.245 0.161 0.161 0.161 0.51 0.50 0.66 0.57 0.408 0.417
10 0.275 0.106 0.106 0.106 0.24 0.23 0.26 0.24 0.695 0.694
ZW: H q @ 5 intervals
d e 4 4 0 a ] a 2 a 12 N/A P (est) P (sample)
1 0.000 0.000 -0.001 -0.001 0.022 0.023 0.023 N/A 0.023 0.032
5 0.000 -0.001 -0.001 -0.001 0.022 0.026 0.027 N/A 0.387 0.404
10 0.000 -0.001 -0.001 -0.001 0.025 0.025 0.026 N/A 0.670 0.688
ZW: H x @ 5 intervals
d 4 4 0 M i M i M  12 TP P (est) P (sample)
3 ^ 9 1 0.189 0.189 0.189 0.66 0.66 0.91 0.89 0.028 0.034
0.161 0.161 0.161 0.50 0.49 0.65 0.57 0.389 0.406
10 0.107 0.107 0.107 0.24 0.23 0.26 0.24 0.671 0.685
For WLW, upon comparing with the paired case, slightly better type I errors
(more conservative) and higher powers, are found to have been achieved for the 
indicators. Notably, the power exceeds the theoretical power in all settings and the 
correlations are consistent. Similar trends are observed in the results for the two 
methods, but the type I error rates when using WLW, are slightly more conservative 
than those using ZW.
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6.6.4. Progression-Free Survival
As already described in Sections 4.3.4 and 4.5.2, PFS analysis considers either TTP or 
death (OS), whichever occurs first, as an event. This condition imposed a strong 
dependence between the two endpoints (PFS, OS); hence higher correlation compared 
to the indicators case. Consequently, their results differ, as shown in Table 6.10 and 
Figure 6.6 (d) for PFS.
Table 6.10: Simulation results for the PFS under the null and alternative using WLW 
and ZW (ZW results correspond to Table 5.7).
WLW: H 0
d e 4 4 6 a i a 2 a 12 N/A P (est) P (sample)
1 0.000 0.000 0.000 0.000 0.025 0.024 0.024 N/A 0.608 0.611
5 0.000 0.000 0.000 0.000 0.025 0.025 0.025 N/A 0.779 0.784
10 0.000 -0.001 -0.001 -0.001 0.025 0.024 0.025 N/A 0.879 0.881
WLW: H i
d e 4 4 e l- f i1 l-fi2 M  12 TP P (est) P (sample)
1 0.223 0.213 0.222 0.216 0.84 0.80 0.90 0.88 0.608 0.613
5 0.252 0.156 0.165 0.158 0.56 0.52 0.59 0.53 0.779 0.786
10 0.275 0.100 0.106 0.101 0.24 0.23 0.25 0.22 0.879 0.881
ZW: H 0 @ 5 intervals
d 0 4 4 0 a j a 2 a 12 N/A P (est) P (sample)
1 0.000 0.000 -0.001 0.000 0.025 0.023 0.024 N/A 0.589 0.601
5 0.000 0.000 0.000 0.000 0.026 0.025 0.026 N/A 0.755 0.779
10 0.000 -0.001 -0.001 -0.001 0.024 0.023 0.025 N/A 0.869 0.882
ZW: H i @5 intervals
d 4 4 0 M i M 2 M  12 TP P (est) P (sample)
J j l 2 j 0.214 0.225 0.218 0.83 0.81 0.90 0.89 0.592 0.601
0.156 0.167 0.159 0.55 0.52 0.59 0.53 0.755 0.779
10 0.102 0.108 0.103 0.24 0.23 0.25 0.23 0.869 0.882
Again, the findings for WLW are similar to the corresponding results for ZW. 
As anticipated, the marginal powers are now closer to the global power as the 
estimates of 6 tend to vary slightly. Nevertheless, it is to be noticed that the correlation 
values remain consistent.
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6.6.5. Recurrent Events TT
For the recurrent event using total time, highly dependent events are imposed as T\ is 
directly contained within T2 (Section 4.6.1). The simulation results for recurrent TT 
using WLW and ZW are given in Table 6.11 and in Figure 6.6 (e).
Table 6.11: Simulation results for recurrent events TT under the null and alternative 
using WLW and ZW (ZW results correspond to Table 5.8).
W L W : Ho
d e 4 4 9 a 1 a 2 « 1 2 N / A P (est) P (sample)
1 0 . 0 0 0 0.000 0.001 0.000 0.026 0.025 0.026 N / A 0.556 0.557
5 0 . 0 0 0 0.001 0.000 0.001 0.027 0.025 0 . 0 2 8 N / A 0.745 0.753
10 0 . 0 0 0 0.001 0.001 0.001 0.025 0.025 0.026 N / A 0.856 0.856
W L W : H 1
d 0 4 4 e 1-fii 1-0 2 T P P (est) P (sample)
1 0.293 0.283 0 . 4 3 7 0.318 0.87 0 . 9 6 0.95 0.94 0.552 0.552
5 0.311 0.192 0.240 0.200 0.54 0.57 0.58 0.55 0.744 0.750
10 0.317 0.117 0.131 0.118 0.23 0.23 0.24 0.22 0.851 0.853
Z W : H 0 @ 5 intervals
d 9 4 4 9 a ] a 2 a  12 N / A P (est) P (sample)
1 0.000 0 . 0 0 0 0.001 0.000 0.026 0.025 0.027 N / A 0.539 0.557
5 0.000 0 .0 0 1 0.001 0.001 0 . 0 2 8 0.025 0 . 0 2 8 N / A 0.730 0.751
10 0.000 0 .0 0 1 0.001 0.001 0.026 0.025 0.026 N / A 0.848 0.855
Z W : H x @ 5 intervals
4 4 9 l-/?i 1-02 I-/? 12 T P P (est) P (sample)
jd & 9 l 0.282 0 . 4 3 0 0.317 0.86 0 . 9 6 0.95 0.94 0.543 0.555
0.192 0.238 0.200 0.53 0.57 0.58 0.55 0.730 0.749
10 0.118 0.131 0.120 0.24 0.24 0.24 0.23 0.848 0.856
Again, we see findings similar to those for earlier cases, but with a type I error 
rate for d = 5 slightly inflated, but still within the 95% PI (0.022, 0.028). The global 
power exceeds the theoretical power at all correlation settings. These results, 
compared with those for ZW, are very similar indeed. For example, the marginal
estimate 02 is larger than the global 9  and the marginal power 1 - is higher than
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the global power (d —1); for its detailed description the reader can be referred to 
Section 5.2.5.
6.6.6. Recurrent Events GT
As explained in Section 4.6.1, the recurrent GT model is technically different from the 
TT model. The results for recurrent GT are summarized in Table 6.12 and Figure 6.6
(f).
Table 6.12: Simulation results for recurrent events GT under the null and alternative 
using WLW and ZW (ZW results correspond to Table 5.9J.
WLW: # 0
d e _j 4 4 9 a i « 2 «  12 N/A P (est) P (sample)
1 0.000 -0.001 0.000 0.000 0.026 0.025 0.027 N/A 0.017 0.014
5 0.000 0.001 0.000 0.000 0.026 0.023 0.025 N/A 0.223 0.221
10 0.000 0.001 0.000 0.001 0.026 0.027 0.026 N/A 0.352 0.345
WLW:
d e 4 4 0 l- f i l l-/?2 I -/?  12 TP P (est) P (sample)
1 0.235 0.231 0.227 0.229 0.71 0.57 0.90 0.88 0.017 0.017
5 0.271 0.182 0.137 0.163 0.49 0.25 0.56 0.49 0.222 0.224
10 0.289 0.117 0.069 0.096 0.23 0.10 0.22 0.19 0.350 0.348
ZW: H 0 @ 5 intervals
d 0 4 4 0 a ] a  2 a  12 N/A P (est) P (sample)
1 0.000 -0.001 0.000 0.000 0.025 0.025 0.026 N/A 0.040 0.030
5 0.000 0.001 0.000 0.000 0.026 0.022 0.022 N/A 0.305 0.235
10 0.000 0.001 0.000 0.001 0.026 0.027 0.020 N/A 0.512 0.352
ZW: H } @5 intervals
d 4 4 0 1-jffi l-/?2 1 “/? 12 TP P (est) P (sample)
1 0.229 0.228 0.228 0.70 0.58 0.90 0.88 0.045 0.030
( 0.180 0.137 0.162 0.49 0.25
0.53 0.49 0.306 0.238
10 ‘U!289 0.116 0.069 0.096 0.23 0.10 0.19 0.19 0.511 0.355
When compared with the results for ZW, the type I error rates for WLW are
less conservative and the global powers for WLW are higher than theoretical powers 
in all settings. Like ZW, WLW yields marginal power 1 - fh that exceeds the global
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power ( d  -  10); the marginal Q x is bigger than the global 6 . Overall, the latter method
obviously wins concerning the accuracy of the correlation estimates, whilst ZW gave 
an overestimation for recurrent GT.
6.6.7. Summary of Correlation Ratios
In Section 5.2.7, the correlation ratios obtained from ZW were plotted for each case, 
comparing the results when five and ten intervals were used ( k  = 5, 10). It was 
concluded that k  = 5 gave a better estimate than k  = 10. In this section, only the former 
is considered and the correlation ratios for ZW are now compared to those of WLW. 
The plots of the sample correlation /?(SamPie) versus the derived correlation /?(est) for the 
six cases are given in Figures 6.6 (a) to (1).
Again, a linear plot with y = x is an ideal situation indicating that the estimated 
correlation, p(est) for either method is exactly the same as the correlation p(sampie) 
observed from its own samples of 10,000 replications. In all cases, WLW performs 
consistently well with ratios of 0.99 to 1.00, while those for ZW vary from 0.95 to 
0.98 for most cases, except for the recurrent GT with 1.40. Figure 6.6 (a) shows that 
for the complete data, WLW gives a ratio of 0.99 compared to 0.95 for ZW. The 
former performs well at varying degrees of correlation, while the latter tends to 
perform slightly less well at higher correlations. In Figures 6.6 (b) to (f), the 
correlation ratios when using WLW are 1.00 for all the five cases. Meanwhile, when 
using ZW, the correlation ratios for the paired, related indicators, recurrent TT and 
recurrent GT are 0.98, 0.97, 0.98, 0.98 and 1.40 respectively.
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Figure 6.6: Plots of the sample correlation /Sample) versus the derived correlation t) 
for the six cases using WLW and ZW ( k  =  5).
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To investigate further the 40 % overestimation for recurrent GT when using 
ZW, a comparison between the components that make up the correlation is performed. 
The values of the variances Vi, V 2 and the covariance C12 when using ZW are 
compared to those for WLW. Apparently, both methods give consistent variances; 
hence the difference is solely attributable to the covariance, C12. Next, an exploration 
of the impact of the censoring proportion on the correlation ratio of recurrent TT and 
GT models is undertaken.
On the basis of the evident accuracy of WLW in estimating correlation, it is 
assumed to yield the “true” correlation, and hence the estimate using ZW is compared 
to that using WLW in this exercise without any replicates. Using the same codes 
earlier to generate recurrent TT and GT data, while setting d  = 10, k  = 5, and the 
censoring proportion is varied from 0.01 to 0.90. The correlation ratios given by 
p  zw) / yO(WLW) are plotted against the censoring proportion in Figure 6.7.
Figure 6.7: Correlation ratio against censoring proportion (percentage) for recurrent 
TT and recurrent GT ( d  = 10, under H q)
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Ideally, all the points should lie on the horizontal line at y  =  1, indicating 
accurate estimation of correlation: as observed for the case of recurrent TT. However, 
it is clear that for the recurrent GT, estimate of the correlation is only accurate when 
only 0.1% is censored. It is to be recalled that the earlier simulation was set at a 
censoring proportion of 40%, giving a correlation of 1.4 times higher as shown here. 
Upon increasing the censoring proportion, the correlation overestimation gets bigger, 
indicated by the upward gradient of the points. For example, the correlation is about 5 
times higher when the data set is 90% censored. Closer examination unveils that the 
covariances when using ZW are substantially larger than those given by WLW, while 
the variances remain consistent. In Section 4.3.1, it was explained that, with heavy 
censoring, the contribution of the marginal failures diminishes and the estimator relies 
largely on the risks sets and the combined failures. This finding renders the ZW 
formulation for covariance estimation unsuitable for recurrent GT.
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6.7. Overall Results: WLW vs ZW
In the previous sections, the results for each of the six cases investigated have been 
described in turn. This section now compares WLW to ZW in terms of their overall 
performance based on the key measures specified: type I error, power and correlation 
ratio. Under each hypothesis, 18 sets of data (six cases each with three varied 
correlations) are used to summarize the three key measures for each method. Figure
6.8 (a) and (b) respectively display the type I error rates for both methods, identified 
by cases and degrees of correlation. Figure 6.8 (c) shows how the power varies for all 
six cases with the degrees of correlation imposed, while the last chart summarizes all 
the correlation values for both methods, the gradient measuring the overall correlation 
ratio of P(est/P(sampie) for each method. Consistently with the previous chapter, a 
diagonal line of y  =  x  serves as a reference line for an ideal situation; points below or 
above it are described accordingly.
Figure 6.8: Type 1 error rates, powers and correlation ratios of ZW versus WLW.
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Figure 6.8 (a) shows that both methods give type I error rates within the 95% 
probability interval (0.022, 0.028). The points above the diagonal line (y = x) indicate 
the better performance of WLW in detecting any departure from the null hypothesis, 
and vice versa. It is evident that WLW seems to perform better than ZW by the 
predominance of points above the line leaving only seven points underneath. Figure
6.8 (b) shows no particular trend for type I error rates with regard to varied 
correlations.
The power of ZW is comparable to that of WLW as is evident in Figure 6.8 
(c). Both methods give powers equal to or more than 0.89 (1 - /? = 0.90 ± 0.01) at low 
correlation (d = 1), but when a higher correlation is imposed by increasing the subject 
effect, the power reduces accordingly for both methods. It is to be recalled that such 
behaviour is expected owing to the discrepancy in 6 setting as explained in Section 5.1 
earlier. The appearance of two points slightly below the diagonal line for power 
suggests that WLW is only slightly better than ZW: ZW suffers a slight power loss 
owing to its interval nature, as already noted.
In Section 4.3, the main theme of this thesis, correlation has been described in
great detail; an overall comparison of ZW with WLW in terms of the correlation ratio
is now given. In total, 72 data points (each being the mean of 10,000 samples) are
used in the plot below which includes all cases under the null and alternative
hypotheses for both methods. Figure 6.8 (d) portrays the estimated correlation against
the correlation from its own samples, indicated by /?(est) and p (sample) respectively. An
accurate estimation of the correlation by WLW is evident, with virtually all points
lying on the regression line (y = x), while ZW shows an overall underestimation of
about 1%. The two outliers for ZW belong to the recurrent GT case, in which severe
overestimation has been reported; excluding this case altogether gives an overall
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underestimation by 2%. Theoretical equality of the correlation between the two 
estimates of the treatment advantage and that between two score statistics given in 
equation (6.29) is hereby validated accordingly.
All in all, the two methods demonstrated similar trends in all the six cases 
explored, with the exception of an overestimation of the correlation for recurrent GT 
when using ZW.
6.8. Discussion
ZW provides a conceptually straightforward approach to the analysis of multivariate 
survival data. The benefits of our method are (i) ease of use: simple computation and 
(ii) good interpretability: straightforward derivation based on marginal analyses, 
unlike WLW, which is based on non-standard adjusted statistics. By design, ZW is 
capable of analyzing naturally interval-censored data whereas WLW was not 
specifically intended to cater for such data. Meanwhile the disadvantages when 
dealing with continuous data are that ZW requires categorization into intervals, and 
consequently might lose a little power. Despite their technical differences (Section 
6.4), extensive simulations show that our new method is accurate, consistent and 
comparable to WLW in the five main bivariate cases investigated.
As reported earlier, ZW works well with modelling of total time, but as far as 
recurrent events gap time is concerned, the correlation estimate is accurate only for a 
very small censoring proportion. As shown in Section 6.6.6, ZW overestimates 
increasingly with increasing censoring proportion. This could be due to inaccurate 
estimation of the probabilities of each combined outcome for the paired intervals for 
GT. As already noted in Chapter 4, the covariance formulation implies that, with 
heavy censoring, the contribution of the marginal failures diminishes and the estimator
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relies largely on the risks sets and the combined failures. That this proposed method is 
not applicable to recurrent gap time is an interesting finding, but not one explainable 
here.
With regard to WLW, it actually uses concepts similar to the jackknife 
(Section 6.1.4), although the original paper by Wei et al. (1989) makes no reference to 
any such similarity. The much emphasized issue of overestimation by WLW (Kelly & 
Lim, 2000), is rather an inevitable scenario when using total time convention for 
recurrent events since the effect for T\ is carried over into Ti. Kelly & Lim (2000) 
concluded that WLW is most appropriate for data arising from different types of event 
from the same individual rather than for recurrent events, while our simulations show 
that no one case affirms its superiority: it performs equally well in all six cases 
explored. Kelly & Lim (2000) also commented that the within subject correlation was 
not satisfactorily accounted for by employing the robust variance, but that the reason 
is unknown. Metcalfe & Thompson (2007) also argued on the same point, but 
commentary is rather unclear on how else to address it. As derived in Section 4.3, our 
proposed method embeds within-subject correlation directly in the computation of 
covariance which considers the pair of intervals for each subject exclusively.
WLW assumes continuous survival times while ZW is based on interval- 
censored survival times. Nevertheless, the former has been applied to interval- 
censored data using the real data sets in Section 6.5 which showed acceptable results. 
Extensions of WLW for multivariate interval-censored data have earlier been studied 
by Goggins & Finkelstein (2000), and Kim & Xue (2002). Hence its application here 
serves as further evidence of its flexibility in the analysis of bivariate survival data.
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As earlier noted, both ZW and WLW are marginal models which assume 
proportional hazards. In marginal models with total time risk intervals, the 
information in the early part of the total observation period will be used several times: 
once for each event. This induces a greater weight on the first recurrence considered 
(as observed in Figure 6.3, Section 6.2). The alternative frailty models which include a 
common random effect to adjust for within-subject correlation are available in the 
literature (Vaupel et al., 1979; Clayton & Cuzick, 1985; Klein, 1992). They estimate 
the covariate effect on the recurrence, conditionally on a specified dependence 
structure. Such models can be of interest for a full modelling of the recurrent event 
process, but are of far less interest in studies which focus on the average covariate 
effect.
In terms of usability, ZW requires simple calculations which can be achieved 
by a MS Excel spreadsheet or something like it, whereas WLW involves complex 
formulation which necessitates some programming or standard software packages. It 
is to be noted that only the SAS software package was considered in this study, for 
suitability and convenience purposes. Other software packages for analyzing 
correlated survival data are namely Stata, S-Plus and R, MLwiN, and WinBUGS. A 
good review of their different capabilities, including those of SAS, is provided by 
Kelly (2004).
Workable for practical applications to real data and comparable to the 
established WLW, our proven method ought to contribute a new alternative method 
for the analysis of correlated survival data.
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Chapter 7. Conclusions and Further Work
Our proposed method, ZW has proved useful for finding estimates of correlations and 
treatment effects. Its performance is comparable to that of WLW and it has a clearer 
interpretation. To my knowledge, this is the first successful development of the global 
score test methodology for bivariate survival data. The derivation of the covariance 
between two score statistics using an interval-censored model, viewed as a viable 
alternative to the logrank, is a new approach. The relationship between the old 
jackknife technique and WLW has also been clarified in this thesis. The new method, 
ZW should be a useful contribution of knowledge to survival analysis. However, it 
does not outperform the established method, WLW.
The whole procedure of ZW enables estimation of correlations, and thus has 
many practical uses. Among these are (i) combined null hypothesis testing to establish 
whether a linear combination of effects is equal to zero and (ii) global null hypothesis 
testing, establishing whether all effects are equal to zero, both of which have been 
demonstrated in this thesis. Nevertheless, various problems were encountered and 
should be investigated further, such as the unsuitability of ZW for handling recurrent 
events gap time.
Two key questions relating to the issues discussed in Section 5.1 are: “How to 
formulate the correct treatment advantage between-subject for simulation purposes?” 
and “How to achieve equality of the proportional hazards ratios?”. In situations where 
these ratios are unequal (as observed in the cases of PFS and recurrent events), a 
method to estimate the theoretical power, comparable with the method achieved by 
Bolland et al. (2009) for binary data, should be devised. It is also essential to account 
adequately for the within-subject correlation or between-subject correlation or both.
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Essentially, the application of the global score approach to interval-censored 
survival data is valid as long as the assumption of proportional hazards is adequately 
met. That having been said, the global score test approach can be adapted to combine 
normally distributed, Poisson-distributed or other types of endpoint which can also be 
mixed together. This promising method can be further developed to allow adjustment 
for combining composite endpoints, for example, two different types of endpoint 
arising from binary and survival data whereby the treatment effects are measured on 
log-odds ratio and log hazard ratio respectively.
In situations where the failures are unequally distributed across intervals, ZW 
may not be as efficient as established for the equal failure distribution. As noted 
earlier, the global test methodology may be most suitable when none of the endpoints 
captures all of the information on a patient’s condition, for example, a case involving 
the multiple stroke scales cited in Chapter 2. Similar features of outcome measures 
exist in mental health studies; hence it could be a potential application area of this 
methodology.
In this study, apart from the treatment advantages, only the correlation
between the two score statistics (as well as) was investigated. For further
understanding of correlated endpoints, perhaps it is worthwhile to consider the
correlation between 7j and T2 directly, as was attempted by Fleischer et al. (2009).
Connections between ZW and frailty modelling should also be investigated to yield
better insight into subject effects. Unfortunately, due to resource constraints, some
extended investigations were not feasible and hence have to be considered as further
work. These include adjustment for covariates and the construction of joint confidence
regions for multiple hazard ratios. Implementations of sequential and multiple testing
procedures are worth investigating as these are becoming increasingly popular in view
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of minimizing the cost of trials. Additionally, comparison of multiple active 
treatments to a common control may be attempted.
I am pleased that the results from this thesis are encouraging, although some 
investigations could not be completed according to the original plan. Nevertheless, 
that does not diminish the knowledge and skills I have learned throughout this study. I 
now look forward to continuing teaching and collaborating on new research projects. I 
am already excited about the huge potential for growth of medical statistics, across 
Asia generally and within Malaysia specifically.
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APPENDIX
A. SAS Codes for ZW Specific for Analysis of Hip Revision Data
*Hips bilateral data using ZW for 2 intervals;





tla = 1; t2a = 1;
do i = &imin to &imax;
tla = tla + (tl > cutl (i));
t2a = t2a + (t2 > cut2 (i));
end;
tl=tla; t2=t2a;
keep id trt tl t2 censl cens2;
run;
data add;
set bilat end=lastval; 
do j = &imin to &imax;
do k = &imin to &imax; 
if trt=2 then do;
array affe{&imax,&imax } ffe&imin-ffe&last; 
atffe= (tl=j)* (censl=l)*(t2=k)*(cens2=l); 
affe {j,k} = sum(atffe, affe {j,k}, 0); 
retain ffe&imin-ffe&last 0;
array afse {&imax,&imax } fse&imin-fse&last; 
atfse= (tl=j)*(censl=l)*(t2>k); 
afse {j,k} = sum(atfse, afse {j,k}, 0);
retain fse&imin-fse&last 0;
array afme{&imax,&imax } fme&imin-fme&last; 
atfme= (tl=j)*(censl=l)*(t2=k)*(cens2=0); 
afme {j,k} = sum(atfme, afme {j,k}, 0); 
retain fme&imin-fme&last 0;
array amfe{&imax,&imax } mfe&imin-mfe&last; 
atmfe= (tl=j)*(censl=0)*(t2=k)*(cens2=l); 
amfe {j,k} = sum(atmfe, amfe {j,k}, 0);
retain mfe&imin-mfe&last 0;
array asse {&imax,&imax } sse&imin-sse&last; 
atsse= (tl>j)*(t2>k);
asse {j,k} = sum(atsse, asse {j,k}, 0);
retain sse&imin-sse&last 0;
array asfe {&imax,&imax } sfe&imin-sfe&last ; 
atsfe= (tl>j)*(t2=k)*(cens2=l); 
asfe {j,k} = sum(atsfe, asfe {j,k}, 0); 
retain sfe&imin-sfe&last 0;
array asme {&imax,&imax } sme&imin-sme&last;
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atsme= (tl>j)*(t2=k)*(cens2=0);
asme {j,k} = sum(atsme, asme {j,k}, 0) ;
retain sme&imin-sme&last 0;
array amse {&imax,&imax } mse&imin-mse&last; 
atmse= (tl=j)* (t2>k)*(censl=0); 
amse {j,k} = sum(atmse, amse {j,k}, 0); 
retain mse&imin-mse&last 0;
array aole {&imax}ole&imin-ole&imax;
aole{j} = sum( affe {j,&imin},afse {j,&imin},afme {j,&imin}); 
retain ole&imin-ole&imax 0;
array ao2e {&imax}o2e&imin-o2e&imax;
ao2e{k} = sum( affe {&imin, k}, asfe {&imin,k},amfe {&imin,k}); 
retain o2e&imin-o2e&imax 0;
array asle {&imax}sle&imin-sle&imax;
asle{j} = sum( asfe {j,&imin},asse {j,&imin},asme {j,&imin}); 
retain sle&imin-sle&imax 0;
array as2e {&imax}s2e&imin-s2e&imax;






do j = &imin to &imax;
do k = &imin to &imax; 
if trt=l then do;
array affc{&imax,&imax } ffc&imin-ffc&last; 
atffc= (tl=j)* (censl=l)* (t2=k)* (cens2=l); 
affe {j , k} = sum(atffc, affe {j,k}, 0) ; 
retain ffc&imin-ffc&last 0;
array afse {&imax,&imax } fsc&imin-fsc&last; 
atfsc= (tl=j)*(censl=l)*(t2>k); 
afse {j,k} = sum(atfsc, afse {j,k}, 0); 
retain fsc&imin-fsc&last 0;
array afme{&imax,&imax } fmc&imin-fmc&last; 
atfmc= (tl=j)*(censl=l)*(t2=k)*(cens2=0); 
afme {j, k} = sum(atfmc, afme {j,k}, 0);
retain fmc&imin-fmc&last 0;
array amfc{&imax,&imax } mfc&imin-mfc&last; 
atmfc= (tl=j)* (censl=0)*(t2=k)*(cens2=l); 
amfe {j , k} = sum(atmfc, amfe {j,k}, 0) ;
retain mfc&imin-mfc&last 0;
array asse {&imax,&imax } ssc&imin-ssc&last; 
atssc= (tl>j)* (t2>k);
asse {j,k} = sum(atssc, asse {j,k}, 0);
retain ssc&imin-ssc&last 0;
array asfe {&imax,&imax } sfc&imin-sfc&last ;
atsfc= (tl>j)*(t2=k)*(cens2=l);
asfe {j,k} = sum(atsfc, asfe {j,k}, 0);
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retain sfc&imin-sfc&last 0;
array asme {&imax,&imax } sme&imin-sme&last; 
atsmc= (tl>j)*(t2=k)*(cens2=0); 
asme {j,k} = sum(atsmc, asme {j,k}, 0); 
retain sme&imin-sme&last 0;
array amse {&imax,&imax } mse&imin-mse&last; 
atmsc= (tl=j)*(t2>k)*(censl=0); 
amse {j,k} = sumfatmsc, amse {j,k}, 0); 
retain msc&imin-msc&last 0;
array aolc {&imax}ole&imin-ole&imax;
aolc{j} = sum( affe {j,&imin},afsc {j,&imin},afme {j,&imin}); 
retain ole&imin-ole&imax 0;
array ao2c {&imax}o2c&imin-o2c&imax;
ao2c{k} = sum( affe {&imin, k}, asfe {&imin,k}, amfe {&imin,k}); 
retain o2c&imin-o2c&imax 0;
array aslc {&imax}sle&imin-sle&imax;
aslc{j} = sum( asfe {j,&imin},asse {j,&imin}, asme {j,&imin}); 
retain sle&imin-sle&imax 0;
array as2c {&imax}s2c&imin-s2c&imax;





IF lastval ~= 1 THEN DELETE; 





do j = &imin to &imax;
do k = &imin to &imax; 
array aole {&imax } ole&imin-ole&imax; 
array aolc {&imax } ole&imin-ole&imax; 
array aol {&imax } olx&imin-olx&imax; 
array asle {&imax}sle&imin-sle&imax; 
array aslc {&imax}sle&imin-sle&imax; 
array arle {&imax}rle&imin-rle&imax; 
array arle {&imax}rle&imin-rle&imax; 
array arl {&imax}rlx&imin-rlx&imax; 
array aql {&imax}qlx&imin-qlx&imax; 
array aZl {&imax}Zlx&imin-Zlx&imax; 
array aVl {&imax}Vlx&imin-Vlx&imax; 
aol{j}= sum(aolc{j}, aole{j}); 
arle{j}= sum(aole{j}, asle{j}); 
arle{j}= sum(aolc{j}, aslc{j}); 
arl{j}= sum(arlc{j}, arle{j}); 
aql{j}= -log(1-(aol{j}/arl{j}));
aZl{j } = aql{j}*(arle{j}*aolc{j}-arlc{j}*aole{j})/aol{j}; 
aVl{j} = aql{j}**2*arle{j}*arlc{j}*(arl{j}-aol{j})/
(aol{j}* (arl{j} - l ) );
array ao2e {&imax } o2e&imin—o2e&imax; 
array ao2c {&imax } o2c&imin-o2c&imax;
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array ao2 {&imax } o2x&imin-o2x&imax; 
ao2{k}= sum(ao2c{k}, ao2e{k}); 
array as2e {&imax}s2e&imin-s2e&imax; 
array as2c {&imax}s2c&imin-s2c&imax; 
array ar2e {&imax}r2e&imin-r2e&imax; 
array ar2c {&imax}r2c&imin-r2c&imax; 
array ar2 {&imax}r2x&imin-r2x&imax; 
array aq2 {&imax}q2x&imin-q2x&imax; 
array aZ2 {&imax}Z2x&imin-Z2x&imax; 
array aV2 {&imax}V2x&imin-V2x&imax; 
ao2{k}= sum(ao2c{k}, ao2e{k}); 
ar2e{k}= sum(ao2e{k}, as2e{k}); 
ar2c{k}= sum(ao2c{k}, as2c{k}); 
ar2{k}= sum(ar2c{k}, ar2e{k}); 
aq2{k}= -log (1-(ao2{k}/ar2{k}) ) ;
aZ2{k} = aq2{k}*(ar2e{k}*ao2c{k}-ar2c{k}*ao2e{k})/ao2{k}; 
aV2{k} = aq2{k}**2*ar2e{k}*ar2c{k}*(ar2{k}-ao2{k})/
(ao2{k}*(ar2{k}-1));
array affe {&imax,Simax } ffe&imin-ffe&last;
array afse {&imax,&imax } fse&imin-fse&last;
array asse {&imax,&imax } sse&imin-sse&last;
array asfe {&imax,&imax } sfe&imin-sfe&last;
array arte {Simax,&imax } rte&imin-rte&last;
array affe {&imax,&imax } ffe&imin-ffe&last;
array afse {&imax,&imax } fsc&imin-fsc&last;
array asse {&imax,&imax } ssc&imin-ssc&last;
array asfe {&imax,&imax } sfe&imin-sfc&last;
array arte {&imax,&imax } rte&imin-rte&last;
array aff {&imax,&imax } ff&imin-ff&last;
array af s {Simax,&imax } fs&imin-fs&last;
array ass {&imax,&imax } ss&imin-ss&last;
array asf {&imax,&imax } sf&imin-sf&last;
array art {&imax,&imax } rt&imin-rt&last;
array af tl {&imax,&imax } flt&imin-flt&last;
array aft2 {&imax,&imax } f2t&imin-f2t&last;
array aC {&imax,&imax } C&imin-C&last;
aff{j,k} = sum(affe{j,k},affc{j,k});
asf{j,k} = sum(asfe{j,k},asfc{j,k});
af s {j ,k} = sum(afse{j,k},afse{j,k});
ass{j,k} = sum(asse{j,k},asse{j,k});
arte{j,k} = sum(affe{j,k},afse{j,k},asse{j,k}




aC{j,k}=(aql{j}*aq2{k}*((arle{j}*ar2e{k}*artc{j , k}+ (arlc{j}*ar2c{k}*a 
rte{j,k}))*((aff {j,k }*art{j,k}- (aftl {j,k}*aft2 {j,k }))))
/ (aol{j}*ao2{k}*(art{j,k}* * 2 ) )) ;






Zs= sum(Zl, Z2)*sum(VI,V2)/sum(sum(VI,V2), 2*Cov);




thetaz=((Vl-Cov)/(sum(VI, V2,-2*Cov)))*thetal + ((V2-Cov)/
(sum(VI, V2,-2*Cov)))*theta2;^optimal theta;
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theta: p: Vs Zs Z1 VI Z2 V2 Cov Cor vthetaz;
run;
proc print data = summary ; *ZW method;
title "ZW bilat at &imax intervals";
var Z1 Z2 Zs VI V2 Vs Cov Cor p: theta: vthetaz;
run;
proc means data = summary ; *ZW method;
title "ZW bilat at &imax intervals";
var Zl Z2 Zs VI V2 Vs Cov Cor p: theta: vthetaz;
run;
%mend;
%hct( imin=l , imax=2, last=4);
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B. SAS Codes for WLW Specific for Analysis of Bladder Cancer Data
*Bladder Cancer (TT) Data Using WLW; 
options nolabel;




set blad tt; 
trtl = trt*(visit = 1); 
trt2 = trt* (visit = 2 ) ; 
run;
ods output parameterestimates=estw; 
ods output testaverage=eta;
PROC PHREG data = blad tt outest = estl covs (aggregate);
MODEL tstop*status(0) = trtl-trt2;
TREATMENT: test trtl,trt2/average e;*gives estimate of global 
treatment effect ;




PROC MEANS data = outl noprint;
BY id;
VAR dtl-dt2;




READ all var{dtl dt2} into x; 
v = x' * x;
RESET noname;
vname = {"trtl", "trt2"};
corr = v[l,2]/SQRT(v[l,1]#v[2,2]);
v[l,l] = 1/v [1,1];
v [2 , 2 ] = 1 /v [2 , 2 ] ;
v [1,2] = v [1,2] # v[l,l] # v [2,2]; 
v [2 ,1] = v [ 1, 2 ] ;
CALL SYMPUT('wlwCorr',LEFT(CHAR(corr,6,4)));
PRINT, "estimated covariance matrix (WLW)", ,
v[colname = vname rowname = vname format = 1 0 . 5 ] ;  
PRINT, "estimated correlation", corr[colname="corr"];
CREATE rcov from vfcolname = vname rowname = vname];




data rcovl;*split for merging later; 
set rcov;
if VNAME=1trt2' then delete; 






if VNAME='trtl' then delete; 
if VNAME='trt2' then VNAME = ' est 1 ; 
rename trtl=covz trt2=v2w;
run;





if parameter=1trt2' then delete;
if parameter='trtl' then parameter = ' est ' ;




if parameter='trtl' then delete;
if parameter=1trt2' then parameter = ' est ' ;




if Label='TREATMENT' then Label = ' est ' ; 
drop zscore;
rename estimate=w3 probz=p3 stderr=s3 Label=VNAME;;
run;
data est;








vpw = sum(vlw, v2w);
zpw = sum(zlw, z2w);
vsw = (vpw)**2/ sum(vpw, 2*covz);







plw = (1-probnorm(-wl/sl)); 




title "Bladder WLW TT ";
var w: vlw v2w vsw zlw z2w zsw c: p: theta: eta3 ;
run;
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C. SAS Codes for Comparison between The Jackknife, Exact Delta-Beta and
DFBETA Influences
^Compare Jackknife, Exact Delta-Beta & DFBETA for Bladder Data (TT);





if id ne &i;
run;
ods output parameterestimates=estw;
proc phreg data = blad ttl2 outest = estl2 ; 
model tstop*status (0) = trtl-trt2;
Trtl= Trt * (Visit=l);
Trt2= Trt * (Visit=2); 
strata visit; 
run;





if parameter='trt2* then delete;
if parameter='trtl' then parameter = &i ;




if parameter=’trtl' then delete;
if parameter='trt2' then parameter = &i ;
rename estimate=w2 probchisq=p2 stderr=s2 parameter=VNAME;
run;
data cov;











%macro iter (n) ;
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if trtl= then trtl=-0.3 6 2 7 4 1 8 ;*JK's average of 86 (n-1 
estimates);
if trt2='.' then trt2=-0.5 5 2 0 3 6 2 ;  
exl=-0.3 6 2 6 6 0 6 - w l;*exact delta beta; 
ex2=-0.5 5 1 7 8 4 2 - w 2;
vexl=(wl--0.3 6 2 6 6 0 6 ) * * 2 ;*exact var; 






covj k=sqrt(vj kl)*sqrt(vj k2);
keep wl w2 trtl trt2 exl ex2 jkl jk2 vjkl vjk2 covjk vexl vex2
covex;
run;






merge blad.dt_all blad.calcl ; 




read all var{dtl dt2} into x;
v = x' * x;
reset noname;
vname = {"trtl", "trt2"};
corr = v [ 1 , 2 ] /SQRT(v[1 , 1 ]#v[ 2 , 2 ] );
v [ l , l ]  = l / v [ l , l ] ;
v  [2,  2] = 1 / v  [2,  2] ;
v [ 1 , 2 ]  = v [ 1 , 2 ]  # v [ l , l ]  # v [ 2 , 2 ] ;  
v [ 2 , 1 ]  = v [ 1 , 2 ]  ;
CALL SYMPUT('wlwCorr',LEFT(CHAR(corr,6 , 4 ) ) ) ;
PRINT, "estimated covariance matrix DFBETA WLW", ,
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v[colname = vname rowname = vname format = 1 0 . 5 ]  
corr[colname="corr"];
CREATE rcov from v[colname = vname rowname = vname];






read all var{exl ex2} into x;
v = x' * x;
reset noname;
vname = {"trtl", "trt2"};
corr = v [1,2]/SQRT(v[l,1]#v[2,2]);
v[l,1] = 1/v [1,1];
v [2 , 2 ] = 1 /v [2 , 2 ] ;
v [ 1 , 2 ] = v [1 , 2 ] # v[l,l] # v [ 2,2 ] ;  
v [2,1] = v [ 1, 2 ] ;
CALL SYMPUT('wlwCorr',LEFT(CHAR(corr,6 , 4 ) ));
PRINT, "estimated covariance matrix: EXACT", ,
v[colname = vname rowname = vname format = 1 0 . 5 ]  
corr[colname="corr"];
CALL SYMPUT('wlwCorr',LEFT(CHAR(corr,6 , 4 ) ));
PRINT, "estimated correlation: EXACT", corr[colname="corr"]; 
CREATE rcov from v[colname = vname rowname = vname];






read all var{jkl jk2] into x;
v = x' * x;
reset noname;
vname = {"trtl", "trt2"};
corr = v [1,2]/SQRT(v[1,1]#v[2,2]);
v[l,1] = 1/v [1,1];
v [2 , 2 ] = 1 /v [2 , 2 ] ;
v [1, 2] = v [1,2] # v[l,l] # v [2,2]; 
v [2 , 1] = v [ 1, 2 ] ;
CALL SYMPUT('wlwCorr',LEFT(CHAR(corr,6 , 4 ) ) ) ;
PRINT, "estimated covariance matrix: JACKKNIFE", , 
vfcolname = vname rowname = vname format = 1 0 . 5 ]  
corr[colname="corr"] ;
CREATE rcov from vfcolname = vname rowname = vname];
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